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ABSTRACT 
 
PETO’S PARADOX AND THE EVOLUTION OF CANCER SUPPRESSION 
Aleah F. Caulin 
Shane T. Jensen 
Carlo C. Maley 
 
In order to successfully build and maintain a multicellular body, somatic cells must be 
constrained from proliferating uncontrollably and destroying the organism. If all 
mammalian cells were equally susceptible to oncogenic mutations and had identical 
tumor suppressor mechanisms, one would expect that the risk of cancer would be 
proportional to the body size and lifespan of a species. This is because a greater number 
of cells and cell divisions over a lifetime would increase the chance of accumulating 
mutations that result in malignant transformation. Peto’s paradox is the clash between the 
theory that cancer incidence should increase with body size and lifespan, and the 
observation that it does not. In this thesis, I present the first comprehensive survey of 
empirical evidence across mammals in support of Peto’s paradox in addition to 
computational models that explore the numerous hypotheses that may help resolve the 
paradox. I provide a detailed examination of tumor suppression in African elephants 
(Loxodonta africana) and show that the genome contains redundant copies of the tumor 
suppressor gene TP53.  I give evidence that these redundant copies are actively 
transcribed and also observe an increased apoptotic response after exposure to ionizing 
radiation, which may be linked to the expression of these genes. Few genomes of large, 
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long-lived organisms are currently available, which motivated my work to provide the 
sequence and de novo assembly of the humpback whale (Megaptera novaeangliae) 
genome. In this genome, I discovered a set of tumor suppressor genes that have evolved 
at an accelerated rate along the whale lineage, which is suggestive of adaptation. 
Additionally, I find one gene that has undergone convergent evolution between the 
African elephant and the humpback whale. The overarching goal of my research is to 
gain a better understanding of how evolution has suppressed cancer in large, long-lived 
organisms in the hopes of ultimately developing improved cancer prevention in humans.  
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CHAPTER 1: INTRODUCTION 
 
“Evolution is a light which illuminates all facts, 
a curve that all lines must follow." 
(Teilhard de Chardin 1959) 
 
 
 
Cancer is the second leading cause of death in the United States (Hoyert and Xu 2012). 
Billions of dollars have been invested in cancer research; however, despite these efforts, 
33% of Americans are diagnosed with cancer in their lifetime and 25% of our population 
still dies from this disease (ACS 2013). In this thesis, I approach the problem of cancer 
from a non-traditional angle, using evolutionary theory as the foundation for my research. 
I focus heavily on comparative genomics to gain insight into how evolution has shaped 
cancer suppression mechanisms across species. The long-term goal of this study is to 
translate the knowledge we gain from non-model organisms to the clinic, in hopes of 
decreasing the lifetime cancer risk of humans and stopping cancer in individuals before it 
begins.  
 
THE EVOLUTIONARY THEORY OF CANCER  
Cancer is a consequence of multicellularity and a striking example of multi-level 
selection. The theory of cancer initiation and progression is deeply rooted in evolutionary 
and ecological concepts (Merlo et al. 2006). Cancer progresses through somatic 
evolution, whereby genetic and epigenetic instability generates fitness variation among 
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cells. Throughout an organism’s lifetime, cells accumulate mutations, which can 
eventually lead to the initiation of a malignancy. Mutations arise from both endogenous 
and exogenous damage, in addition to errors in DNA synthesis that are not properly 
repaired. The population of somatic cells within a tumor satisfy the three necessary and 
sufficient conditions for natural selection (Nowell 1976):  
1. There must be variation within the population. A tumor is a heterogeneous 
population of cells with somatic genetic and epigenetic alterations. 
 2. The variation must be heritable. Genetic and epigenetic mutations are inherited 
by both daughter cells when a cell divides.  
 3. There must be differential survival and reproduction (i.e. fitness). In some 
cases, the genetic and epigenetic mutations provide cells with survival and/or 
reproductive advantages over other cells. 
Genetic and epigenetic changes can result in the eight ‘hallmarks of cancer’, all of 
which provide a fitness advantage to cancer cells relative to the healthy somatic cells: (i) 
self sufficiency of growth-signals, (ii) insensitivity to anti-growth signals, (iii) evasion of 
apoptosis, (iv) sustained angiogenesis, (v) limitless replicative potential (i.e. stabilization 
of telomeres), (vi) immune system avoidance, (vii) modification of cell metabolism, and 
(viii) the ability to invade new tissue and metastasize (Hanahan 2000, Hanahan and 
Weinberg 2011). The somatic evolution that takes place within mutant cell populations 
can result in cancer (Nowell 1976, Merlo, Pepper et al. 2006). Understanding this process 
through an evolutionary perspective is essential not only to guide treatment, but 
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additionally, and perhaps more importantly, for discovering ways to effectively intervene 
in order to prevent the development of cancer all together.  
  Just as selection acts at the cellular level, selection also acts at the level of the 
organism. This has led to the evolution of tumor suppressor mechanisms, such as cell 
cycle checkpoints and apoptosis, which act as safeguards to prevent somatic mutations 
from propagating in the cell population within a multicellular organism (Bernstein et al. 
2002). DNA damage sensing and repair are crucial for resolving mutations as they arise, 
while premature senescence and apoptosis act as the second line of defense when 
mutations cannot be sufficiently repaired (Kinzler and Vogelstein 1997, Campisi 2003). 
Maintaining the integrity of DNA is essential for all forms of life, from unicellular to 
multicellular organisms; however, additional mechanisms have evolved in multicellular 
organisms to enforce cooperation and eliminate selfish cells in order to prevent cancer 
(Domazet-Loso and Tautz 2010).  
Limiting the replicative potential of cells is thought to be an important mechanism 
involved in suppressing tumorigenesis (Campisi 1997, Campisi 2001). When a cell 
undergoes senescence, it is removed from the pool of dividing cells and can no longer 
pass on mutations it may harbor. Cells have been found to senesce in response to a 
variety of stresses such as mutation, over-expression of an oncogene and changes in 
chromatin organization (Campisi 2005). Additionally, the complex dynamics of stem 
cells and their lineages (e.g. asymmetric divisions, transient amplifying cells leading to 
terminally differentiated cells, and having only a small number of stem cells) helps to 
maintain the integrity of each tissue while most mutations occur in evolutionary dead 
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ends (i.e. cells that will become terminally differentiated) (Cairns 1975, Clevers 2005, 
Greaves 2007). 
 Specific tissue architectures (e.g. intestinal crypts) can also aid in tumor 
suppression by providing a physical barrier that separates small groups of stem cells, 
protects them in a niche and requires progeny to differentiate and slough off (Gatenby et 
al. 2010). When mutant cells arise and are not eliminated by any of these mechanisms, 
the immune system may be able to detect them and remove them before a malignant 
tumor is formed (Shankaran et al. 2001). Though these mechanisms are not necessarily 
solely in place to suppress tumorigenesis, the need to repress cancer has provided a 
strong selective pressure to fine-tune these systems throughout approximately one billion 
years of evolution in multicellular eukaryotes (Graham 1992, Knoll et al. 2006).   
 
PETO’S PARADOX 
The challenge of suppressing somatic evolution (i.e. cancer) dramatically increases with 
larger bodies and longer lifespans. If all mammalian cells were equally susceptible to 
oncogenic mutations and had identical tumor suppressor mechanisms, one would expect 
that the risk of cancer would be proportional to the body size and lifespan of a species.  A 
greater number of cells in larger animals, and a greater number of lifetime cell divisions 
in long-lived animals, should increase the chance of accumulating oncogenic mutations. 
Some evidence exists that this is true within species (Altman and Schwartz 1978, Albanes 
1998, Nunney 2013); however, there is no indication that this relationship holds across 
species. It is well documented that carcinogenesis is an increasing function of age (Frank 
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2007), and larger organisms generally have longer lifespans (Speakman 2005), which 
further suggests that we should see increased cancer incidence in large, long-lived 
animals. Peto’s paradox is the clash between the theory that cancer incidence should 
increase with body size and lifespan, and the observation that it does not (Figure 1) (Peto 
et al. 1975, Peto 1977, Caulin and Maley 2011, Roche et al. 2012).  
Cancer rates across multicellular animals only vary by approximately two-fold 
even though the difference of size among mammals alone can be on the order of one 
million-fold (Leroi et al. 2003, de Magalhães and Costa 2009). The exact functional 
relationship between body size and expected cancer risk is unclear; however it is assumed 
to be an increasing function (Figure 1). In comparing laboratory rodents and humans, 
which differ in maximum lifespan by a factor of 40 and size by three orders of 
magnitude, about 30% of both rodents and humans develop cancer within their lifetime 
(Rangarajan and Weinberg 2003). The general explanation for this is that large, long-
lived animals are more resistant to carcinogenesis than small, short-lived animals (Dawe 
et al. 1969, Cairns 1975, Peto, Roe et al. 1975, Peto 1977, Graham 1992, Roche, 
Hochberg et al. 2012). However, how they accomplish this resistance has yet to be 
established. 
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Figure 1. Summary of the current knowledge of Peto's paradox. Theory would 
predict that cancer incidence would increase with body size (blue curve); however across 
species the average probability of cancer is roughly constant (red line). Within a species 
we observe that body mass is associated with cancer risk (purple). This figure is adapted 
from Roche et al. 2012. 
 
In the seminal paper bringing attention to this paradox, Sir Richard Peto noted: 
“in the evolutionary diversification of mammals, enormous changes in cellular 
susceptibility to oncogenesis have developed. These may be nicely illustrated by 
comparing mice and men: a man has 1,000 times as many cells as a mouse…and we 
usually live at least 30 times as long as mice do. Exposure of two similar organisms to 
risk of carcinoma, one for 30 times as long as the other would give perhaps 304 or 306  
(i.e. a million or a billion) times the risk of carcinoma induction per epithelial cell. Are 
our stem cells really, then, a billion or a trillion times more ‘cancer proof’ than murine 
stem cells…Why don’t we all die of multiple carcinomas at an early age? Presumably 
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some concomitant of our evolved ability to grow big and to live for three score years and 
ten is involved” (Peto 1977). Selection pressure for cancer suppression is stronger in 
species that are larger and live longer, thus humans have evolved more effective cancer 
suppression than mice, and larger animals, such as elephants and whales, have evolved 
more effective cancer suppression than humans. Understanding the molecular 
mechanisms involved in the evolution of tumor suppression could suggest new methods 
of cancer prevention in humans.  
 
THE NEED AND POTENTIAL FOR CANCER PREVENTION  
Cancer has proven difficult to cure. Since former U.S. president Richard Nixon declared 
the “War on Cancer” over 40 years ago, little progress has been made on reducing 
lifetime risk of cancer and increasing survival rates for patients with late stage diagnoses 
(Etzioni et al. 2003, ACS 2013). The majority of cancer research focuses on treatment 
rather than prevention and this often leads to the recurrence of tumors that are resistant to 
therapy. With 109–1012 cells in a tumor and perhaps 105 mutations (Bielas et al. 2006, 
Sjoblom et al. 2006, Greenman et al. 2007, Mardis et al. 2009), it appears that in many 
cases therapy selects for a resistant clone (Merlo, Pepper et al. 2006). Increasingly, 
attention is turning to cancer prevention so as to avoid this scenario entirely. 
A proven strategy in drug development has been to seek natural products that 
have been honed by millions of years of evolution to generate the desired effect 
(Newman and Cragg 2007). Peto’s paradox suggests that the same approach can be used 
in cancer research. If large, long-lived animals, such as the whales, have evolved 
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mechanisms capable of suppressing cancer 1,000 times better than humans, they may 
hold the key for cancer prevention in humans.  
 
HYPOTHESES TO RESOLVE PETO’S PARADOX 
Limited research efforts have been focused on resolving Peto’s paradox. However, there 
are many hypotheses that might explain how organisms could overcome the burden of 
cancer despite an increased number of cells and extended lifespan. Some have been 
previously proposed (Totter 1980, Nunney 1999, Hahn and Weinberg 2002, Leroi, 
Koufopanou et al. 2003, Nagy et al. 2007, Klein 2009, Roche, Hochberg et al. 2012) and 
other mechanisms that we outline below are novel, to the best of our knowledge. Large 
bodies and long lifespans have evolved independently along multiple lineages; therefore, 
we would not expect that all large, long-lived animals have evolved the same 
mechanism(s) to suppress cancer, unless the suppression stems from an innate 
characteristic which they all share. Differences in diet and carcinogenic exposures 
(including pathogens, which are currently known to be associated with 15% of human 
cancers (zur Hausen 1999)) are unlikely explanations because there are many-fold 
differences in size between organisms with similar environments (e.g., dolphins and 
whales) and similar diets (e.g., elephants and mice are both herbivores). Here we present 
some possible mechanisms that might have evolved to reduce the expected correlation 
between body size, lifespan and cancer risk.  
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Lower Somatic Mutation Rates 
If large animals have lower somatic mutation rates per cell generation, then more cell 
divisions would need to occur, compared to smaller animals, in order for a cell to acquire 
the necessary mutations to become malignant. Mutation rate is a function of the error rate 
and the rate at which these errors are repaired. A lower somatic mutation rate could be 
achieved through a number of mechanisms including better DNA damage detection and 
repair mechanisms, or better elimination of mutated cells. It appears that at least for the 
liver, the mutation rates per cell division are comparable between mice and humans 
(Leroi, Koufopanou et al. 2003),  though more advanced methods to measure somatic 
mutation rates in vivo are needed to fully explore this hypothesis.  
 
Redundancy of Tumor Suppressor Genes 
Tumor suppressor genes (TSGs) are genes that increase the chance of progression to 
cancer when they are inactivated or deleted. Computational models have shown that cells 
of larger animals should have less tolerance for TSG inactivation, given that a phenotype 
occurs when both alleles are mutated (Roche et al. 2013). Added redundancy of tumor 
suppressor genes could suppress cancer in large animals by requiring more mutations 
occur to induce a malignant phenotype (Nunney 1999, Leroi, Koufopanou et al. 2003), 
and therefore making cells more tolerant to some TSG mutation (Figure 2).   
The number of pathways that need to be inactivated to induce malignancy, 
typically through the mutation of TSGSs, differs between species with transformational 
 10 
resistance thought to be highest in whales and lowest in mice (Lichtenstein 2005). For 
instance, the transformation of fibroblasts requires that 6 signal pathways be affected in 
humans, compared to only 2 in mice (Rangarajan et al. 2004). In support of the 
possibility of redundant TSGs, transgenic mice that contain an extra copy of p53 
(including its regulatory elements) gain an increased resistance to cancer and show no 
signs of premature aging (García-Cao et al. 2002). Similar results have been reported for 
p16 and ARF (Matheu et al. 2004). If large, long-lived animals evolved redundant copies 
of tumor suppressors, it might explain how they are not more prone to cancer any more 
so than smaller animals.  
Redundancy could also be manifested in terms of TSG expression. Many tumor 
suppressor genes are tissue specific (Payne and Kemp 2005). Cells of larger species could 
have evolved expression patterns such that in any given cell more TSGs are expressed 
compared to smaller, shorter-lived animals, even though there might be the same number 
of TSGs in the genome. Cells could alter their expression of TSGs via epigenetic 
changes, introduction of transcription factor binding sites or non-coding RNA. This 
hypothesis would predict that large animals would have more ubiquitously expressed 
TSGs than smaller species.  
 
Elimination of Proto-oncogenes 
A complementary solution would be to eliminate a set of proto-oncogenes from the 
genomes of large, long-lived organisms. If there were fewer proto-oncogenes or proto-
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oncogenic pathways that could generate the phenotypes necessary for cancer, there would 
be a reduced likelihood of cancer (Figure 2). This is supported by an experiment 
demonstrating that Hras1 null mutant mice develop significantly fewer papillomas than 
wild type mice (Ise et al. 2000). This option might be constrained by selective pressures 
on the remaining pathways to produce the adaptive phenotypes that had been encoded in 
the deleted pathway. Proto-oncogenes serve specific cellular functions; so eliminating 
them could be deleterious for other reasons.  
 
 
Figure 2. Mechanisms of cancer suppression. Assume that the ancestor of a large, 
long-lived organism has two pathways initiated by cytokines (triangles) such that if either 
one is disrupted the result is a hallmark of cancer. The example shown is for increased 
cell proliferation but could apply to any hallmark (A). A large organism could decrease 
its risk of cancer by evolving redundant copies of tumor suppressor genes (squares) (B) 
or by removing proto-oncogenes (circles) and tumor suppressor genes to eliminate an 
entire pathway (C) so that there are fewer carcinogenic loci in the genome that are 
vulnerable to mutation. This figure is reprinted from the publication Trends in Ecology 
and Evolution, Vol. 26(4), Aleah F. Caulin and Carlo C. Maley. Peto’s Paradox: 
evolution’s prescription for cancer prevention. pages 175-182, Copyright (2011), with 
permission from Elsevier. 
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Lower selective advantage of mutant cells 
Another hypothesis to resolve Peto’s paradox proposes that the fitness effect of specific 
mutations may differ in larger animals. For example, a haploinsufficient gene in mice 
could be completely recessive in a larger animal, requiring mutations to occur on both 
alleles in order to gain a selective advantage over neighboring cells during carcinogenesis 
in the larger species (Leroi, Koufopanou et al. 2003). This would decrease the possibility 
that mutations at this locus would contribute to progression towards cancer, which has 
been observed in a tissue-specific manner. The tumor suppressor Trp53 (the mouse 
homolog to human TP53) usually requires both alleles of the gene to be null in order to 
see a mutant phenotype; however, in some tissues, Trp53 is haploinsufficient and losing 
only one allele produces a phenotype in mice (Payne and Kemp 2005). If all cancer-
associated genes required both alleles to be mutated in order to produce a phenotype, it 
would double the number of mutations required for a malignancy.  
 
More sensitive or efficient apoptotic processes 
The apoptotic propensity of cells might differ between large and small organisms. Cells 
from large bodies could be more sensitive to DNA damage or the activation of an 
oncogene and thus would be more apt to apoptose (Klein 2009). Support for this 
hypothesis comes from observations of human and mouse cell culture experiments. When 
human cells are exposed to methylating agents, many die via apoptosis triggered by the 
methylation damage. A much higher percentage of mouse cells survive and continue 
dividing regardless of the damage inflicted by the treatment (Humbert et al. 1999). 
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Apoptosis due to DNA damage eliminates the damaged cell from the population instead 
of repairing the DNA and possibly propagating remaining mutations in the tissue. 
However, there is likely a trade-off between apoptosis preventing cancer and accelerating 
aging due to depletion of the stem cell pool (Tyner et al. 2002). 
 
Increased sensitivity to contact inhibition 
Additionally, selfish cellular proliferation can also be suppressed by signals from the 
microenvironment (Klein 2009). For example, cell contact inhibition has been noted to 
differ between human, mouse and naked mole-rat (Heterocephalus glaber) cells. In 
culture, naked mole-rat cells stop dividing at much lower densities than human and 
mouse cells due to the early activation of the p16 pathway which results in 
hypersensitivity to contact inhibition (Seluanov et al. 2009). Although naked mole-rats 
and mice are small animals, the former live significantly longer than the latter (28 years 
(Buffenstein and Jarvis 2002) versus 4 years (Turturro et al. 1999)). In 250 necropsies of 
naked mole-rats that died in captivity, zero had cancer (Buffenstein 2005). 
Hypersensitivity to contact inhibition might have evolved to suppress cancer allowing the 
naked mole-rat to live longer, though this cellular response has only been verified in vitro 
(Seluanov, Hine et al. 2009). Similar signals for early cell senescence may be triggered in 
large, long-lived organisms to inhibit uncontrolled proliferation, and decrease the risk of 
tumorigenesis.  
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Shorter Telomeres 
Telomere length appears to be a fundamental check on the proliferative capacity of cells 
(Monaghan 2010). Telomeres shorten with every cell cycle and when they become too 
short to protect the chromosomes’ ends, the cell senses those ends as DNA double strand 
breaks, usually leading to apoptosis (d'Adda di Fagagna et al. 2003, Shay and Wright 
2010). Even though stem cells express telomerase, which helps to rebuild telomeres, they 
generally do not express enough to prevent telomere shortening due to proliferation (Shay 
and Wright 2010). Within rodents, repression of telomerase activity coevolved with 
increased body mass, resulting in decreased expression in larger species (Seluanov et al. 
2007). However, the long-lived, cancer-resistant naked mole-rat does express telomerase 
and has continuously proliferating cells, suggesting that larger bodies are a greater risk 
factor for cancer than longevity (Seluanov, Chen et al. 2007, Seluanov et al. 2008). We 
hypothesize that large, long-lived animals might have shorter telomeres (or erode them 
faster) than smaller animals, limiting the number of times their cells can divide and 
reducing opportunities to accumulate carcinogenic mutations, which could be assayed in 
vitro.  
 
Different tissue architecture  
Alternatively, tumor suppression mechanisms can evolve at the level of the tissue as 
opposed to within individual cells. Changes in tissue architecture could influence the 
frequency of cancers by altering the way cells are compartmentalized and/or the 
dynamics of the tissue (Leroi, Koufopanou et al. 2003). Most tissues are comprised of 
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small proliferative units, e.g. the crypts of the intestines. It has been proposed that this 
hierarchical structure is a crucial cancer prevention mechanism (Gatenby, Gillies et al. 
2010). Since differentiating cells are evolutionary dead-ends because they will stop 
dividing and eventually slough off, the effective population size of a somatic tissue 
depends mainly on the number and dynamics of stem cells (though a mutation which 
disrupts differentiation in a non-stem cell might also generate a carcinogenic cell lineage) 
(Michor 2007). Under a model of “serial differentiation” it is possible to increase the 
number of cells and the amount of cell turnover without increasing the number or 
proliferative activity of somatic stem cells, simply by adding non-stem stages (Pepper et 
al. 2007). Altering the number of stem cells, the crypt density or the dynamics of 
differentiation and division could enhance the tissue’s ability to prevent malignant 
transformation. 
 
More effective immune system 
The immune system has been found to play a role in preventing tumorigenesis and 
provides yet another possible resolution to Peto’s paradox. Immune system efficiency 
against virus-associated cancers might also account for some differences observed in 
cancer rates within people (Klein 2009), but this could apply to non-viral cancers as well. 
Initially, tumors are likely to be immunogenic. When mice are treated with carcinogens, 
tumorigenesis is delayed by immune system surveillance (Koebel et al. 2007). However, 
as the tumor co-evolves with the immune system, tumor variants that go undetected are 
selected (termed “immunoediting”) (Pawelec et al. 2010). “Chronic antigenic stress” can 
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result in exhaustion of the immune system leading to ineffective surveillance, similar to 
observations of chronic viral infections (Pawelec, Derhovanessian et al. 2010). Large, 
long-lived organisms might have improved immune surveillance to eliminate neoplastic 
cells before they become malignant.  
 
Less Reactive Oxygen Species due to Lower Basal Metabolic Rate 
A lower somatic mutation rate could also be a result of metabolism. Reactive oxygen 
species (ROS) are byproducts of metabolism and can cause DNA damage thought to 
contribute to aging and cancer (Wiseman and Halliwell 1996, Hoeijmakers 2009, 
Sedelnikova et al. 2010). The rate at which ROS are produced in a cell is a function of the 
basal metabolic rate (BMR) (Ku et al. 1993).  BMR per unit mass (mass-specific BMR) 
is proportional to M-1/4, where M is body mass (Savage et al. 2007) and has been shown 
to correlate with the amount of oxidative damage (Adelman et al. 1988). This leads to the 
prediction that cancer incidence, if largely caused by endogenous DNA damage, should 
also be proportional to M-1/4 (Herman et al. 2011). Knocking out oxidative repair genes, 
and therefore allowing DNA damage from ROS to persist, results in increased tumor 
susceptibility in a variety of tissues, suggesting that DNA damage caused by ROS plays a 
causal role in tumor formation (Xie et al. 2004). Large animals should produce fewer 
ROS due to their lower mass-specific BMR and consequently have less endogenous DNA 
damage (Totter 1980).  
 There is some evidence linking cancer incidence to metabolism. The average 
BMR of women is 10% lower than that of men after adjusting for body mass, 
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composition, activity and age (Totter 1980) and women consistently have lower rates of 
cancer (ACS 2013). Naked mole-rats, for which spontaneous cancer has yet to be 
reported (Buffenstein 2005), have a mass-specific BMR that is much lower than expected 
given their size (de Magalhães and Costa 2009). Additionally, caloric restriction inhibits 
cancers in animal models and one explanation for this is that the decrease in caloric 
intake lowers the metabolic rate, therefore producing less ROS and subjecting the DNA 
to less endogenous damage (Longo and Fontana 2010). These observations could all be 
attributed to cells having less endogenous oxidative damage, which effectively results in 
a lower somatic mutation rate and a reduced cancer risk.  
 
Formation of hypertumors 
Nagy et al. have proposed an alternative hypothesis to resolve Peto’s paradox: the 
formation of ‘hypertumors’ (Nagy, Victor et al. 2007). Natural selection within a tumor 
might favor cheater cells that take advantage of vasculature built by angiogenic cells. 
These cheaters could grow and parasitize the primary tumor by forming a ‘hypertumor’ 
that would reduce the overall fitness of the tumor and possibly cause the tumor to regress. 
Nagy et al. argue that lethal tumors must be drastically larger in larger animals, giving the 
hypertumor more time to evolve and force the parent tumor to become necrotic (Nagy, 
Victor et al. 2007). This model predicts that tumors in large organisms should be 
disproportionately more necrotic when compared to lethal tumors in smaller organisms, 
and that large animals should carry a burden of many non-lethal tumors (Nagy, Victor et 
al. 2007), though these predictions have yet to be tested experimentally. 
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 Since large bodies have evolved multiple times, independently throughout 
evolution, each lineage may have evolved a different mechanism to overcome the 
problem of cancer. However, the last two hypotheses involving BMR and hypertumors 
would apply to all large, long-lived animals and perhaps provide some universal answer 
to Peto’s paradox. For practical reasons, we have focused our research efforts on 
exploring the hypotheses of redundant tumor suppressor genes and the apoptotic response 
of cells to DNA damage.  
 
OVERVIEW OF THESIS 
In this thesis, I investigate the underlying evolutionary basis for Peto’s paradox through 
the use of computational modeling and comparative genomics. In Chapter 2, I discuss 
currently published evidence for the existence of the paradox and present an empirical 
analysis of necropsy data to provide improved estimates of cancer incidence in non-
human mammals and additional support for the paradox. In Chapter 3, I outline two 
models to explore the various hypotheses that have been proposed to explain Peto’s 
paradox. I find that there are multiple biologically relevant solutions and choose to focus 
subsequent work on the copy number of cancer-associated genes which is discussed in 
detail in Chapter 4. In Chapter 5, I present my discovery of redundant copies of the tumor 
suppressor gene TP53 in the African elephant genome and argue that these extra copies 
may be responsible for the hypersensitivity to ionizing radiation that I have analyzed. 
Chapter 6 explains the methods that I used to de novo assemble the genome of the 
humpback whale, which is one of the largest and most long-lived organisms that has been 
 19 
sequenced to date. In Chapter 7 I provide an evolutionary analysis of the humpback 
whale genome (in addition to the African elephant) where I find evidence of convergent 
and accelerated evolution in specific tumor suppressor genes. In Chapter 8, I propose 
future experiments that will further our understanding of cancer suppression mechanisms. 
If we can understand how evolution has shaped these mechanisms to allow for large, 
long-lived organisms to suppress cancer, this knowledge could be applied towards 
improved methods of cancer prevention in humans. 
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CHAPTER 2: EMPIRICAL EVIDENCE IN SUPPORT OF PETO’S PARADOX 
 
 
INTRODUCTION 
Cancer incidence records for wild and captive animals are not well documented for most 
species as the majority of animals live and die unseen (McAloose and Newton 2009). 
This makes it difficult to directly compare records of humans and other animals, but it is 
still clear that cancer incidence does not scale with body size across species. For example, 
blue whales are thought to be the largest animals to have ever lived (Small 1971) and are 
three orders of magnitude larger than a human. However, if blue whales had one 
thousand times higher cancer incidence than humans, they would likely die before they 
were able to reproduce and the species would have quickly gone extinct (Lichtenstein 
2005). The mere existence of whales suggests that is it possible to substantially reduce 
the rate of cancer incidence relative to humans. 
 Cancer death rates vary approximately two-fold across multicellular animals of 
drastically different size (Leroi, Koufopanou et al. 2003). When wild mice are raised in 
protected laboratory conditions 46% die of cancer (Andervont and Dunn 1962).  Cancer 
is also responsible for about 20% of dog deaths (Morris and Dobson 2001), roughly 25% 
of human deaths in the United States (ACS 2013) and 18% of beluga whale deaths 
(Martineau et al. 2002), though the latter were living in a highly polluted estuary. Rare 
cases of cancer are discovered in blue whales, giving no evidence of elevated cancer risk 
in these species (Martineau, Lemberger et al. 2002, Newman and Smith 2006). 
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Additionally, a radio-epidemiologic study suggests that dinosaurs may have even had a 
decreased risk of cancer, relative to modern-day animals (Rothschild et al. 2003, 
McAloose and Newton 2009). Contrary to what we observe; if the probability of cancer 
scaled with size and longevity, mice should have the lowest incidence of these examples. 
However, cancer seems to account for approximately the same percentage of deaths, 
despite the size and lifespan of species (Figure 3). 
Interestingly, within a species, size is associated with an increased cancer risk. In 
humans, having a leg length 3-4mm above average results in an 80% higher risk of non-
smoking-related cancers (Albanes 1998). This trend is also seen in children and dogs. 
Children with bone cancers tend to be taller and osteosarcomas occur in large dogs 200 
times more frequently than small and medium breeds (Altman and Schwartz 1978, 
Nunney 2013). There has likely not been enough time for larger dogs to evolve additional 
mechanisms to protect them from this increased risk and counteract the extreme artificial 
selection for size imposed by humans. This suggests that animals which evolved to be 
larger as a species developed mechanisms to offset the increased cancer risk associated 
with an increased number of cells. Conversely, above average individuals do not possess 
additional defenses compared to smaller organisms within their species, and therefore fall 
victim to cancer with greater probability. 
 
CANCER INCIDENCE DATA OF ZOO MAMMALS 
Necropsy data from animals in captivity confirms that cancer incidence does not increase 
with body size or lifespan across species varying orders of magnitude in both size and 
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lifespan. We compiled 14 years of necropsy data collected by the San Diego Zoo (Griner 
1983) and counted the recorded instances of tumors for mammals. In over 830 necropsies 
across 36 mammals we found a total of 37 incidences of cancer, which is only an overall 
incidence of 4.5%. A previous study, which did not require a minimum of 10 necropsies 
per species, found that 2.75% of species had neoplasms at the time of necropsy (Effron et 
al. 1977). The highest rate of cancer in the data we analyzed was found in Tasmanian 
devils, though none of the cases were linked to the contagious facial cancer in that 
species. Tasmanian devils have very low genetic diversity, likely due to multiple 
population bottlenecks which are thought to be caused by disease (Guiler 1983). It is 
possible that a cancer-susceptibility allele increased in frequency due to these 
bottlenecks, leaving the remaining population highly vulnerable to malignant 
transformation.  
A logistic regression model was fit to the data to test if body mass and maximum 
lifespan are good predictors of cancer incidence for each species. We found no evidence 
to support the predictive value of these characteristics (Figure 3). We also used a logistic 
regression to examine all combinations of mass, lifespan and mass-specific basal 
metabolic rate since these features are highly correlated; however, we still found no 
significant relationship with cancer incidence (Figure 4). If anything, the trend is toward 
a lower risk of cancer in animals with increased mass and lifespan. These analyses 
provide the first systematic evidence to support Peto’s Paradox. 
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Figure 3. Tumor incidence in captive mammals. Cancer incidence does not increase 
with body size and lifespan. The product of mass and lifespan is not a good predictor of 
cancer incidence as shown by the logistic regression (model fit shown as red line). The 
elephant data point is from data collected from Elephant Encyclopedia database and is 
based off of 644 annotated deaths (Koehl 1995-2012). All other data are from necropsies 
at the San Diego Zoo (Griner 1983) and each point is supported by a minimum of 10 
necropsies.  
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Figure 4. Logistic regression models for tumor incidence. Logistic regression models 
for tumor incidence in zoo animals show no significant correlation between tumor 
incidence and body size, lifespan, mass specific basal metabolic rate (msBMR) or any 
combination of those variables. The log(mass*lifespan) plot is shown in Figure 3. 
 
AGE INCIDENCE AND LIFETIME RISK OF CANCER IN ELEPHANTS 
Next we specifically investigated the cancer incidence in the largest extant terrestrial 
mammal, the elephant. If elephants had the same biology as humans, and cancer 
incidence scaled linearly with the number of cells and lifespan of a species, with 100-fold 
more cells and lifespans up to 65 years (de Magalhães and Costa 2009), which is more 
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than half the average human lifespan, elephants should get approximately 50-fold more 
cancers than humans. We analyzed data from the Elephant Encyclopedia (Koehl 1995-
2012) on the cause of death for elephants in captivity in order to get an estimate of their 
age-incidence and overall lifetime risk of cancer (Figure 5). Out of 644 annotated deaths 
there were 20 cases of cancer/lethal tumors, resulting in a lifetime cancer incidence of 
3.1%. The true cancer incidence is obscured by the fact that necropsies are not performed 
on all of the animals at time of death and elephants are frequently euthanized for reasons 
such as arthritis, aggression and injury. Many of the animals are euthanized because of 
“age related issues” which are unspecified and interfere with the cancer incidence data 
since this prevents many elephants in captivity from reaching the age at which they 
would naturally die. To get a more comprehensive estimate we calculated an inferred 
cancer incidence by assuming the same percentage of deaths with an unknown cause 
would be due to cancer as deaths with known causes (see Methods).  Using this 
calculation, the lifetime cancer death rate in elephants in captivity only increased to 4.8%, 
compared to the 25% lifetime cancer mortality rates in humans in the United States (ACS 
2013) and 13% worldwide (Ferlay et al. 2010). How are elephants suppressing cancer 
more effectively than humans? 
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Figure 5. Cause of death in captive elephants. Approximately 3.1% of elephants die of 
cancer, which given their size and lifespan is much lower than we would expect. Because 
not all elephant deaths are well annotated, we calculated an estimated lifetime cancer 
risk, which increases the cancer incidence estimate to 4.8% (see Methods). The inferred 
cancer rates for each age group are shown in black and the observed rates are shown in 
blue.  
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METHODS 
We compiled necropsy data collected by the San Diego Zoo (Griner 1983) to estimate 
cancer incidence in mammalian species. The analysis was limited to species with a 
minimum sample size of ten. This restriction gave a total of 832 necropsies across 36 
species of mammals of which there were 37 reported cases of cancer and/or lethal 
tumors.  Tumors that lacked full pathology reports, as well as cases noted as hyperplasias, 
were counted towards cancer incidence so as to not drastically underestimate the values. 
Adult body mass, maximum lifespan and mass specific basal metabolic rate (msBMR) 
data (Table 1) were collected from the AnAge database (de Magalhães and Costa 2009). 
We performed a logistic regression to determine if body mass, lifespan, msBMR or a 
combination of these variables was a good predictor of cancer incidence within a species. 
The logistic regression was done on both a log and linear scale, but plotted on a log scale 
to easily visualize the large range of masses.  
Data on 644 elephants (both African (Loxodonta africana) and Asian (Elephas 
maximus)) were obtained from the online Elephant Encyclopedia database (Koehl 1995-
2012). Elephants in the circus, at temples, and owned by private dealers were excluded 
from the analysis since treatment of these animals is often not held to the same standards 
as a zoo or sanctuary. Causes of death were divided into seven categories: cancer, 
euthanized because of cancer, non-cancer disease, euthanized for a reason other than 
cancer, unspecified disease, euthanized for an unspecified reason, and exogenous cause 
of mortality. Inferred cancer rates were calculated by assuming the same percentage of 
deaths with an unknown cause would be due to cancer as deaths with known causes. For 
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example, if cancer makes up x percent of deaths with a known cause, then we assume 
cancer is also responsible for x percent of the deaths with an unspecified cause (i.e. 
“disease unspecified” and “euthanized unspecified”).  
We used the following methodology to infer cancer deaths among the unspecified 
cases. The fraction of cancers reported in deaths with a specified disease is 𝑓!" and the 
fraction of elephant euthanizations attributed to cancer is 𝑓!", where the subscript k 
represents ‘known’ and the d and e represent ‘disease’ and ‘euthanized’ respectively. The 
number of deaths from unspecified diseases that we infer to be cancer is equal to 𝑓!"×𝑁!", where 𝑁!" is the number of deaths caused by an unspecified disease. Similarly 
the number of unspecified euthanizations that we infer to be cancer is equal to 𝑓!"×𝑁!", 
where 𝑁!" is the number of euthanizations with no specified reason. We take the ceiling 
integer for each of these values as a conservative measure to not underestimate the cancer 
incidence. The inferred cancer rate is equal to !!"×!!"   !   !!"×!!"   !!!"!!!"! , where 𝐶!" 
and 𝐶!" are the number of cancer cases in the known disease population and the known 
euthanized population respectively and N is the total number of elephant deaths.  
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Common Name 
 
# necropsies 
 
# tumors 
Adult 
mass (Kg) 
Maximum 
lifespan (yrs) 
msBMR 
(W/g) 
Striped Grass Mouse 13 0 0.05 4.5 0.00452 
Philippine Tarsier 13 0 0.12 16.0 0.00381 
Pygmy Marmoset 15 0 0.12 18.6 0.00541 
Treeshrew 13 1 0.20 12.4 0.00424 
Marmoset 18 3 0.26 16.5 0.00446 
Squirrel Monkey 17 0 0.93 30.2 0.00529 
Prairie Dog 16 3 1.13 11.0 0.00212 
Fennec Fox 10 0 1.25 16.3 0.00232 
Viriginia Opossum 11 0 3.00 6.6 0.00186 
Rock Hyrax 76 1 3.60 14.8 0.00202 
Parma Wallaby 34 1 4.25 15.9 unknown 
Armadillo 74 2 5.50 22.3 0.00136 
Racoon 15 0 6.00 21.0 0.00215 
Tasmanian devil 18 9 6.50 13.0 0.00141 
Darma Wallaby 14 0 6.50 15.1 0.00162 
Tree Kangaroo 18 0 7.20 26.9 0.00114 
Blue Monkey 27 2 9.00 37.8 0.00223 
Koala 26 1 9.30 22.1 0.00121 
Black-backed Jackal 18 1 10.25 16.7 0.00279 
Hamadryas Baboon 18 0 18.00 37.5 0.00166 
Collared peccary 16 0 20.20 31.5 0.00162 
African Wild Dog 40 3 26.50 17.0 0.00377 
Eastern Wallaroo 40 0 30.00 22.0 0.00111 
Pronghorn 25 1 46.10 15.5 0.00147 
Cheetah 13 3 53.50 20.5 0.00161 
Red Kangaroo 15 0 55.00 25.0 0.00110 
Capybara 13 0 55.00 15.1 0.00139 
Cougar 11 0 63.00 23.8 0.00133 
Reindeer 16 0 101.25 21.7 0.00141 
Harbor Seal 35 2 115.00 47.6 0.00267 
Tiger 17 2 119.70 26.3 0.00097 
Llama 18 0 140.00 28.9 0.00130 
Blue Wildebeest 25 0 164.50 24.3 0.00117 
Donkey 19 1 165.00 47.0 0.00093 
Lion 52 1 175.00 27.0 0.00097 
Moose 13 0 386.00 22.0 0.00088 
 
Table 1. Tumor incidence, mass, lifespan, and metabolic rate of zoo mammals. 
Necropsy data was collected by the San Diego Zoo over 14 years (Griner 1983). Body 
mass, maximum lifespan and mass specific basal metabolic rate (msBMR) were all 
obtained from the AnAge database (de Magalhães and Costa 2009). 
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DISCUSSION 
Previous to this study, Peto’s paradox lacked strong empirical evidence that cancer risk 
does not increase with body size or lifespan across species. Our analysis provides the first 
comprehensive survey across mammals in support of Peto’s paradox. The mammalian 
species we investigated span five orders of magnitude in size and one order or magnitude 
in lifespan. They range from the striped grass mouse at 51g and living only 4.5 years, to 
the African elephant weighing 4,800Kg and living for approximately 65 years (de 
Magalhães and Costa 2009).  We find no evidence of an increased cancer risk in larger, 
more long-lived animals. If anything, the regression lines show a trend of decreased 
incidence as the 𝑙𝑜𝑔 𝑚𝑎𝑠𝑠  ×  𝑙𝑖𝑓𝑒𝑠𝑝𝑎𝑛  increases, though no regression trends were 
statistically significant in either direction. We observe this across all combinations of 
features that we tested. The model for the relationship between cancer incidence and 
msBMR looks like it goes in the opposite direction of all other models; however this is 
because the larger animals have a smaller msBMR.  
Studies should continue to collect cause of death information for non-model 
organisms. Many of the species we analyzed had less than 20 specimens, but as these 
numbers increase we can gain a more comprehensive view of cancer prevalence across 
mammals and which species may harbor enhanced suppression compared to humans. 
These data suggest that there should no longer be a debate of whether or not Peto’s 
paradox exists; however, the challenge remains to explain the driving forces of this 
paradox, which we investigate in later chapters.  
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CHAPTER 3: COMPUTATIONAL MODELS OF CANCER INCIDENCE 
 
 
INTRODUCTION 
Computational methods are frequently used to model cancer incidence (Beerenwinkel et 
al. 2007, Calabrese and Shibata 2010, Martens et al. 2011, Do et al. 2013). Typically 
these models address questions involving cancer initiation and progression in humans. In 
this work, we used previously developed models of colorectal cancer incidence to ask a 
new question: what values of the parameters governing cancer incidence allow for the 
age-incidence of cancer to be similar across body sizes that differ by orders of 
magnitude?  
 Our goal was to explain Peto’s paradox using parsimonious models and gain 
insight into how evolution may have fine-tuned factors that greatly influence cancer risk, 
such as, mutation rate, cell division rate, and the number of hits required for 
carcinogenesis. We used two models, which are generally similar but differ in the 
dynamics of cell lineages. Both models maintain a constant population of size N and have 
non-overlapping generations, representing the cell dynamics of normal colon tissue. We 
first explored a simple algebraic model (Calabrese et al. 2004, Calabrese and Shibata 
2010), which assumes that mutations accumulate over time at a fixed rate determined by 
the number of cell divisions. Given a population of N cells, the model allows one to 
calculate the probability of a cell having the required number of mutations (k) to initiate 
cancer after d divisions (Figure 6A).   
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The second model is based on a Wright-Fisher process and was previously used to 
examine progression from a benign polyp to a malignant colorectal tumor (Beerenwinkel, 
Antal et al. 2007). A Wright-Fisher process differs from the previous model because it 
allows for cell lineage death (Figure 6B). Given a population of N cells in generation t 
with identical fitness, each cell has equal probability (1/N) of being the parent of any 
single cell in generation t+1. With probability 1  –    !! !, a cell from generation t will not 
have any progeny in generation t+1 and thus that the lineage will be completely 
eliminated from future generations. This model also has a constant mutation rate per cell 
division and defines cancer to be the accumulation of k mutations in one cell. 
 
Figure 6. Model representation of cancer progression. In the algebraic model (A) 
(Calabrese and Shibata 2010), cell lineages accumulate mutations over time, which are 
passed on to their daughter cell in the next generation and there is no cell death. In the 
Wright-Fisher model (B) (Beerenwinkel, Antal et al. 2007), cells gain mutations over 
time, but each lineage has a chance of dying and being eliminated from the population. In 
both models, cancer occurs when a cell accumulates k mutations. The single light blue 
cell represents the zygote to show that all cells came from a single initial lineage.  
 
A. B. 
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MODEL 1: ALGEBRAIC MODEL OF CANCER INCIDENCE 
Calabrese and Shibata devised a simple mathematical equation to express the probability 
of a human developing colorectal cancer given their age (Calabrese and Shibata 2010).  
Their equation produces results which closely match incidence data from the 
Surveillance, Epidemiology and End Results (SEER) database (SEER 2001). The 
probability of an individual developing colorectal cancer after a given number of stem 
cell divisions is 
p = 1-(1-(1-(1-u)d)k)Nm 
where u is the mutation rate per gene per division, d is the number of stem cell divisions 
since birth, k is the number of rate limiting mutations required for cancer to occur, N is 
the number of effective stem cells per crypt and m is the number of crypts per colon 
(Calabrese and Shibata 2010). 
The model also shows that the increased cancer risk observed in taller women in 
the SEER data set can be fit by simply increasing the parameter m to account for a larger 
colon (Calabrese and Shibata 2010). Using the same rationale, we varied the parameter m 
from 1.5 x 103 to 1.5 x 1010 to see how the total number of stem cells in the colon 
changes the lifetime (90 year) risk of developing colorectal cancer (Figure 7). Though we 
do not know exactly how the number of colonic crypts scales with body mass, estimates 
from human and mouse suggest that for every order of magnitude increase in body size, 
the number of crypts increase proportionally (see Methods). We used the same values as 
Calabrese and Shibata for all other parameters, which are listed in Table 2.  
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Parameter Value Definition 
u 3x10-6 Mutations/ongenic pathway/cell division 
d Age(days)/4 Divisions since birth (rate = 1 div./4 days) 
k 6 Rate liming mutations required for cancer 
N 8 Effective stem cells per crypt 
m [1500 – 1.5x1010] Crypts per colon 
 
Table 2. Model parameters. These parameters used for the algebraic model to see how 
colorectal cancer incidence scales with body size. Parameter values were taken from 
(Calabrese and Shibata 2010). The mutation rate assumes that there are three genes (1Kb 
each) per pathway and a background mutation rate of 10-9 mutations per base pair per cell 
division.  
 
If we use the blue whale as an example of an animal that is on the order of 1,000 
times the size of a human, where m could equal 1.5 x 1010 crypts, this model predicts that 
all blue whales would have colorectal cancer by age 90 (Figure 7A). More specifically, 
when we solve the equation for years zero through 90 we find over 50% of whales would 
have colorectal cancer by age 50 and all would have colorectal cancer by age 80 (Figure 
7C). The estimate for an animal 1,000 times smaller than a human (e.g. a mouse) is 
barely above zero even after 90 years. In reality, a mouse only lives a maximum of 4 
years (de Magalhães and Costa 2009), so based on this equation they should never get 
colorectal cancer. The chance of an individual person getting colorectal cancer by age 90 
is about 2.5% according to this model and 5.3% as reported by the American Cancer 
Society (ACS 2013). It is implausible that 100% of blue whales actually get colorectal 
cancer by age 80. Though we do not know how often blue whales are getting colorectal 
cancer, they have been reported to occasionally have other cancers (Martineau, 
Lemberger et al. 2002, Newman and Smith 2006) and can live for over 100 years (de 
Magalhães and Costa 2009). The poor fit of this model suggests that there is something 
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fundamentally different in the initiation and progression of cancer in large, long-lived 
animals compared to humans.  
 
Figure 7. Estimated risk of colon cancer relative to body size. The probability was 
calculated using the algebraic model with the parameters listed in Table 2 (Calabrese and 
Shibata 2010) (A). Blue dots for mouse, human and whale indicate the estimated risk of 
colon cancer occurring within 90 years of life given the approximate number of cells in a 
human colon, 1,000 times fewer cells to represent the mouse, and 1,000 times more cells 
to represent the whale. The red dot indicates the lifetime risk of colon cancer according to 
the American Cancer Society which is about 5.3% for men and women averaged together 
(ACS 2013). The estimated age-incidence of cancer for human and whale, given this 
model, is shown in plots B and C respectively. This figure is adapted from the publication 
(Caulin and Maley 2011) with permission from Elsevier.  
 
Next we investigated the set of parameter values that would allow the estimated 
age incidence of colorectal cancer in large animals to be similar to that of humans, which 
would match the empirical observation of Peto’s paradox (Chapter 2).  We tested 10,000 
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mutation rates ranging from 3.0x10-8 to 3.0x10-5 and solved for the value that minimized 
the difference between the estimates for human risk over 90 years and the calculated 
values for other species, given the number of colonic crypts. This analysis demonstrates 
that mere 3.2-fold decrease in mutation rate can account for a 1,000-fold increase in body 
size (Figure 8). The somatic mutation rates for an elephant and whale would need to be 
4.6x10-10 and 3.13x10-10 respectively, in order for them to each have the same age 
incidence of colon cancer as humans (Figure 7B). 
 
Figure 8. Estimated somatic mutation rates scaling with size. Mutation rate estimates 
show that a 3.2-fold decrease enables an animal that is 1000X larger than a human to 
have the same cancer risk. The mutation rates shown in the plot resulted in cancer risk 
predictions for the given number of cells that best matched the estimates for human (i.e. 
1.2x108 colonic stem cells).  
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Additionally we tested if altering the number of hits required for carcinogenesis 
(k) could allow cancer rates to be approximately equal across many orders of magnitude 
in size. Keeping all other parameters consistent with the values listed in Table 2, we 
varied k to range from 6-10. With 10 required hits, an animal 1000X larger than a human 
would have less than a 0.002% chance of getting cancer by age 90. However, just two 
extra hits (i.e. k=8) for an animal this size, gives the closet match to the human incidence 
curve (where k=6), and is slightly below with a lifetime risk of only 1.5%.  
Another hypothesis that has been proposed to explain Peto’s paradox involves 
changing the dynamics, or population size, of the dividing stem cells in structures such as 
crypts. With this model, we find that even if each crypt contained only one stem cell, a 
whale would still be predicted to have a lifetime colorectal cancer risk of 96%, so this is 
an unlikely solution to the paradox. However, changing the stem cell division rate from 
once every 4 days to once every 13 days for an animal with one thousand times more 
crypts than a human reduces the lifetime cancer risk to 2.2% and the age incidence line 
closely matches that of human.  
Though our modeling efforts here are simplistic, they are still informative. We 
can likely rule out the possibility of large, long-lived organisms having fewer stem cells 
per crypt to explain Peto’s paradox; however changing the division rate, mutation rate 
and number of required hits for carcinogenesis all seem feasible and the estimated values 
are in a normal biological range.  
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MODEL 2: WRIGHT-FISHER MODEL OF CANCER INCIDENCE 
Our previous implementation of the algebraic model (Calabrese and Shibata 2010) of 
colorectal cancer ignores many dynamics of the cell populations. We incorporated 
slightly more realistic behaviors by implementing an adapted version of a previously 
published Wright-Fisher based model, which allows for cell lineage death (Beerenwinkel, 
Antal et al. 2007). We have simplified the model to maintain a constant population of 
size N, where N represents the entire population of crypt stem cells in the colon. This 
allows us to greatly reduce the computational complexity and more easily compare the 
results to the algebraic model (i.e. Model 1). 
Using the same parameters that are in Table 2 and calculating colorectal cancer 
risk across orders of magnitude in stem cell number (i.e. body size), we find that the 
Wright-Fisher model provides a much lower estimate of lifetime risk. After 1,000 
simulations of a human colon, the 90-year cancer risk is only 0.4% and for 1000-times as 
many stem cells, representing a whale colon, just over 25% of individuals get colon 
cancer (Figure 9). These lower values are expected when using the same input as in the 
algebraic model because the incorporation of random cell lineage death lowers the 
probability of a cell becoming cancerous since it not only has to accumulate all k 
mutations, but it also must avoid being eliminated from the population. However, 25% is 
still an extremely high rate when only considering one cancer type (i.e. colorectal 
cancer). In humans, the lifetime risk of most individual cancers are well below 10% with 
the exception of breast (12.4%) and prostate cancer (16.2%) (ACS 2013).  
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We also notice that the lifetime risk of colon cancer seems to level off around 
25% for the largest species modeled (Figure 9). This inflection point is a consequence of 
the probability of losing a cell lineage becoming independent of population size when the 
population is sufficiently large in a Wright-Fisher model. As we explained in the 
beginning of this chapter, the probability that a given cell in generation t has no progeny 
in generation t+1 is equal to   1− !! !.  As N increases we can make the following 
approximation: 
lim𝑵→  ! 1− 𝒙𝑵 ! ~  𝒆𝒙 
Therefore, when N is sufficiently large, the probability of cell lineage death is 
independent of the population size and becomes a constant (e-1 ≈ 0.37), which likely 
explains why cancer risk levels off of N ≥ 1010 with this model. 
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Figure 9. Updated estimates of colon cancer risk relative to size. Risk was calculated 
by running 1000 replicates of the Wright-Fisher based model three independent times for 
each stem cell value (1.2x105 – 1.2x1011). According to this model and the parameters in 
Table 2, the human lifetime risk of colorectal cancer is 0.4% and 25.3% for an animal 
1000 times as large. 
 
As we had done with the previous model, we swept through different parameter 
values to find if the colorectal cancer incidence of whales could be lowered to match the 
estimate for humans. We show that just one additional required hit for colon cancer (i.e. 
k=7) can account for the risk due to the 1,000-fold increase in cell numbers. This one 
additional hit, which represents an extra pathway, decreases the lifetime risk of large 
animals, like whales, to 0.6% which closely matches the human estimate of 0.4% for k=6.  
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Decreasing the mutation rate for larger animals also greatly reduces their lifetime 
risk.  Given 1.2x1011 crypt stem cells, a rate of 1.3x10-6 mutations per oncogenic pathway 
per division decreases the lifetime risk of cancer to the same as humans. This is only a 
2.3 fold decrease from the value used to represent the human mutation rate in this model 
(compared to a 3.2-fold decrease we found in Model 1). Additionally, we show that this 
result can also be obtained by decreasing the cell division rate to once every 8.5 days. 
This results in a lifetime risk of 0.5% and a rate of one division every 9 days lowers this 
below the human estimate to 0.2%. However, decreasing the number of stem cells to be 
just one per crypt cannot sufficiently lower the risk to be comparable to humans, which is 
consistent with our results from the previous analysis.  
Under this model, we estimate what parameter values allow the lifetime risk of 
colorectal cancer to be roughly equal between human and an animal 1000 times as large. 
The results are similar to what we obtained from the algebraic model; however the 
numerical changes are less extreme because of the effect that cell lineage death has on the 
random chance of a cell accumulating the necessary carcinogenic mutations.  
  
METHODS 
Justification for Assuming Colon Crypt count Scales with Body Mass 
A human colon is on average 1.5 meters long and 6cm in diameter (Horton et al. 2000), 
which gives an approximate area of 3x103cm2 (i.e diameter x π x length). The total 
number of crypts is estimated to be 1.5x107 (Yatabe et al. 2001), so the crypt density is 
approximately 5,000 crypts per cm2. A mouse, which is 3 orders of magnitude smaller 
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than a human, has roughly 6cm2 of colon (6cm long and 0.3cm in diameter) (Pickhardt et 
al. 2005). Using the same crypt density, we calculate there to be approximately 3x104 
crypts in a mouse colon, which is the expected 3 orders of magnitude change.  
 
Algebraic Model 
The algebraic model, which we have repurposed to explore solutions to Peto’s paradox, 
was originally detailed in previous publications (Calabrese, Tavare et al. 2004, Calabrese 
and Shibata 2010). We use the same equation to calculate the risk of colorectal cancer 
given the age of the individual: 
p = 1-(1-(1-(1-u)d)k)Nm 
where u is the mutation rate per gene per division, d is the number of stem cell divisions 
since birth, k is the number of rate limiting mutations required for cancer to occur, N is 
the number of effective stem cells per crypt and m is the number of crypts per colon 
(Calabrese and Shibata 2010). We wrote a script in C to run through the model using 
ranges for each parameter and the results were plotted in R.   
 
Wright-Fisher Model 
Dr. Trevor Graham wrote the code that was adapted for this analysis for his own 
implementation of the Wright-Fisher model of colorectal cancer. The model in our 
analysis maintained a constant population size with non-overlapping generations where 
each cell of the new generation choses a parent cell to inherit its mutant status from. This 
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occurs with equal probability (1/N) because we are not considering selective coefficients, 
as to make it more comparable to the algebraic model and avoid using parameters that 
lack good experimental measurements. Given a population of N cells, the probability of a 
configuration of cells with 0 to k mutations at a given time (t+1) can be expressed using 
the following multinomial distribution: 
𝑁! 𝑡 + 1 ,… ,𝑁! 𝑡 + 1   ~    𝑁 𝑡 !𝑁! 𝑡 !…𝑁! 𝑡 ! 𝜃!!! !!!!!  
 
where Ni(t) is the population size of cells at time t with i mutations and 𝜃!  is the 
probability that a cell in generation t+1 will have j mutations: 
𝜃! =    𝑑 − 𝑖𝑗 − 𝑖!!!! 𝑢!!! 1− 𝑢 !!!𝜔!𝑥! 𝑡  
This has been formally detailed in the original publication (Beerenwinkel, Antal et al. 
2007).  In our implementation, each instance of the model represents one colon with N 
crypt stem cells. For each set of parameters, the model was run 1,000 times in order to 
estimate the frequency of cancer. We ran a minimum of three independent replicates of 
the 1,000 runs to make sure the number of cases reported to have cancer (i.e. contain k 
mutations) was consistent and we averaged across the replicates. R was used to visualize 
and plot the data.  
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DISCUSSION 
These models are not intended to accurately represent the complexity of neoplastic 
progression; however we can still gain insight into what hypotheses may feasibly explain 
the observation of Peto’s paradox. Interestingly, we find that the values that can resolve 
Peto’s paradox by decreasing the lifetime cancer risk in large organisms fall within 
normal biological constraints. We were most surprised by the seemingly small changes in 
mutation rate that can account for a thousand-fold increase in body size resulting in 
cancer rates equivalent to humans. Estimates of the human somatic mutation rate span 
orders of magnitude and range from 10-11 to 10-9 mutations/base/division (Chu et al. 1988, 
Loeb 1991, Strauss 1992, Drake et al. 1998, Jones et al. 2008). One study that derives 
somatic mutation rates from specific loci across eukaryotes finds that the per base 
mutation rates for human and mouse are 5.0 ×10-11 and 1.8 ×10-10 respectively (Drake, 
Charlesworth et al. 1998). This 3.6-fold decrease in mutation rate in human cells 
compared to murine cells is close to the results of our modeling, which suggest that a 2 to 
3-fold decrease in mutation rate can account for a 1000-fold increase in body size. This 
effective decrease in mutation rate may be accomplished by having better DNA repair, 
more efficient removal of mutated cells, or less endogenous damage as a result of a lower 
mass-specific basal metabolic rate (Caulin and Maley 2011). 
We were also able to resolve Peto’s paradox by increasing the number of rate-
limiting hits required for transformation and by reducing the rate of stem cell divisions. 
Both models show that with just 1-2 additional hits, the risk of cancer can be greatly 
reduced in large animals. Therefore, we might anticipate finding redundant pathways or 
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additional tumor suppressor genes that add robustness to existing pathways in animals 
that have evolved this tumor suppression mechanism to better combat cancer.   
To sufficiently decrease the lifetime risk of colon cancer in large animals like 
whales, we estimated that the division rate would be once every 8.5 days to once every 13 
days, depending on the model. Crypt stem cell in mice divide once a day (Snippert et al. 
2010); however human measurements are limited and are estimated to be at least once per 
week (Kang and Shibata 2013). Because we do not have accurate measurements for 
human, this result is more qualitative, but stresses that only small changes would need to 
occur in animals much larger than humans.  One could investigate this by measuring the 
mitotic index of colonic crypts across species spanning orders of magnitude in size. We 
obtained samples of dolphin and whale colon; however the tissue was too degraded for us 
to get accurate estimates.  
 Though we were able to use simple models to gain insight into a complicated 
disease; there are many assumptions that go into these models that we must acknowledge 
when interpreting the results. These models assume that all mutations are evolutionarily 
neutral. That is, they provide no selective advantage to the clone, and so do not drive a 
clonal expansion. The model also assumes a constant population size and a constant 
mutation rate. Additionally, all k mutations necessary for cancer are required to occur in 
one single cell, which ignores the possibility of cell cooperation (Axelrod et al. 2006) and 
does not address clonal expansions, which would drastically alter the time to accumulate 
the mutations (Nowell 1976). The Wright-Fisher model (Model 2) was originally 
developed to model one single crypt as it progresses from a benign polyp to an invasive 
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tumor (Beerenwinkel, Antal et al. 2007). We have expanded the initial cell population to 
represent all stem cells in the colon; however, this ignores the compartmentalization 
structure provided by crypts since it allows a cell to provide more offspring in the next 
generation than just the population size of a single crypt. This simplification was made to 
drastically reduce the computational complexity, otherwise to model one colon would 
require running the model on a single crypt stem cell population millions-billions of 
times and then repeating this 1,000 times to estimate the cancer incidence. Our approach 
enabled us to run the analysis in a reasonable amount of time and allowed for more direct 
comparisons with the algebraic model (Model 1), which also did not consider the effects 
of the crypt structure.  
 We did not run these models to find exact numerical values for each parameter in 
a whale, as these will likely all vary depending on the exact model being considered. 
Rather, the goal of this analysis was to gain theoretical insight into the most realistic 
hypotheses to resolve Peto’s paradox. We found that decreasing the mutation rate or 
division rate, or increasing the number of required hits can all sufficiently reduce the 
lifetime cancer risk in an animal orders of magnitude larger than a human; however 
decreasing the number of stem cells per crypts is not a likely solution. The necessary 
changes in the mutation rates and number of required hits are small and are well within 
biologically feasible ranges. These values could be the focus of future experiments 
designed to measure the somatic mutation rates and determine the number of pathways 
that must be mutated to transform cells across species that span a wide range of sizes. 
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CHAPTER 4: COPY NUMBER OF CANCER GENES IN MAMMALS 
 
 
INTRODUCTION 
Cancer-associated genes are generally divided into proto-oncogenes and tumor 
suppressor genes. Proto-oncogenes are defined as genes that increase the chance of 
progression to cancer when they are over-expressed or inappropriately activated 
(Adamson 1987). Tumor suppressor genes, on the other hand, are genes that increase the 
chance of progression to cancer when they are inactivated or deleted. Tumor suppressor 
genes often follow the ‘two hit hypothesis’ that requires both alleles to be mutated before 
causing a phenotypic change (Knudson 1971), though some are haploinsufficient such 
that inactivating a single allele is sufficient to cause a mutant phenotype.  
Tumor suppressor genes are sometimes further divided into “caretakers” and 
“gatekeepers” (Kinzler and Vogelstein 1997).  Caretakers help maintain genome integrity 
by preventing DNA damage and performing DNA repair. These functions evolved 
billions of years before multicellularity and are essential to all forms of life (Domazet-
Loso and Tautz 2010). Gatekeepers control cell proliferation and signaling by enforcing 
checkpoints to ensure that cells at risk for neoplastic transformation do not continue to 
propagate. They do this by forcing cells to withdraw from the cell cycle via senescence or 
undergo programmed cell death (i.e. apoptosis) if the caretakers cannot repair them 
properly (Campisi 2005). Gatekeepers generally act in the interest of the whole organism 
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and often are not beneficial to a single cell, so it may not be surprising that many of them 
evolved with the emergence of multicellularity (Domazet-Loso and Tautz 2010).  
 As discussed in Chapter 1, the addition of tumor suppressor genes and the 
elimination of proto-oncogenes (or potentially oncogenic pathways) have been proposed 
as hypotheses to explain Peto’s paradox. Additional tumor suppressors would provide 
robustness to the system and require a cell to accumulate a greater number of mutations 
in order to become malignant. Theoretically, gene duplication followed by persistence of 
a redundant function performed by each gene copy should not be evolutionarily stable 
because one gene can be altered without an immediate phenotypic consequence (Vavouri 
et al. 2008). However, the loss of redundancy in this case would lead to a cancer 
susceptible phenotype, and thus a reduction in fitness, allowing selection to maintain the 
redundant copies. It seems that functional redundancy is not simply a temporary result of 
gene duplication and can persist for many years after the duplication event. For example, 
the MAP1 and MAP2 genes, which are essential for cell proliferation, have both 
maintained duplicate functions in humans and yeast (S. cerevisiae), which diverged more 
than one billion years ago (Li and Chang 1995, Bernier et al. 2005). Though there may be 
no immediate phenotypic change if one copy of a duplicated tumor suppressor gene is 
deactivated, we predict that the selective pressure of increased cancer risk in large, long-
lived animals is strong enough to stably maintain the functional redundancy and enhance 
cancer suppression.  
The alternative to redundant tumor suppressor genes is the idea that the removal 
of proto-oncogenes or oncogenic pathways would minimize the number of vulnerabilities 
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within a cell and decrease the probability of an activating mutation occurring and 
promoting carcinogenesis. The ‘null oncogene’ hypothesis predicts that functional 
haploidy (meaning only one allele is active) at the loci of proto-oncogenes would reduce 
the risk of sporadic cancers (Davenport et al. 2002). Similarly, a decrease in cancer risk 
could also be achieved by removing some loci of proto-oncogenes so one could 
hypothesize that the number of proto-oncogenes in a genome might decrease as body size 
increases.  
Because large bodies arose independently multiple times throughout evolution, 
we have no reason to believe that the copy number of a specific gene would scale with 
body size, as each lineage likely evolved different mechanisms to suppress cancer. 
Therefore, our initial hypothesis was that tumor suppressor gene families would expand 
and the total number of tumor suppressor genes (or possibly just caretakers or 
gatekeepers) would increase with body size. We also investigated whether or not the total 
number of proto-oncogenes decreased with body size. In subsequent analyses, we 
focused on specific tumor suppressor genes to discover if any were amplified in at least 
one genome of a large, long-lived organism.  
 
EVOLUTION OF CANCER GENE FAMILIES IN MAMMALIAN GENOMES 
If the evolution of large, long-lived animals involved the genomic amplification of tumor 
suppressor genes, these would appear as expanded gene families in those organisms. We 
developed a genome-wide BLAST search intended to find all genes within a gene family 
based on one representative. For example, we could accurately identify the extensively 
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studied TP53 gene family (TP53, TP63 and TP73) across species as our positive control 
by using TP53 as the query gene. In order for a BLAST hit to be considered as an 
instance of the given gene family, we required that it pass several filters based on 
coverage, significance, function, and location (see Methods). We applied the BLAST 
search and filters to a highly curated set of 81 cancer genes to count the number of proto-
oncogenes and tumor suppressor genes in eight mammalian genomes. We did not find a 
positive correlation between body mass and the number of genome hits for any of the 
cancer gene categories (one example shown in Figure 10).  
 
Figure 10. Number of tumor suppressor genes across mammals. The number of 
tumor suppressor genes does not increase with body mass. Based on our BLAST search 
we find no positive correlation between tumor suppressor genes as a whole, or 
gatekeepers and caretakers together with body mass. This was tested with a linear 
regression and is true on both the linear and log scale. The log (base 10) of the mass in 
grams is shown here to ease visualization of the range of masses.  
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Though we did not find a positive correlation between body mass and the number 
of TSGs as we had predicted, there is a week negative correlation with the number of 
gatekeeper genes (r2 = 0.66, p-value = 0.015) and proto-oncogenes (r2 = 0.51, p-value = 
0.047). The relationship is also true for the combination of gatekeepers and caretakers; 
however, caretakers alone do not show any significant correlation with mass (r2 = 0.27, p-
value = 0.10). The negative association is driven solely by the lower counts found in cow 
and is completely abolished if the cow data point is removed from the analysis. 
Interestingly, we found a strong correlation between the number of proto-oncogene and 
gatekeeper hits, which seems independent of size (r2 =0.85, p-value < 0.001) (Figure 11). 
We do not find this relationship between proto-oncogenes and caretakers (r2 = 0.13, p-
value = 0.36). Next we tested if any of the cancer gene categories correlated with lifespan 
or the product of mass and lifespan, since these features are highly correlated; however 
we found no significant relationships.  
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Figure 11. Correlation between proto-oncogenes and gatekeepers. There is a strong 
linear correlation between the number of proto-oncogenes and gatekeepers. Based on our 
BLAST search for cancer-gene families, the number of proto-oncogenes and gatekeepers 
found in a genome are highly correlated (r2 =0.85, p-value < 0.001). Cow is the largest 
animal shown and has the lowest number of both gene types, though the rest of the data 
points are not in order of size.  
 
 
COPY NUMBER OF TUMOR SUPPRESSOR GENES IN MAMMALS 
Our BLAST analysis above is not sensitive enough to pick up small changes in individual 
gene copy numbers so we undertook a follow-up analysis to examine the copy number of 
specific tumor suppressor genes in mammals. We focused on increased copies of tumor 
suppressor genes since it is difficult to confirm a gene deletion in draft genomes due to 
possible incompleteness and misassemblies.  
 We used a comprehensive list of 830 human tumor suppressor genes (Higgins et 
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Ensembl BioMart (version 72). Genes that were found to have a “one:many” relationship 
to the human tumor suppressor gene in at least on mammal were considered for 
downstream analysis. Our results revealed that 382 of the genes (46%) have at least one 
species with one or more additional orthologs to the human gene; though often these are 
listed in the database as “apparent orthologs” and are not high confidence calls. Only 
11% of the genes (99) have 3 or more paralogs in at least one mammal and this decreases 
to a set of 36 genes (4.3%) when we filter on a minimum of 4 copies of a gene. To limit 
false positives due to the unknown certainty of low copy number increases, we focused 
on the instances of extreme gene amplification. We found that 19 tumor suppressor genes 
had five or more paralagous genes (i.e. at least 4 extra copies relative to the human 
genome) (Table 3). Some genes in the list (e.g. IL6 and CTGF) are perhaps better known 
for oncogenic activity; however, they are included in the list of 830 genes because there 
are published reports of them demonstrating tumor suppressive behavior in certain tissues 
(Higgins, Claremont et al. 2007). 
 Our results show a number of interesting outliers with evidence of massive gene 
amplification (Table 3). The most extreme case is the FBXO31 gene in the microbat 
(Myotis lucifugus) with 63 annotated copies. No other mammalian genome in the 
Ensembl database has more than one copy of this gene; however, the recent publication 
of the Brandt’s bat (Myotis brandtii) genome reveals 57 copies of FBXO31 (Seim et al. 
2013). This gene encodes an F-box protein that mediates the DNA damage response by 
promoting the degradation of Cyclin D1 through polyubiquitination to induce cell cycle 
arrest in G1 (Santra et al. 2009). Though the microbat is only 10g, it can live up to 34 
years (de Magalhães and Costa 2009) so one hypothesis is that these additional tumor 
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suppressors may decrease the cancer risk of the bat, that would otherwise be heightened  
by their increased longevity (Danilov et al. 2013).  
 
Gene	   Common	  Name	   Scientific	  Name	   Copy	  #	  
FBXO31	   Microbat	   Myotis	  lucifugus	   63	  
TP53	   African	  elephant	   Loxodonta	  africana	   12	  
IL6	   Tree	  shrew	   Tupaia	  belangeri	   12	  
LCN2	   Guinea	  pig	   Cavia	  porcellus	   12	  
CTGF	   Lesser	  hedgehog	  tenrec	   Echinops	  telfairi	   9	  
ING4	   Rock	  hyrax	   Procavia	  capensis	   9	  
ALOX15	   Microbat	   Myotis	  lucifugus	   8	  
MAL	   Horse	   Equus	  caballus	   8	  
MSMB	  
	  	  
Opossum	   Monodelphis	  domestica	   8	  
Guinea	  pig	   Cavia	  porcellus	   6	  
AKR1B10	   Rat	   Rattus	  norvegicus	   7	  
LIF	  
	  	  
Rock	  hyrax	   Procavia	  capensis	   7	  
African	  elephant	   Loxodonta	  africana	   5	  
TCEB2	   Rat	   Rattus	  norvegicus	   7	  
TNFRSF10A	   Pig	   Sus	  scrofa	   7	  
TNFRSF10B	   Pig	   Sus	  scrofa	   7	  
AKR1B1	   Rat	   Rattus	  norvegicus	   6	  
SLIT2	   Cat	   Felis	  catus	   6	  
CST5	   Rat	   Rattus	  norvegicus	   5	  
IFNB1	  
	  	  
Cow	   Bos	  taurus	   5	  
Squirrel	   Ictidomys	  tridecemilineatus	   5	  
S100A11	   Bushbaby	   Otolemus	  garnettii	   5	  
 
Table 3. Tumor suppressor genes amplified in non-human mammals. This list 
includes all tumor suppressor genes that we found to have at least four additional copies 
(i.e. 5 total copies) in mammalian genomes based on the “1:many” ortholog annotation 
provided by Ensembl.  
 
The second highest gene copy number we came across was 12 which included 
TP53, IL6 and LCN2. Because the focus of this work is on Peto’s paradox, the 12 copies 
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of the canonical tumor suppressor gene TP53 in the African elephant stood out as the 
most interesting. TP53 is mutated in the majority of human cancers and plays a crucial 
role in multiple tumor suppressive pathways including apoptosis, senescence and DNA 
repair (Hollstein et al. 1991). Redundant copies of this gene could greatly reduce the risk 
of tumorigenesis and has been experimentally shown in mice (García-Cao, García-Cao et 
al. 2002). Chapter 5 will discuss the amplification of TP53 in the African elephant in 
detail.  
  Additionally, the African elephant genome has 5 copies of LIF (leukemia 
inhibitory factor). LIF is a target of p53 and can induce cell differentiation in immune 
cells (Gearing et al. 1987). However, the closest sequenced relative to the African 
elephant, the hyrax (Procavia capensis), has 7 copies of LIF. When we looked at the 
mammals with less than 5 copies, we found that the lesser hedgehog tenrec (Echinops 
telfairi) also has 3 copies of the gene so we can assume that this amplification occurred 
before the speciation of these animals within Afrotheria and, though it may be 
biologically interesting, it is not likely an explanation to Peto’s paradox. 
The other species listed in Table 3 that are of interest include the horse (Equus 
caballus) and cow (Bos taurus). The horse draft genome (EquCab2) has 8 orthologs to 
the human tumor suppressor gene MAL, which are located in tandem on scaffold 15. The 
only other species in the database with any duplicate copies is the microbat with a total of 
two MAL loci. This gene is involved in T-cell differentiation (Alonso and Weissman 
1987) and apical transport of membrane and secretory proteins (Cheong et al. 1999, 
Puertollano and Alonso 1999). Down regulation of this gene has been linked to multiple 
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epithelial cancers, including colon, cervical and esophageal (Mimori et al. 2003, Lind et 
al. 2008, Horne et al. 2009). The tumor suppressive properties of MAL have been verified 
in head and neck squamous cell carcinoma where the decrease of expression is associated 
with tumorigenesis and the exogenous expression of MAL decreased cell proliferation 
and increased apoptosis (Cao et al. 2010). 
The final gene from our analysis with more than four copies in a large organism is 
IFNB1 found in the cow.  This gene belongs to the class of interferon genes known for 
their role in triggering the immune response to eradicate pathogens and tumor cells 
(Siegal et al. 1999, Takaoka et al. 2003). However, we also see the same number of 
redundant copes (5) in the squirrel genome and 2 copies (i.e. 1 extra copy) in the guinea 
pig, horse and hyrax genomes, which makes it less likely to be directly involved with 
enhanced tumor suppression in large, long-lived animals.  
 
METHODS 
BLAST Analysis for Gene Family Expansions 
Curation of the cancer gene list was performed by Dr. Li-San Wang. We retrieved protein 
sequences of more than 300 genes from the Cancer Genome Anatomy Project (CGAP) 
website (Riggins and Strausberg 2001).  We focused on genes with either oncogene (22 
genes) or tumor suppressor (59 genes) classifications by CGAP. Other genes were 
classified as partners of fusion genes by CGAP, and were excluded from our analysis.  
We further divided the tumor suppressor genes into two groups: caretakers (CT; 28 
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genes) if the gene had gene ontology annotations suggesting their functionality in DNA 
damage repair; otherwise genes were classified as gatekeepers (GK; 31 genes).  We used 
the NCBI gene ontology annotation for human, and checked for each gene if it is 
associated with a gene ontology term (or a descendant of such term in the gene ontology 
hierarchy) having “DNA damage” or “DNA repair” in its description. 
Genomes from the NCBI RefSeq database were used as BLAST databases against 
the 81 human cancer related query genes in order to count the number of total hits in each 
genome. We limited the analysis to fully sequenced mammals: cow, chimp, dog, horse, 
macaque, mouse, opossum and rat. For a BLAST hit to count as an independent instance 
of that gene in a given genome it had to meet our criteria of coverage, significance, 
location, reciprocity and functionality. First, the union of all hits to that sequence in the 
subject's genome must cover at least 50% of the human query gene. Second, one of the 
BLAST hits in this region must have an e-value ≤ 10-5 and all other hits counting towards 
the 50% coverage must have e-values ≤ 10-3. Third, the BLAST hit must be greater than 
1Mb away from any other determined location of the query gene in the given subject 
genome.  The location of hits for each organism, based on these criteria, was used as 
input into the UCSC Genome Browser to retrieve the predicted protein sequences 
determined by the N-SCAN algorithm. These sequences were then used for a reciprocal 
BLAST back to human RefSeq protein sequences (release 37). In order for a region to 
count as a true hit in a non-human species, the predicted protein sequence must return a 
top hit in the human genome that is either the original human query gene that produced 
that hit, or a paralogous gene. Paralogs were defined by the Ensembl Genome Browser 
 58 
(Release 56). N-SCAN was also used to determine the functionality of the genomic 
regions to exclude known pseudogenes and intergenic regions that were not predicted to 
be genes. These criteria were determined by comparison of our results to known p53 gene 
families (as reported by Ensembl release 56) as a positive control. The numbers of hits 
for each of the 81 individual genes were tallied as proto-oncogenes, caretakers and 
gatekeepers for each organism.  
Body mass data (Smith 2003, de Magalhães and Costa 2009) and the evolutionary 
distance from humans was taken from the literature (Chen and Li 2001, Patterson et al. 
2006, Bininda-Emonds et al. 2007, Gibbs et al. 2007, Murphy et al. 2007). We fit a linear 
regression model to the data using the statistical package R to determine the relationship 
between the number of each gene type (proto-oncogenes, caretakers, and gatekeepers) 
and the animals’ body mass (representing the total number of cells in the organism). We 
tested this on both a log and linear scale.  
 
Determining Copy Number of Tumor Suppressor Genes 
A list of 830 tumor suppressor genes was downloaded from the Memorial Sloan 
Kettering CancerGenes database (Higgins, Claremont et al. 2007). This list includes all 
genes that have been associated with tumor suppressive behavior in at least one instance 
and have been assigned Gene Ontology terms related to these functions such as ‘positive 
regulation of apoptosis’ and ‘negative regulation of cell proliferation’.  Genes appear in 
this list regardless of whether or not they also have been reported to have oncogenic.  
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We obtained the orthologous relationships for 36 non-human mammals from 
Ensembl BioMart (version 72): alpaca, armadillo, bushbaby, cat, chimpanzee, common 
shrew, cow, dog, dolphin, African elephant, ferret, gibbon, gorilla, guinea pig, hedgehog, 
horse, kangaroo rat, letter hedgehog tenrec, macaque, marmoset, megabat, microbat, 
mouse, mouse lemur, opossum, orangutan, panda, pig, rabbit, rat, rock hyrax, sloth, 
squirrel, tarsier, Tasmanian devil, and tree shrew. 
 Genes that were found to have a “one:many” relationship, as annotated by 
Ensembl, to the human tumor suppressor gene in at least on mammal were considered for 
downstream analysis. The top genes were filtered based on the maximum number of 
times they occurred in any one species. All genes in Table 3 occurred at least 5 times in 
the species indicated. 
 
 
DISCUSSION 
We have analyzed the overall number of cancer-associated genes (divided into proto-
oncogenes, gatekeepers and caretakers) in addition to a more detailed study of the copy 
number of individual cancer genes across 36 mammals. Our data does not support our 
initial hypothesis that the total number of tumor suppressor genes would increase 
proportional to body mass. Instead we see a trend in the opposite direction, where larger 
animals have fewer proto-oncogenes and gatekeepers. The association is eliminated if the 
cow is removed from the analysis. This may indicate that the correlation is an artifact of 
the cow draft assembly, though it is possible that the genome truly has fewer tumor 
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suppressors and proto-oncogenes compared to the other species. The correlation between 
the number of gatekeeper and proto-oncogenes suggests that there has been selection to 
balance the risk of the addition of an oncogene with the addition of a gatekeeper gene. 
This could also be evidence of the elimination of potentially oncogeneic pathways as 
discussed in Chapter 1 (Figure 2C).  
A major caveat in this study is the difficulty in verifying a true gene deletion in a 
draft genome in the presence of incomplete assemblies, misassemblies, and inaccurate 
annotations. There may also be missing cancer genes in non-human species with little 
homology to the human gene sequences. However, we had added the time since the most 
recent common ancestor with human to our linear model and this did not change any 
results. Human tumor suppressor genes were used for this analysis, but in doing so we 
made the assumption that they perform the same function in the other species, which 
have not been experimentally verified. Additionally, we limited ourselves to these known 
tumor suppressor genes, but there may be additional genes acting as tumor suppressors in 
other species that would have been missed, in addition to possible flaws in our filtering 
criteria that could cause some genes to be missed. As an example, we set requirement that 
in order for two hits to be considered as separate instances of a query gene, they had to be 
at least 1Mb apart; however, if a gene were duplicated in a tandem repeat, we would 
likely only count as one copy. 
Despite these limitations, we find a few genes that have been dramatically 
amplified in specific mammalian genomes, the most interesting of which is the discovery 
of 12 TP53 copies in the genome of the African elephant genome. Another potentially 
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interesting gene in terms of Peto’s paradox MAL which is found to have 8 copies in the 
horse genome and 2 in microbat. This could be an example of convergent evolution 
where a large animal (horse) and a small, long-lived animal (microbat) that both evolved 
extra copies of the same gene to overcome their increased risk of cancer. Further analysis 
and experimentation would need to be performed in order to determine the function of 
these copies and whether or not they provide enhanced suppression of carcinogenesis.   
We chose to pursue the TP53 amplification in the elephant to verify that their 
presence in the draft genome is not due to sequencing errors or misassemblies, and search 
for evidence of functionality. This work will be detailed in Chapter 5. Analyses such as 
this one are able to identify potentially interesting genes that may have a role in enhanced 
tumor suppression of large and long-lived organisms, and as more genomes become 
available gene amplifications in other species of interest can be brought to light for 
further investigation.  
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CHAPTER 5: AMPLIFICATION OF TP53 IN AFRICAN ELEPHANTS 
 
 
INTRODUCTION 
There is selection upon the life history of organisms to suppress cancer long enough to 
maximize successful reproduction (Kirkwood 2005, DeGregori 2011). Selection has led 
to more effective cancer suppression in humans compared to mice, and more effective 
cancer suppression in elephants and whales compared to humans. However, the question 
still remains, how do large, long-lived animals suppress cancer better than smaller 
animals with shorter lifespans? Our results discussed in Chapter 4 suggest one possible 
mechanism of elevated cancer suppression: amplification of TP53. 
TP53 (encoding protein p53) is a crucial tumor suppressor gene mutated in the 
majority of human cancers (Hollstein, Sidransky et al. 1991). Sometimes called the 
“guardian of the genome” (Lane 1992), p53 might be better known as the “Achilles heel 
of the genome.” Many critical signaling pathways require p53, including DNA repair, 
apoptosis and cellular senescence (reviewed by (Ko and Prives 1996)). Inactivation of 
this protein can lead to suppression of apoptosis, increased proliferation, genomic 
instability, invasion and metastasis, four of the hallmarks of cancer (Hanahan and 
Weinberg 2011, Solomon et al. 2011). People lacking a functional copy of the TP53 gene 
due to inherited germline mutations have Li-Fraumeni Syndrome.  They have more than a 
90% lifetime risk of cancer and are often diagnosed with multiple primary tumors (van 
Meerbeeck 1979, Gonzalez et al. 2009, Testa et al. 2013). Evolution appears to have left 
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an extreme vulnerability to cancer in our genomes. Additional functional copies of TP53 
would provide robustness that could help prevent carcinogenesis by increasing the 
number of mutations required to lose normal p53 function. In fact, mice genetically 
engineered to have extra copies of TP53 show significant reductions in cancer (García-
Cao, García-Cao et al. 2002). 
 
VALIDATION OF TP53 AMPLIFICATION IN AFRICAN ELEPHANTS 
In the previous chapter, we found that the African elephant (Loxodonta africana) genome 
contained 12 TP53 paralogs, according to the Ensembl database homology annotations. 
Further analysis, based on the alignments from the UCSC Genome Browser, revealed 20 
copies of the tumor suppressor gene TP53 in the draft genome LoxAfr3. We observe a 
large number of TP53 copies reported in both Ensembl (12 protein coding copies and 1 
pseudogene; release 72) and GenBank (1 protein coding copy and 19 pseudogenes) 
(Table 4). Apart from the differing numbers between the two databases, the automated 
gene annotations used by Ensembl predicted some abnormally short introns in the genes 
annotated as protein coding (e.g. 2 nucleotides), with only one copy having a gene 
structure comparable to that of TP53 found in all other mammals (referred to hereafter as 
the ancestral copy). The other 19 copies, annotated as pseudogenes by GenBank, lack 
introns, which suggests they are a result of retrotransposition (referred to hereafter as 
retrogenes or processed copies).  
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We directly resequenced these multiple copies in order to verify their presence in 
the African elephant genome. Initially, PCR primers were uniquely designed for each 
copy (based on the 12 Ensembl TP53 protein coding paralogs discussed in Chapter 4) and 
the products were sequenced. However, due to their high similarity, when the product 
was run on a gel and the target size bands were extracted, we found that each primer set 
amplified multiple retrogenes (Figure 12).  
We overcame this challenge by cloning the TP53 loci and sequencing 192 clones, 
which enabled us to confirm the presence of 18 retrogenes (GenBank accessions 
KF7185855-KF715872), all supported by multiple clones (Figure 13). Primers were 
chosen in conserved flanking sequences around the retrogenes to amplify approximately 
2Kb fragments from each genomic location. Transformed colonies were picked, then the 
2Kb fragment was amplified and linearized by PCR and purified for Sanger sequencing. 
We assembled full-length sequences of the inserted fragment for each clone that yielded 
quality sequence from all sequencing primers spanning the region. The cloned sequences, 
in addition to the published sequences, were aligned with MUSCLE (Edgar 2004) and 
this multiple alignment was used to construct a maximum likelihood phylogeny to 
determine the number of TP53 copies that we were able to capture (Figure 13).  
Eleven of the 18 sequenced retrogenes are similar but not identical to previous 
GenBank copies (Table 4). There was no evidence for eight of the published processed 
copies, which may be due to under-sampling of clones, misassembly in the published 
genome, or differences between individual elephants. An additional seven cloned 
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sequences have support from multiple clones but are not found in either database. There 
may also be additional copies of TP53 in the genome that were missed by our primers. 
 
Figure 12. PCR products for 12 TP53 copies in the African elephant. Primers for each 
of the 12 TP53 copies annotated as protein coding genes by the Ensembl database (Table 
4) were used in an attempt to amplify the different copies. PCR gave the expected sizes 
(A) and the bands were excised and sequenced. The sequence traces revealed a mix of 
retrogene copies present in each band. Here we show an example of the PCR product (top 
row of the alignment) from primers designed to capture the Ensembl gene 
ENSLAFG00000027820 (outlined by a black rectangle) aligned to the 12 Ensmebl 
sequences (B).  The sequence trace below the alignment shows the heterogenous 
positions due to the mixture of loci in the sequencing reaction.  
 
The percent identities of the pairwise alignments of each processed copy to the 
coding sequence (CDS) of the ancestral TP53 copy range from 85-88%. The GenBank 
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CACTGT CCCCAGMAGCRGAGGCAGTAGACRAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAG
CACTGT CCCCAGMAGCAGAGGCAGTAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAG
CACTGT CCCCAGMAGCRGAGGCAGTAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAG
CACTGT CCCCAGMAGCAGAGGCAGTAGACRAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAG
CACTGT CCCCAGMAGCRGAGGCAGTAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAG
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CCCT CACTGT CCCCAGMAGCRGAGGCAGTAGACRAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGAAGCCYC- - - - - - - - - - - - - - - T ACACT - - - - -
CCCT CACTGT CCCCAGAAGCGGAGGCAGTAGACAAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGAAGCCCC- - - - - - - - - - - - - - - T ACACT - - - - -
CT CT CACTGT CCCCAGCAGCAGAGGCAATAGACGAT CTACTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAGTAT CAGAAGCCCC- - - - - - - - - - - - - - - T ACACT - - - - -
CCCT CACTGT CCCCAGCAGCGGAGGCAGTAGATGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGAAGCCCC- - - - - - - - - - - - - - - T ACACT - - - - -
CT CT C A T ACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGC A GCTG CT CA G A TAT CAGAAGCCCC- - - - - - - - - - - - - - - T ACACT - - - - -
CCCT CACTGT CCCCAGCAGCGGAGGCAGTAGT CAAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGGTGGGGCT CAAGGAATAT CAGAAGCACC- - - - - - - - - - - - - - - T ACACT - - - - -
CCCT CACTGT CCCCAGCAGCAGAGGCAATAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGAAGCCT C- - - - - - - - - - - - - - - T ACACT - - - - -
CCCT CACTGT CCCCAGCAGCAGAGGCAATAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGACTAT CAGAAGCCT C- - - - - - - - - - - - - - - T ACACT - - - - -
CCCT CACTGT CCCCAGCAGCAGAGGCAGTAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGAAGCCCC- - - - - - - - - - - - - - - T ACGCT - - - - -
CT CT CACTGT CCCCAGCAGCAGAGGCAGTAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGAAGCCCC- - - - - - - - - - - - - - - T ACGCT - - - - -
CCCT C G T ACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGGCTAGAAAGC A GCTG CT CA G A TAT CAGCAGCCCCTGCACCAGCCACCCT TACACC- - - - -
CCCT CACTGT CCCCAGCAGCGGAGGCAGTAGACGAT CTGCTACT CCCAGAAGATGCTGCAGACTGCCTAGAAAGCCAAGCTGGGGCT CAAGGAATAT CAGCAGCCCCTGCACCAGCCACCCT TACACC- - - - -
CCCACACTACCCCCGGCAGTGGAGGTCATGGACGAT CTGCTACT CT CAGAAGACACTGCAAACTGGCTAGAAAGCCAAGTGGAGGCT CAGGGAATGT CCACAACCCCTGCACCAGCCACCCCTACACCGGTGG
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
T GT TAGGGTCCAT CCAGTAGGGGCAGAGGCT T T CT CCTGCT T CT TACT TGACCT CCCTACAACCT TATGAGGTATGCAGAGAAGGTGGGT TAT T CCCAT T CCACAGT TGAGGAAACTGAGGCT TACAGAGGCT
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
T GACACACAAAATGCTAT T T T CT T CT TGGCTGCT T TGCCTGCAAT TAGGGTACT TACCAT CAGGGGGCAGTGGTGGCT CAGAGACAATGGCT T T TGGT CATAACT T CAGAATAT CAGCT TGTACAAT TGTACA
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A. 
B. 
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sequence (gi:100663725) was used over the Ensembl prediction for the ancestral copy 
because it showed higher homology to other mammalian p53 sequences and had the 
expected exon structures. Within the processed copies, the percent identity ranges from 
86-99% based on all pairwise alignments. The copies cluster into two groups of closely 
related paralogs: 6 in one cluster (Group A) and 12 in the other (Group B) (Figure 
13).  Between groups A and B the average percent identity is approximately 88% and 
within groups the percent identity is greater than 95% on average.  
Additionally, we find evidence of conservation within the sequences flanking the 
retrogenes. The 574bp downstream of the suspected stop codon range from 83-86% 
conservation between the retrogene sequences and the 574bp downstream of the ancestral 
coding sequence. Pairwise comparisons of retrogenes show that the 260 bases 5’ to the 
assumed start codon are not as highly conserved between the retrogenes and the ancestral 
copy and have percent identities ranging from 57-61%. However, the 14 bases 
immediately 5’ of the start codon are conserved with 100% identity across all 18 
retrogenes and the ancestral gene. The transcript of the ancestral TP53 in the African 
elephant has yet to be sequenced and annotated so the boundaries for the 5’ and 3’ 
untranslated regions (UTRs) are currently unknown. Upon further analysis of the 5’ and 
3’ sequences, we discovered that each copy is sandwiched between two mammalian 
interspersed repeats (MIRs), as annotated by RepBase, which may play an important role 
in how this gene has increased its copy number in the elephant genome.  
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Figure 13. Phylogeny of TP53 clones in the African elephant. The African elephant 
genome has at least 19 copies of TP53. Capillary sequencing of retrogene clones reveals 
18 distinct clusters of processed TP53 copies (shown as colored blocks numbered 1-18) 
in a maximum likelihood phylogeny. The genes split into two main groups (labeled 
Group A and Group B). The sequenced clones are shown as black circles and published 
sequences from GenBank are shown as red squares. The branch labeled ‘elephant’ is the 
coding sequence of the ancestral TP53 and ‘hyrax’ represents the coding sequences from 
the hyrax TP53. 
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We sought to determine when in evolutionary time the processed retrogene copies 
of TP53 were introduced into the elephant. The hyrax (Procavia capensis) is the most 
closely related species to the African elephant with a sequenced genome and contains 
only one copy of TP53 based on the draft genome proCap1. These lineages diverged 
between 54 and 65 million years ago (Eizirik et al. 2001, Kitazoe et al. 2007), placing a 
rough upper bound on the age of the introduction of the processed TP53 sequences.  
 
EVIDENCE OF TRANSCRIPTIONALLY ACTIVE RETROGENES 
Next we tested if the extra processed copies of TP53 could contribute to cancer resistance 
in elephants and thus help to explain the phenomenon of Peto’s paradox. RNA was 
collected from treated and untreated PBMCs at various time points. The RNA samples 
were treated with DNase I and reverse transcribed with poly-T primers to create cDNA 
for downstream analyses. Primers were designed to distinguish the processed p53 copies 
from the ancestral sequence by spanning a region where Group A and B processed genes 
had different length deletions relative to each other. We performed PCR on the cDNA to 
look for presence of the retrogene transcripts. The primers allow for some degenerate 
binding and do not match all of the copies exactly, but if they were to bind and form 
products the ancestral copy, group A and group B of the processed genes would be 214, 
201 and 185 base pairs long, respectively. The primers have highest identity to the 
retrogenes and after running a 1.5% agarose gel with the PCR products we see two bands, 
one at size 201bp and one at 185bp (Figure 14). The forward primer is located in the 
homologous region spanning exon two and three and the reverse primer is in exon three 
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which eliminates the possibility of the multiple products being from different isoforms of 
the ancestral TP53 transcript. The bands were excised from a 10% polyacrylamide gel, 
which gave better separation when compared to agarose, and sequenced with Sanger 
sequencing to verify the copies (Figure 15). It was difficult to get a perfect cut separating 
the two bands with no contamination of one band to the other, so the sequence traces 
have some noise, likely from carry-over of the other PCR product. However, in instances 
where the sequencing is clean, it does appear that there are multiple retrogenes expressed 
from both group A and group B because we can pick up heterogeneous positions that 
correspond to the expected sequences of the various copies.  
A.                B.      
          
Figure 14. PCR products of TP53 transcripts. The	   p53	   retrogenes	   are	   actively	  transcribed.	  RNA	  isolated	   from	  irradiated	  and	  non-­‐irradiated	  elephant	  PBMCs	  was	  treated	  with	  DNase	   I,	   reverse	   transcribed	  with	   poly-­‐T	   primers	   and	  PCR	   amplified	  with	   primers	   to	   distinguish	   the	   two	   groups	   of	  TP53	  retrogenes	   (groups	   shown	   in	  
Figure 13)	  from	  the	  ancestral	  transcript.	  Shown	  here	  is	  the	  PCR	  product	  from	  cDNA	  prepared	   from	   the	   RNA	   sample	   at	   5hr	   after	   treatment	   with	   2Gy	   IR	   run	   on	   1.5%	  agarose	   (A)	   and	   10%	   polyacrylamide	   (B)	   for	   better	   separation	   and	   clarity	   of	   the	  bands.	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Figure 15. Capillary sequencing of excised gel bands from PCR of elephant cDNA. 
The above alignment is a screenshot from Seaview showing a segment of the ancestral 
TP53 coding sequence, retrogene sequences from groups A and B and the aligned PCR 
product sequences (outlined by black rectangles) from the gel bands that were excised 
from the 10% polyacrylamide gel (Figure 14). This is evidence that retrogenes from both 
groups are actively transcribed. The sequences traces are shown below with the red box 
indicating the region that is deleted from the retrogenes in Group relative to those in 
Group A. 
 
We were able to verify that at least a subset of the retrogenes were actively 
transcribed, so we ran qPCR in hopes of quantifying the total expression of TP53. 
Unfortunately, we were unable to design successful Taqman probes that could 
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differentiate between the retrogenes and the ancestral transcripts. We exposed both 
elephant and human peripheral blood mononuclear cells (PBMCs) to 2Gy gamma-
irradiation to try and induce higher expression of TP53.  qPCR was performed on RNA 
from the treated (2Gy IR) and untreated cells at time points 1hr, 5hr, 18hr and 24hr after 
exposure. TP53 primers for the elephant samples were designed for the ancestral 
transcript only. We find no change of mRNA expression in human or elephant in 
irradiated cells compared to untreated cells. This is consistent with previous work 
showing that p53 is regulated at the protein level in response to DNA damage, thereby 
maintaining average levels of transcription (Giaccia and Kastan 1998). We performed a 
coupled in vitro transcription/translation assay to test if the retrogenes were able to 
produce proteins; however we did not find any evidence of successful translation.  
 
APOPTOTIC RESPONSE TO GAMMA-IRRADIATION IN ELEPHANT CELLS 
We hypothesized that if the extra copies of TP53 are functional, elephant cells would 
either undergo more efficient DNA repair or have a higher rate of apoptosis compared to 
human cells when exposed to DNA damage. Better DNA repair would result in fewer 
somatic mutations while undergoing apoptosis in cells deemed ‘too damaged to repair’ 
prevents any mutations from that cell from being propagated through future generations. 
We collaborated with Dr. Joshua Schifman and Ashley Chan at the University of Utah to 
investigate radiation-induced apoptosis in elephants. We found that African elephant 
PBMCs apoptose at significantly elevated rates compared to human cells when exposed 
to γ-IR (Figure 16).  PBMCs isolated from fresh African elephant blood, were exposed to 
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2Gy IR. Cells were stained with DAPI at different time points after exposure (1hr, 5hr 
and 24hr) and apoptotic cells were visualized and counted under the microscope. We 
analyzed the proportion of apoptotic cells at each time point in both treated and untreated 
samples. The difference of these two proportions (treated – untreated) was calculated 
along with the standard error of the difference. We tested if there was a significant 
difference in the amount of apoptosis in elephant when compared to human (see Methods 
for details). By 24 hours after 2Gy IR treatment, significantly more elephant cells had 
undergone apoptosis compared to human cells (Figure 16A).  
 
 
Figure 16. Elephant PBMCs are hypersensitive to gamma irradiation. Cells	   were	  stained	   with	   DAPI	   and	   apoptotic	   cells	   were	   counted	   at	   1,	   5	   and	   24	   hours	   after	  treatment	  (A).	  The	  experiment	  was	  repeated	  using	  cell	  sorting	  based	  on	  Annexin	  V	  and	  PI	  staining	  (B)	  and	  supports	  the	  DAPI	  results.	  P-­‐values	  less	  than	  0.05	  are	  shown	  above	  pairs	  of	  bars.	  The	  error	  bars	  represent	  the	  95%	  confidence	  interval.	  Negative	  values	  are	  a	  result	  of	  more	  untreated	  cells	  undergoing	  apoptosis	  at	  that	  time	  point	  than	  the	  treated	  cells.	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To verify the DAPI results, treated and untreated cells were stained with Annexin 
V and propidium iodide (PI) and sorted by flow cytometry at each time point. Cell sorting 
was able to verify that elephants have significantly more apoptotic cells in response to IR 
than the human samples (Figure 16B). The increased amount of observed apoptosis is not 
due to more DNA damage in elephant cells than human cells. We have confirmed this by 
counting pH2AX foci in treated and non-treated cells over 24 hours for both human and 
elephant PBMCs (Figure 17). These data suggest that the threshold for the amount of 
DNA damage that is tolerated by a cell for repair is lower in elephants than in humans. 
	  
 
Figure 17. pH2AX foci counts in elephant and human PBMCs. PBMCs.	  There	  is	  no	  significant	  difference	  between	  the	  percentage	  of	  cells	  with	  pH2AX	  foci	  after	  2Gy	  IR	  treatment	  in	  elephant	  (left)	  and	  human	  cells	  (right).	  NT	  indicated	  “no	  treatment”	  by	  irradiation	  and	  2Gy	  indicates	  the	  intensity	  of	  irradiation.	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undergo the same increased rate of apoptosis relative to human cells when exposed to 
2Gy IR (Figure 18A).  We also observe that the severity of the apoptotic response due to 
treatment decreases with age. The youngest Asian elephant (7 years) has approximately 
30% apoptotic cells due to IR, while the older elephants (27-35) all are have less than 
20% (Figure 18B). Our previous results that aggregated the different elephants are not 
driven by the extreme apoptosis in the young elephant because each individual elephant 
shows significantly increased apoptosis (p < 0.05) due to IR relative to the human 
samples.  
 
Figure 18. Apoptotic response in human, African elephant and Asian elephants. 
Asian elephant cells undergo significantly more apoptosis in response to 2Gy IR when 
compared to human cells (A). The experiment was done using cell sorting based on 
Annexin V and PI staining. P-values less than 0.05 are shown above pairs of bars (A). 
The error bars represent the 95% confidence intervals. Each biological replicate is shown 
for humans, African and Asian elephants (B). The apoptotic response appears to decrease 
with age. Ages are noted in the legend. 
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We performed RNAseq on the African elephant and human RNA collected from 
treated (2Gy γ-IR) and untreated cells at the five-hour time point. We mapped the reads 
to their respective draft genomes using Tophat (Kim et al. 2013) and calculated the 
transcript abundance of each gene with Cufflinks (Pollier et al. 2013). Cufflinks was used 
to calculate the normalized FPKM (fragments per kilobase of exon per million fragments 
mapped) to compare the treated and untreated expression levels. Cellular responses to γ-
irradiation are largely driven by protein modifications, so we examined the expression of 
genes that are transcriptionally activated in p53-dependent apoptosis, cell cycle arrest and 
DNA repair (Soissi 1996, Tokino and Nakamura 2000) (Figure 19).  We found that the 
human PBMCs show more drastic induction of genes compared to the African elephant; 
however this may be due to the fact that the transcriptome mapping is guided by gene 
annotations and in the elephant these are all computational predictions so there may be 
disagreements with the actual transcripts that are resulting in poor mapping.  An increase 
in BAX expression is highly associated with p53-dependent apoptosis (Miyashita et al. 
1994) and we see this in both human and elephant. There is little change in the other 
genes shown in Figure 19 in the elephant, suggesting that the apoptotic pathway is 
responding to the irradiation more strongly than the DNA repair and cell cycle arrest 
pathways.  
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Figure 19. Induced Gene Expression after 2Gy Irradiation. The log-ratio of FPKM 
values (fragments per kilobase of exon per million fragments mapped) values of 
irradiated cells to untreated cells from RNAseq data for African elephant and human 
PBMCs were compared. Genes that are expressed during p53-dependent apoptosis (blue), 
cell cycle-arrest (yellow), and DNA-repair (green) are shown. PUMA is not annotated in 
the elephant genome.  
 
Previous studies have shown that tissues with higher baseline expression of TP53 
mRNA are more sensitive to DNA damage (Komarova et al. 2000). We compared the 
human and elephant FPKM values for the baseline in untreated cells and our results 
suggest that elephants have slightly higher mRNA expression of TP53 (8.15 FPKM vs. 
5.61 FPKM). Technical and biological replicates would need to be performed with 
RNAseq in order to determine if this relationship is significant and may contribute to the 
heightened apoptotic response in elephants. 
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We also compared the expression of MDM2. The MDM2 protein is a negative 
regulator of p53 and is shown to increase in expression in response to DNA damage to 
ensure that p53 returns to the basal level in surviving cells (Perry 2004). The baseline 
FPKM values in untreated elephant and human PBMCs are 80.4 and 39.1, respectively. 
However, after exposure to 2Gy gamma-IR, the human expression jumps up to 165.4 and 
the elephant MDM2 only increases to 89.8. Lower MDM2 expression has been associated 
with increased sensitivity to radiation in human cells in vitro (Grunbaum et al. 2001), 
which suggests that the p53 protein in elephant is not being negatively regulated as 
strongly as in humans and may be acting more effectively to induce apoptosis.  
 
MATERIALS AND METHODS 
Sequence analysis 
The African elephant genome assembly LoxAfr3 was used for sequence analyses. TP53 
gene locations and sequences from the African elephant genome were obtained from the 
Ensembl database (release 72) and NCBI GenBank. From these two databases we find a 
total of 20 genomic positions that are homologous to TP53. The UCSC Genome Browser 
was used to view these 20 regions and verify that TP53 transcripts of other species 
mapped to each of these locations. The start and stop of these locations was manually re-
annotated based on these alignments to update some annotations that had truncated parts 
of the region homologous to the ancestral TP53 coding sequence (Table 4). Multiple 
alignments were created with MUSCLE (Edgar 2004) and hand edited using Seaview. 
Percent identities between sequences were obtained from the MUSCLE output. PhyML 
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was used to create the maximum likelihood phylogeny for which gap sites were ignored. 
Flanking repeat sequences were annotated on the UCSC genome browser for the LoxAfr3 
genome and re-annotated with RepBase (Kohany et al. 2006) for the retrogenes we 
obtained from cloning and sequencing.  
scaffold start stop strand Ensembl Gene ID GenBank ID 
175 436531 437673 +   100660069 
208 307663 308805 -   100670203 
217 57192 58321 -   100657221 
221 32722 33852 + ENSLAFG00000027348 100669451 
221 320215 321342 + ENSLAFG00000030555 100669732 
281 127150 128270 +   100670118 
294 64102 65230 + ENSLAFG00000027820 100660838 
342 119172 120298 - ENSLAFG00000032258 100673852 
378 23269 24394 + ENSLAFG00000030880 100673452 
406 137208 138342 - ENSLAFG00000027474 100666240 
458 14552 15678 + ENSLAFG00000032042 100661323 
47 11688313 11693871 - ENSLAFG00000007483 100663725 
498 44787 45912 +   100675551 
552 13399 14524 - ENSLAFG00000028692 100668616 
627 40469 41597 +   100667946 
656 10157 11282 - ENSLAFG00000027365 100673935 
76 9269289 9270442 +   100671320 
786 1954 3080 + ENSLAFG00000027669 100669552 
825 4052 5178 + ENSLAFG00000028299 100673857 
928 6773 7899 + ENSLAFG00000026238 100660953 
 
Table 4. Genomic locations of 20 TP53 genes in the published LoxAfr3 genome. 
Genes with no support from resequencing of cloned loci are indicated in gray and black 
entries have high sequence identity with our sequenced clones. The ancestral copy 
containing introns is highlighted in red. ENSLAFG00000032258 is the one Ensembl 
pseudogene annotation. 
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Sample Collection 
Whole blood samples from an individual male African elephant supplied by the Oakland 
Zoo were used for DNA analyses (cloning and re-sequencing). For the gamma-irradiation 
experiments and RNA collection, elephant whole blood samples were obtained from two 
African elephants at Utah’s Hogle Zoo. Asian elephant blood was supplied by the 
Ringling Brothers Barnum and Bailey Center for Elephant Conservation. Human whole 
blood samples were obtained from healthy volunteers under IRB approved protocol at the 
University of Utah under the Cancer Genetics Study (CGS).  
 
DNA Isolation 
The DNA was purified with the DNeasy® Blood & Tissue Kit (QIAGEN) and 
concentrated by precipitating with 1/10 volume 3M sodium acetate (pH 5.2) and one 
volume of isopropanol followed by a 75% ethanol wash. The pellet was re-suspended in 
an appropriate volume of 1X TE buffer, based on the concentration determined by 
nanodrop, and stored at -20°C.  
 
PCR and Capillary Sequencing of 12 Ensemble TP53 Genes 
PCR primers were designed to be specific to each of the 12 copies of TP53 in the African 
elephant genome. They were designed using Primer-BLAST and verified to be specific 
with the UCSC in situ PCR. Each 50uL PCR reaction contained PCR Buffer 
(Invitirogen), a 200uM concentration of each dNTP, 1.5mM concentration of MgCl2, 
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0.2uM of each primer (Operon), 1 unit of Platinum® Taq DNA Polymerase (invitrogen), 
Q-Solution (Qiagen) and 50ng of template DNA. The following PCR program was used: 
94°C for 2 min; 35 cycles of 94°C for 30 sec, 62°C for 30 sec, and 72°C for 1 min; and 
ending with 72°C for 5 min.  
 
GeneID Primers 
ENSLAFG00000028692 5'-AACGAGTCAAAAGCCAGAAGCCACC-3' 
5'-GGGGGCAGTGCTTCACGACC-3' 
ENSLAFG00000027365 5'-GCCACCATCCTGGGCACAGC-3' 
5'-GGTGGGGACAGTGCTGCACG-3' 
ENSLAFG00000027820 5'-TGGGCTCTGGGGGCACCTTC-3' 
5'-CCACAGCTGCACTGGGCAGG-3' 
ENSLAFG00000030880 5'-CCGAAGCCACCATCCTGGGC-3' 
5'-GCTCATAGGGCACCCCACGC-3' 
ENSLAFG00000028299 5'-TGGGCTCTGGGGGCACCTTC-3' 
5'-TGCTGGGGACAGTGAGGGGG-3' 
ENSLAFG00000007483 5'-AGGAAGTCGGGTGGGGAGCC-3' 
5'-GGCAGGGTGGGGACAGCAAC-3' 
ENSLAFG00000027669 5'-TGCTGGGCTCTAGGGGCACC-3' 
5'-CCCACGGCTGCACTGGACAG-3' 
ENSLAFG00000030555 5'-TAGCTGCTGGGCTCTGGGGAC-3' 
5'-ACAGCTGCACTGGACAGGCC-3' 
ENSLAFG00000027348 5'-GCACCTGCTTTCTGGGCGTG-3' 
5'-AAGGGTGGCTGGTGCAGGGG-3' 
ENSLAFG00000032042 5'-ATTTGCTTGGCCCCTGCCCTG-3' 
5'-GCCTCTGCTGCTGGGGACAG-3' 
ENSLAFG00000027474 5'-GGCTCTGGGGGCACCTGCTT-3' 
5'-GCTGCTGGGGACAGTGAGGG-3' 
ENSLAFG00000026238 5'-GGGAAGGGCTCTTCTGGGATGGTC-3' 
5'-AGGTGCTGGGCAGGGGTGTT-3' 
 
Table 5. PCR primers for the 12 Ensemble elephant TP53 genes. These primers were 
used to amplify the 12 Ensembl TP53 genes annotated to be protein coding in the African 
elephant. Their products are show in Figure 12. 
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The PCR reactions were run on a 1.5% agarose gel and visualized by UV light. 
The bands were extracted and purified using the PureLinkTM Quick Gel Extraction Kit 
(Invitrogen). The products were sequenced at the Genomics Core Facility at UCSF and 
analyzed with the CLC Genomics Workbench 5 (CLC Bio). 
 
Cloning and Capillary Sequencing of TP53 Processed Paralogs 
Primers were designed to amplify the TP53 processed copies simultaneously in the 
African elephant to be used in downstream cloning. 15 of the 19 published processed 
copies have sequences that perfectly match the primers and the others only differ by a 
couple of bases. All of the clones we sequenced were able to be captured with the one 
primer set (Forward 5’-GTCAGGTCACCTAGTTTCTGAATTG-3’, Reverse 5’-
GTCAATCCATCAACCAACAGG-3’). We also used a second reverse primer (5’-
GTCAATCCATCAAAAAACAGG-3’) with the same forward primer to try and match 
other copies more specifically, but the same loci were picked up with each set.  Each 
50uL PCR reaction contained 1X final concentration of PCR Buffer (Invitrogen), a 
200uM concentration of each dNTP, 1.5mM concentration of MgCl2, 0.2uM of each 
primer (IDT), 1 unit of Platinum® Taq DNA Polymerase (Invitrogen), and ~50ng of 
template DNA. The following PCR program was used: 94°C for 2 min; 40 cycles of 94°C 
for 30 sec, 55°C for 30 sec, and 72°C for 2 min; and ending with 72°C for 5 min. Product 
sizes were verified by running the samples on a 1.5% agarose gel and visualizing bands 
with UV light.  
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The TOPO® TA Cloning® Kit for Sequencing (Invitrogen) was used to clone the 
PCR products into the PCR®4-TOPO® vector and transform chemically competent 
TOP10 E. coli cells. The kit protocol was followed for 3 cloning and transformation 
reactions: 2 replicates for the PCR products designed to capture the multiple copies of 
TP53 and one control transformation using the pUC19 plasmid. Each reaction was plated 
onto LB 100ug ampicillin agar at 20uL, 40uL and 100uL. Competent cells transformed 
with pUC19 were used as a positive transformation control while untransformed cells 
plated on ampicillin were used as a negative control. 
 To PCR the cloned product and verify the insert, 25uL reactions were prepared so 
that each reaction contained 2.5uL 10X PCR Buffer with MgCl2, 0.5uL dNTPs, 0.25uL 
T3 primer, 0.25uL T7 primer, 21.25uL water and 0.25uL Taq. A single isolated colony 
was scraped from a plate with a pipet tip and placed into a well containing the 25uL of 
PCR master mix. Two 96 well plates of colonies were prepared for a total of 192 
reactions. The PCR program was run as follows: 94°C for 5 min; 30 cycles of 94°C for 
30 sec, 55°C for 30 sec, and 72°C for 2.5 min followed by a 10 minute final extension at 
72°C. 
PCR reactions were diluted by adding 20uL water to 5uL of the PCR product and 
cleaned by adding 1uL SAP (1u/uL), 1 uL Exonuclease I (10u/uL) and 2uL SAP reaction 
buffer (USB® Products, Affymetrix, Inc). The samples (15pmol primer and ~150ng 
purified PCR product in a total volume of 6uL) were submitted to the Genome Core 
Facility at the University of California San Francisco for sequencing using ABI BigDye 
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v3.1 dye terminator sequencing chemistry and the new generation ABI PRISM 3730xl 
capillary DNA analyzer. 
        Four sequencing primers were used for each clone to fully cover the fragment 
with overlap: the T3 promoter 5'-AATTAACCCTCACTAAAGGG-3', the T7 promoter 
5'-TAATACGACTCACTATAGGG-3', 5'-CCTGAGAAGCTGGTTCTGTCC-3', and 5’-
CCAGACGTCAGCATATGATGGA-3’. Sequences traces were examined trimmed and 
assembled using CLC Genomics Workbench (CLC Bio).  
 
Cell Culture 
Ashley Chan performed the cell culture work in Dr. Joshua Schiffman’s lab at the 
Huntsman Cancer Institute (University of Utah). Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll-Paque density-gradient and centrifugation followed by 
a red blood cell lysis.  PBMCs were maintained in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 2% L-glutamine.  
The cells were exposed to 2GY gamma-irradiation (γ-IR) in a RS-2000 X-ray Biological 
Research Irradiator followed by incubation at 37°C and 5% CO2 until given time point 
(1, 5, and 24 hours). 
 
P53 Transcript Expression Assay 
RNA was collected from the treated (2Gy) and untreated elephant and human cells at the 
5-hour time point. The samples were stabilized with RNAlater and purified with the 
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Qiagen RNeasey Kit with on column DNase I treatment. Samples were reverse 
transcribed (RT) with the TaqMan® Reverse Transcription kit (Applied Biosystems) 
using poly-T and random hexamer oligos in separate reactions. The poly-T samples were 
used in downstream analyses.  
 Primers to distinguish the ancestral transcript from possible processed TP53 
transcripts were designed using Primer3 and their specificity to these regions was verified 
using BLAST against all predicted transcripts in the African elephant genome. The 
ancestral TP53 cDNA was amplified using forward and reverse primers (5’-
CCTCCTGGACCCTGTCATCTT-3’ and 5’-AAGCCCAGACGGAAACCATA-3’) and 
the processed p53 cDNA copies were amplified with forward and reverse primers (5’-
CCTGAGAAGCTGGTTCTGTCC-3’ and 5’-GCAGTAGGTCTTCTGGGAAGG-3’). 
Each 25uL PCR reaction contained a final concentration of 1X PCR Buffer (Invitrogen), 
a 200uM of each dNTP, 1.5mM of MgCl2, 0.2uM of each primer (Operon), 1 unit of 
Platinum® Taq DNA Polymerase (Invitrogen), and 1uL template cDNA directly from the 
RT reaction. The following PCR program was used: 94°C for 2 min; 35 cycles of 94°C 
for 30 sec, 55°C for 30 sec, and 72°C for 1 min; and ending with 72°C for 5 min. Product 
sizes were verified by running the samples on a 1.5% agarose gel and visualizing bands 
with UV light. Samples were also run on a 10% polyacrylamide gel to get better 
separation of the bands. 
 Bands were excised from the polyacrylamide gel and the DNA was purified with 
the Qiax II Gel Extraction Kit (Qiagen). The purified products were sequenced by Sanger 
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sequencing at the UCSF Genome Core Facility. Primers used for sequencing were the 
same as those for the PCR reaction.  
Taqman probes were designed to compare the TP53 expression in human and 
elephant after exposure to 2Gy IR. Primers and probes are listed in Table 6. We were 
unable to find Taqman primer/probe sets that passed the requirements for sequence 
composition and location as well as being able to uniquely target the retrogene 
transcripts. Instead we used a primer/probe set that was intended to only bind the 
ancestral TP53 transcript. The qPCR was performed on the Applied Biosystems 7900HT 
real-time quantitative PCR machine at the Genome Analysis Core at the University of 
California San Francisco. 
 
Primer/Probe  Primer/probe Sequence 
LoxA GAPDH forward 5'-CCTGAGCTGAATGGGAAGCT-3' 
LoxA GAPDH reverse 5'-TCAGATCCACCACTGACACGTT-3' 
LoxA GAPDH probe 5'-ACT GGCATGGCCTTCCGTGTCC-3' 
LoxA p53 Forward 5'-TGGGAACTCCTTCCTGAGAATC-3' 
LoxA p53 Reverse 5'-TTCTGAGAGTAGCAGATCGTCCAT-3' 
LoxA p53 probe 5'-TCCCCCACACTACCCCCGGC-3' 
Human GAPDH forward 5'-ATTCCACCCATGGCAAATTC-3' 
Human GAPDH reverse 5'-TGGGATTTCCATTGATGACAAG-3' 
Human GAPDH probe  5'-ATGGCACCGTCAAGGCTGAGAACG-3' 
Human TP53 forward  5'-CTGTCCCTTCCCAGAAAACCT-3' 
Human TP53 reverse  5'-GCAGGGGAGTACGTGCAAG-3' 
Human TP53 probe  5'-CCAGGGCAGCTACGGTTTCCGT-3' 
 
Table 6. Taqman primers and probe sets used for qPCR. 
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RNA Library Preparation and Sequencing 
RNA libraries were prepared and sequenced by the Genome Technology Center at the 
University of California Santa Cruz under the direction of Nader Pourmand. Two 
samples were run for both human and elephant (5hr treated (2Gy), and 5hr untreated 
(NT)). The RNA integrity (RNA Integrity Score >7) and quantity was determined on the 
Agilent 2100 Bioanalyzer following the manufacturer’s recommendations. The total 
RNA (100ng) was treated by DNase using DNase mix from RecoverAllTM Total Nucleic 
Acid Isolation kit (Applied Biosystems/Ambion) and subjected to cDNA synthesis with 
the Ovation RNA-Seq system V2 (Nugen).  
RNA amplification was performed per the manufacturer’s instructions and as 
described in detail in published literature (Tariq et al. 2011). Briefly, the total RNA was 
reverse transcribed to synthesize the first-strand cDNA by using a combination of random 
hexamers and poly-T chimeric primer. Double-stranded DNA (dsDNA) was generated by 
fragmentation of the mRNA template strand using RNA-dependent DNA polymerase. 
The dsDNA was purified using Agencourt RNAClean XP beads. The DNA was 
amplified linearly using a SPIA process in which RNase H degrades RNA in DNA/RNA 
heteroduplex at the 5’-end of the double-stranded cDNA, after which the SPIA primer 
binds to the cDNA and the polymerase starts replication at the 3’-end of the primer by 
displacement of the existing forward strand. Finally, random hexamers were used to 
amplify the second-strand cDNA linearly, as described previously (Tariq, Kim et al. 
2011). 
The double-stranded cDNA obtained after the Ovation V2 RNA-Seq system (0.5–
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1 µg) was used for the library. The cDNAs were sheared down to 350-450bp using the 
manufacturer’s protocol for the Covaris S2. A target insert size of 350-450bp was then 
size-selected using an automated electrophoretic DNA fractionation system, LabChip XT 
(Caliper Life Sciences). Paired-end sequencing libraries were prepared using Illumina’s 
TruSeq DNA Sample Preparation Kit. Following library construction, samples were 
quantified using the Agilent Bioanalyzer per manufacturer’s protocol. The libraries were 
sequenced using the Illumina HiSeq 2000 with sequencing paired-end read length at 2 x 
100 bp. Reads were de-multiplexed using CASAVA (version 1.8.2). 
 
RNAseq Analysis 
Paired-end reads for each of the four samples (Human NT 5hr, Human 2Gy 5hr, Elephant 
NT 5hr, Elephant 2Gy 5hr), with an average of 105 million reads per sample, were 
filtered using fastq-mcf in the ea-utils package (Aronesty 2011). The adapter sequences 
were clipped from the ends and known Illumina artifacts were removed (a FASTA file of 
artifacts was provided by the Department of Energy Joint Genome Institute).  The reads 
were then aligned to their respective genomes (human: hg19; elephant: LoxAfr3) with 
Tophat 2.0.6 (Kim, Pertea et al. 2013) and the FPKM (fragments per kilobase of exon per 
million fragments mapped) values were computed with Cufflinks 2.0.2 and analyzed for 
differential expression with cuffdiff (Pollier, Rombauts et al. 2013). 
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In vitro Translation 
We followed the manufactures protocol for the TNT® T7 Quick Coupled 
Transcription/Translation System (Promega). Reactions were run with plasmid DNA 
isolated from transformed E. coli colonies and PCR products from the cloned 2Kb 
fragments in addition to a positive luciferase control (provided by the kit. We used 
Transcend® Biotin-tRNA as the free tRNA each reaction so that all successfully 
transcribed proteins were biotinylated and could be visualized by binding Streptavidin-
Alkaline Phosphatase, as part of the Transcend Colorimetric Translation Detection 
System.   
 The reaction was subjected to SDS-PAGE. We followed the instructions for this 
from the coupled transcription/translation kit; however we found that denaturing the 
proteins at 70°C for ten minutes, instead of 100°C for two minutes, greatly reduced the 
background signal so we implemented this change. The gel was run in 1xSDS buffer for 
1 hour at 100V and transferred to a PVDF (polyvinylidene difluoride) membrane by 
performing a semi-dry blot for 25 minutes at 15V. The membrane was blocked with 
TBST and incubated with Streptavidin-Alkaline Phosphatase for 60 minutes. Finally the 
proteins were visualized by incubating the membrane with Western Blue stabilizer.  
 
DNA Repair Assay 
Ashley Chan ran the DNA repair assays in Dr. Joshua Schiffman’s lab at the Huntsman 
Cancer Institute. PBMCs were fixed with 2% PFA and adhered at 2x106 cells per slide by 
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Cytocentrifuge. Immunofluorescence analysis was completed for detection of DNA 
repair by pH2AX foci staining with anti-gamma phospho-H2Ax (SER1399) (pH2AX) 
(Millipore Corp) (Wilson et al. 2011).  Alexa Flour anti-rabbit IgG 594 and Alexa Flour 
anti-mouse IgG 488 (Invitrogen) were used to detect primary antibodies.  Cell fields were 
visualized by confocal microscopy based on an Olympus BX41TF confocal imaging 
system. Images were captured at 100X with Picture Frame software (Optronics). Foci 
were manually counted at each time point and allocated to one of 6 categories (0-5, 6-10, 
11-15, 16-20, 21-25, 25+). 
 
Apoptosis Assays 
Ashley Chan ran the apoptosis assays in Dr. Joshua Schiffman’s lab at the Huntsman 
Cancer Institute. Flow cytometric analysis was done to investigate the percent of dead 
cells induced by IR.  Apoptosis was detected by Annexin V staining.  PBMCs were 
seeded in a 96 well plate at 2x105 cells/well.  Cell pellets were collected by 
centrifugation, washed with PBS and re-suspended with fluorescein isothiocyanate 
(FITC) Annexin V/propidium iodide (PI) (Apoptosis Detection Kit II, BD Biosciences).  
Cells were incubated in the dark for 15 minutes with the stain. Data were acquired with a 
Becton-Dickinson FACSCanto II laser cytometer (BD Biosciences). Readings were taken 
using nm excitation and band pass filters.  Predictions for irradiated cell quadrant 
populations were based on x and y mean values previously determined by live statistics 
for non-irradiated cells (i.e. no treatment) at each time point with FlowJo software 
(TreeStar Inc.).  
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Apoptosis was also detected by immunofluorescence.  PBMCs were fixed with 
2% PFA and adhered at 2x106 cells/slide by Cytocentrifuge.  Cells were stained with 
DAPI and visualized for chromatin condensation and DNA fragmentation or stained with 
acridine orange/ethidium bromide (AO/EB) viability stain and visualized for late 
apoptotic cells. Apoptotic cells were manually counted based on cellular blebbing, 
chromatin condensation, and DNA fragmentation.  
 
 
Statistical Analysis of Apoptosis 
The same data analysis was performed for both the DAPI and Annexin V/PI experiments. 
For each sample at each time point, the proportion of apoptotic cells in non-treated 
samples were subtracted from the proportion in the corresponding treated sample (i.e. the 
same blood sample and time point). The standard error for the difference in these 
proportions was calculated with the following equation: 
𝑆𝐸 𝑝!" − 𝑝!" = 𝑝!" 1− 𝑝!"𝑛!" + 𝑝!" 1− 𝑝!"𝑛!"  
where pGy and pNT are the proportions of apoptotic cells in treated (indicated by Gy) and 
non-treated (indicated by NT) cells for a given time point. nGy and nNT are the total 
number of cells (i.e. the sum of viable and apoptotic cells) counted for the sample (treated 
and untreated respectively). Three technical replicates were done for this experiment 
starting with fresh blood samples from the same elephants and humans each time. Each 
time point for an experiment is modeled with a normal distribution with mean 𝛍 equal to 
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(pGy - pNT) and variance 𝛔2 equal to the square of the standard error (SE2). We can 
combined the three experiments for a given individual elephant or human at each time 
point by averaging the three appropriate normal distributions using the following 
equation: 
!!×   N µμ!,σ!! + N µμ!,σ!! + N µμ!,σ!! , 
where the three normal distributions with means 𝛍1, 𝛍2, and 𝛍3 represent three 
independent technical replicates of the experiment. The DAPI experiment only had 
technical replicates, but in the Annexin V data there were 3 technical replicates for 2 
elephants, 2 technical replicates for 2 human subjects and one replicate for another 
human subject. For the Annexin V data with biological replicates, the equation above is 
first used within the technical replicates of each individual and then applied again to 
combine the humans into one distribution N µμ! ,σ!!  and the elephants into another 
distribution N µμ!,σ!!  for each time point.  
 To test if the distribution for the composite elephant data is different than that of 
the composite human data, we performed a significance test for the difference in 
proportions. If σ!!  is the variance for the human data at a given time point and σ!! is the 
variance for the elephant data at a given time point, then the standard error for the 
difference of the differences µμ! −   µμ!  is equal to σ!! +   σ!!. We then calculate the z-
statistic where 𝑧 = !!!  !!!!!!  !!!   and find the corresponding p-value for a two-tailed test given 
a normal distribution.  
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DISCUSSION 
Given the central role that TP53 plays in response to cellular stresses including DNA 
damage, hypoxia, nucleotide deprivation and generally for cancer suppression (Lakin and 
Jackson 1999), it is surprising that humans have not evolved redundant copies. Early 
work in mice showed that there was a tradeoff between p53 activity and aging. Mice with 
constitutively active p53 were resistant to cancer but had accelerated aging (Tyner, 
Venkatachalam et al. 2002). However, follow-up work showed that adding extra copies 
of p53 to the mouse genome, under the endogenous promoter, generated mice that were 
cancer resistant and had a normal lifespan (Garcia-Cao et al. 2002). Mice in the wild 
usually die within a year from predation so there has been no selective pressure to 
suppress cancers that emerge over longer time intervals. In contrast, there has been strong 
selective pressure on elephants, which have on the order of 10,000 times more cells than 
a mouse, to suppress cancer long enough to bear and raise offspring over periods of 
decades. In addition, elephant herds with longer-lived matriarchs are more reproductively 
fit, providing further selective pressure to avoid cancer in aging elephants (McComb et 
al. 2011).  
Our results show that TP53 has gone through a massive expansion along the 
elephant lineage. It is likely that two retrotransposition events occurred, as indicated by 
the two main clusters forming groups A and B in the phylogeny of sequenced TP53 loci 
(Figure 2) and distinguished by different short deletions and flanking sequences, followed 
by amplification via tandem duplications or retrotransposition of the retrogene 
transcripts.  Additionally, our sequence analysis of the 5’ and 3’ regions surrounding the 
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retrogenes revealed that each copy is sandwiched between MIR (mammalian interspersed 
repeat) elements. MIR elements are SINEs (short interspersed elements) that belong to a 
non-autonomous class of retrotransposons. MIRs depend on the reverse transcriptase of 
LINEs (long interspersed elements) in order to complete reverse transcription and 
integrate into the genome in a new location. Interestingly, SINEs have been found to 
form composite transposons, which can mobilize the genomic sequence between two 
flanking repeats (Zelnick et al. 1987). This mechanism would disperse the TP53 
retrogenes around the genome, whereas local duplication would leave the genes 
clustered. Currently the retrogenes annotated by Genbank and Ensembl are all on small 
individual scaffolds and we re-sequenced very little upstream and downstream sequence 
of our clones, so there is no way to tell the genomic positions of these genes. Future 
sequencing of additional flanking sequence and mapping of each copy onto their 
respective chromosomes will reveal their physical proximity to each other and help to 
discover the mechanism behind the evolution of TP53 in the African elephant.  
 Intronless retrotransposed genes, often referred to as processed pseudogenes, 
have previously been thought to be ‘dead on arrival’ (i.e. non-functional); however, there 
has been an increasing number of these genes found to be functional (Pink et al. 2011). 
Recent studies from the ENCODE project estimate that approximately 9% of all 
supposed pseudogenes in the human genome are actively transcribed and ~6% of 
processed pseudogenes are transcribed (Pei et al. 2012). A processed pseudogene of TP53 
found in rat has been shown to be transcriptionally active in response to heat shock in a 
histiocytoma cell line (Sreedhar 2010); however no further studies have been done to 
characterize the function of this gene. Unlike the pseudogene expressed in rat, which has 
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lost the DNA-binding domain (Sreedhar 2010), the elephant retrogenes have retained 
most of the sequence in the transactivation, DNA-binding and tetramerization domains, 
though not with 100% sequence identity. The largest deletion in the retrogenes is in the 
DNA-binding domain and is 15 bases long for retrogenes in Group A and 30 bases long 
for retrogenes in Group B.  
We have shown that at least a subset of the retrogenes are actively transcribed in 
elephant PBMCs and that these cells undergo apoptosis at a significantly increased rate 
compared to human cells when exposed to 2Gy IR. This is evidence that the p53 pathway 
is more sensitive to DNA damage. We hypothesize that the retrogenes are increasing the 
cells sensitivity to DNA damage, and at lower thresholds of damage, these retrogenes are 
triggering p53-dependent apoptosis as opposed to DNA repair, which we find evidence of 
based on BAX expression in the RNAseq analysis. We also find a slightly increased 
baseline expression level of TP53 in the elephant and we do not see a large increase in 
MDM2 in response to IR, both of which can contribute to radiation sensitivity 
(Komarova, Christov et al. 2000, Grunbaum, Meye et al. 2001, Perry 2004). Interestingly, 
overexpression of TP53 under an endogenous promoter in mice causes an increase in 
apoptosis when exposed to IR (García-Cao, García-Cao et al. 2002).  
Apoptosis is an effective way to stop mutations from propagating to future cell 
generations. It has been shown that at critical points in embryonic development, murine 
cells are more likely to undergo apoptosis than repair DNA breaks (Heyer et al. 2000). 
Evolution may have enhanced this response in elephants to counteract the risk of cancer 
that should otherwise increase due to their large body size and long lifespan. We have 
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shown that this phenotype is found in both African and Asian elephants and that the 
response declines with age. A decline in apoptotic response has also been observed in 
aging murine T cells (Spaulding et al. 1997) and human sperm cells, despite an increase 
in DNA damage (Singh et al. 2003). We hypothesize that the higher apoptotic response 
found in younger individuals is due to an increased selective pressure to eliminate 
damaged cells and prevent carcinogenesis before sexual maturity. This increases the 
chance that the individual survives long enough and is healthy enough to successfully 
reproduce.  
Each of the 18 retrogenes contains premature stop codons if they were to be 
translated with no splicing; however, they also all contain open reading frames (ORFs) 
longer than 100 amino acids. We did not find evidence of protein synthesis from the 
retrogenes with the in vitro coupled transcription/translation assay. This may be because 
our retrogenes included flanking sequence that interfered with proper transcription and 
does not prove that the TP53 retrogenes do not function as proteins. It is possibly that 
these retrogenes are making truncated proteins, but we hypothesize that they are acting at 
the transcriptional level and are functional non-coding RNAs. Transcribed processed 
‘pseudogenes’ have been found to occasionally act as microRNA decoys to increase the 
transcript level of the parent gene, as has been found with the tumor suppressor gene 
PTEN (Poliseno et al. 2010, Johnsson et al. 2013). Processed pseudogenes have also been 
shown to regulate the expression of their parent gene through translational interference by 
transcribing antisense RNA to bind to the parent mRNA or by being processed into 
siRNA (Pink, Wicks et al. 2011). One further possibility is that retrogenes in the African 
elephant genome target mutant TP53 transcripts in the cell for degradation such that a 
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wild-type TP53 allele would continue to form non-mutant homo-tetramers and provide 
the cell with fully functional p53 protein. Processed pseudogenes have also been 
associated with increased stability of their parent mRNA (Hirotsune et al. 2003), which 
may explain the altered response to IR in elephant cells.  
The elephant’s solution to Peto’s Paradox is not necessarily the same solution that 
evolved in other large, long-lived organisms. Investigations into whales, naked mole rats, 
and other organisms with these extreme phenotypes should help illuminate the diversity 
of mechanisms that evolution discovered for suppressing cancer. Though we are not 
suggesting genetically engineering redundant copies of TP53 into the human genome, 
there has been some evidence that small molecules may be able to restore function of 
mutant p53 (Rippin et al. 2002, Ventura et al. 2007) and others have been shown to 
stabilize the protein by disrupting the interaction with MDM2 (Issaeva et al. 2004, 
Vassilev et al. 2004, Shangary et al. 2008). The results of evolution in the elephant 
suggest that enhancing TP53 function is a promising direction for cancer prevention in 
humans.  
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CHAPTER 6: DE NOVO ASSEMBLY OF THE HUMPBACK WHALE GENOME 
 
 
INTRODUCTION 
Few genomes of large, long-lived organisms have been sequenced, which greatly limits 
the ability of researchers to make progress on comparative studies of aging and age-
related diseases, such as cancer. To address this information gap, we sequenced and de 
novo assembled the humpback whale (Megaptera novaeangliae) genome. Referred to as 
the ‘drosophila of whales’ among marine biologists (personal communication with Per 
Palsböll), the humpback whale has been studied in much greater detail than other whale 
species. There is a large community of scientists that track humpback whales, perform 
genetic testing, and decode their songs. Because of the amount information that has been 
accumulated about this species, we felt that providing a draft genome would not only 
further our interests in cancer research, but may provide the information needed to 
examine the genetic basis of many humpback whale phenotypes.  
Whales are classified in the order Cetacea, which contains two suborders, 
Odontoceti, the toothed whales (e.g. dolphins), and Mysticeti, the baleen whales (e.g. the 
humpback). Mysticeti and Odontoceti share a most recent common ancestor 
approximately 20-34 million years ago (Murphy, Pringle et al. 2007, Jackson et al. 2009). 
Humpback whales have an observed maximum lifespan of 95 years and have an average 
adult weight of 30,000Kg (de Magalhães and Costa 2009), though they can grow to as 
much as 48,000Kg (Schmidly 1994). They are clearly a prime example of a large, long-
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lived organism with which to study Peto’s paradox.  Very few cases of cancer have been 
reported in this species; however there are documented cases of benign neoplasms 
including a basal lipoma in the central nervous system and fibromas on the tongue and 
skin (Newman and Smith 2006). Humpback whales are closely related to species that are 
orders of magnitude smaller, such as the harbor porpoise (Phocoena pohocoena) (which 
we have plans to sequence with collaborators), which weighs approximately 52.5Kg (de 
Magalhães and Costa 2009). Close evolutionary relationships across magnitudes of body 
sizes make it more straightforward to determine genes involved with the evolution of 
large body size and long lifespan. Other research groups are beginning to sequence 
closely related cetaceans that span a range of sizes, which will enable many interesting 
comparative studies to be performed.  
The individual female humpback whale that was used for this sequencing project 
is already well known in the marine biology community and by local whale-watchers in 
New England. Her name is Salt and she was the first whale in the world to be assigned a 
name (as opposed to a number). She was first spotted by Captain Aaron Avellar in 1975 
in Massachusetts Bay who named her for the distinct white scar pattern on her dorsal fin 
(Knaub 2001). Salt has a history of helping researchers, as she was later seen that same 
year off the coast of the Dominican Republic which provided scientists with valuable 
information to understand the migration patterns of the North Atlantic humpback whales 
(NOAA 2006).  She has been seen every year off the coast of Cape Cod for over 35 
years, with the exception of one, and is estimated to be roughly 45 years old (Knaub 
2012). Salt has mothered 12 calves and is a grandmother to 10 calves, all of which have 
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been named by Captain Avellar and his family, whom continue to monitor Salt and her 
family from year to year (Knaub 2012).  
The humpback whale population has been reduced from a global population of 
more than 200,000 to near extinction as a result of unregulated whaling (Clapham et al. 
1999). In recent years the population of humpbacks has been recovering and the current 
worldwide population is approximately 80,000, as reported by the International Whaling 
Commission (IWC 2013). Researchers have used genetic markers to look at variation 
within the existing populations. They expected to see low diversity due to the extreme 
population bottleneck, however the populations maintain higher levels of nucleotide 
variation among individuals than expected, which is thought to be a preservation of the 
past heterogeneity as opposed to a recent post-bottleneck explosion (Baker et al. 1993). A 
full reference genome would allow for more in depth genetic studies for comparative 
biology as well as to better understand the current population and perhaps aid in 
continued conservation efforts.  
There are a number of other scientific communities that are eager for access to a 
baleen whale genome. The aging community would like to make use of this genome to 
gain insight into what genes may be responsible for the extended lifespans of whales. In 
order to transition successfully to marine life from their land-living ancestor, whales had 
to go through rapid adaptation and this evolutionary history remains encoded in their 
genomes, making this genome of great interest to evolutionary marine biologists seeking 
to understand this transition. We hope that publishing this genome will produce novel 
data that will be used in many fields of science from basic biology to biomedical research 
and could open new doors for cancer prevention. 
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THE COMPLEXITIES OF THE HUMPBACK WHALE GENOME 
The de novo assembly of any mammalian genome from next-generation sequence data is 
a challenge; however the biology of the humpback whale genome makes this effort 
particularly difficult. Previous work on humpback whales revealed the karyotype diploid 
value (2n) is 44 chromosomes (Lambersten et al. 1988). The genome is assumed to be 
around three billion bases, based on measurements of DNA content in cells of toothed 
whales (Gregory 2013). Chromosomal hybridizations have shown that cetacean genomes 
are highly repetitive and studies have since focused on three major repeat sequences 
found in baleen whale genomes (Arnason et al. 1978, Arnason and Widegren 1989). 
About 15% of the genome is estimated to be composed of one tandemly repeated 1.7Kb 
sequence which is typically localized near the telomeric regions of the chromosomes 
(Arnason and Widegren 1989). A 72bp sequence within this repeat has dyad symmetry, 
and approximately 540 bases show similarity to the mammalian LINE-1 element 
(Kapitonov et al. 1998). This repeat is known as the common repeat and is found in all 
examined cetaceans from odontocetes (toothed whales) to mysticetes (baleen whales) 
(Arnason et al. 1984).   
 There is 422bp heavy (GC-rich) satellite found in baleen whales, which is also 
organized in tandem repeats (Arnason and Widegren 1989, Adegoke et al. 1993). 
Roughly one half of this repeat sequence is composed of the subrepeat TTAGGG, which 
is a common motif found in mammalian telomeres so it is not surprising that this repeat is 
distal to the common 1.7Kb component (Arnason and Widegren 1989). The third studied 
repeat is the light (AT-rich) satellite, which has not been sequenced but seems to be less 
conserved based on restriction hybridization patterns from eight species which show a 
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range of fragment lengths (Arnason and Widegren 1984). It localizes in the centromeric 
regions where it is thought that there may be fewer constraints on the evolution of 
repetitive sequences (Arnason and Widegren 1989). 
 Though next-generation sequencing technologies (NGS) have enabled us to 
sequence genomes more efficiently and for less money, resolving repeats with this data is 
an extreme challenge. Repeats that are longer than the read length, which includes these 
common cetacean repeats, can cause a fragmented assembly since they may not be able 
to be anchored to surrounding non-repetitive DNA (Treangen and Salzberg 2012). 
Additionally, repeats can be collapsed resulting in a shorter assembly and complex 
misassemblies (Phillippy et al. 2008, Pop and Salzberg 2008). The two best current 
methods to deal with repeats is by producing longer reads and having long inserts 
between mate-pair reads that can span repeat regions and help anchor them uniquely 
(Treangen and Salzberg 2012). We have pursued both strategies in our assembly of the 
humpback whale genome. 
 
DE NOVO SEQUENCE ASSEMBLERS 
Due to the decrease in sequencing costs, individual labs are now able to sequence a 
genome with next-generation and second-generation sequencing technologies; however, 
de novo assembly from these short reads (~100bp) remains a challenge. This has 
prompted many groups to develop assembly software, all of which have relative 
advantages and disadvantages. There are two main foundations upon which a non-greedy 
assembly algorithm can be built: de Bruijn graphs and overlap graphs (Miller et al. 2010) 
 102 
(Figure 20). We have made use of both strategies, as well as a string-graph algorithm, 
which is a variation of the overlap graph, in order to generate the current draft assembly 
of the humpback whale. 
Our first assembly of the humpback whale was done with the software 
ALLPATHS-LG, provided by the Broad Institute (Gnerre et al. 2011). This algorithm is 
based on a de Bruijn graph (Figure 20D), which are typically chosen for large data sets 
with millions of reads. Reads are broken down into k-mers and each string of k bases is a 
node. Nodes are connected by a directed edge if they overlap by k-1 bases.  De Bruijn 
graphs are known for their computational efficiency because they do not need to 
explicitly compute all pairwise overlaps, which is O(n2) for n reads. Instead, de Bruijn 
graph assemblers scale with the number of unique k-mers in the sequence data. Though 
this saves computational time, it requires a large amount of memory to store the graph, 
which has an upper-bound of O(4k). The default value for ALLPATHS-LG is k=24 for 
the fragment libraries and k=96 for jump libraries, which the developers encourage users 
not to change as many heuristics in their algorithm are highly sensitive to this value 
(Gnerre, Maccallum et al. 2011). Assembly of a mammalian genome therefore requires 
over 500GB of RAM, and the manual recommends a machine with 1TB of RAM.  
A consequence of the de Bruijn graph approach is that the information contained 
in a full read is reduced to k-mers and therefore the information about k-mer adjacency is 
lost. Repeat regions are often collapsed and not easily resolved; however this method also 
eliminates spurious assemblies caused by repetitive sequences at ends of reads which can 
occur with overlap-based assembly methods (Miller, Koren et al. 2010). The major 
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limitation of ALLPATHS-LG and all de Bruijn graph assemblers is that they cannot 
accept a hybrid of sequence data as input, which is what ultimately convinced us to try a 
different assembler.  
 Overlap-based assemblers are more flexible then de Bruijn graphs and can use 
variable length reads as input (Myers et al. 2000, Zimin et al. 2013). Our most recent 
draft assembly of the humpback whale takes advantage of the new MaSuRCA 2.0.1 
assembler (Zimin, Marcais et al. 2013), which is built around an adapted version of the 
Celera Assembler 6.1 (CA)(Myers, Sutton et al. 2000, Miller, Koren et al. 2010). CA is 
an overlap-layout-consensus (OLC) algorithm (Figure 20B) in which each node of the 
graph represents a full read and each directed edge (u,v) denotes an overlap between 
reads u and v, where the edge weight is equal to the maximum length suffix of read u that 
is a prefix of read v (i.e. the size of the overlap between read ends). In addition to 
increased flexibility of read lengths, OLC assemblers are also more robust to sequencing 
errors compared to de Bruijn graphs due to the fact that they look at maximum overlaps 
with high identity between reads and not just of size k-1, where a sequencing error could 
lead to a new branch in de Bruijn graph. After computing all pairwise overlaps, a 
multiple alignment is created and the consensus sequence is extracted. As mentioned 
earlier, repetitive sequences can lead to spurious overlaps; however CA has built in 
methods to deal with repeats and hopefully avoid false merges (Myers, Sutton et al. 
2000).  
 OLC assemblers are not typically used with NGS data because they do not scale 
well with the number of reads obtained from these technologies. MaSuRCA has solved 
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this problem by assembling the paired end reads in to ‘super-reads’ and passing the 
super-reads to the Celera Assembler, along with the accompanying information about 
coverage for each super-read (Zimin, Marcais et al. 2013). To form a super-read, a read is 
extended on each end using a k-mer count lookup table and the extension stops when 
there is no longer a unique solution. Every read is contained in one super-read, though no 
super-read is fully contained in another. Additionally, super-reads can contain many 
reads, which provides drastic data reduction (Zimin, Marcais et al. 2013). The OLC 
algorithm is run on the super-reads, mate-pair reads and any additional long reads that 
can be supplied by the user.  
To generate additional to reads to use as input to MaSuRCA, we used a string 
graph assembler (SGA) (Simpson and Durbin 2012) to pre-assemble subsets of paired-
end reads from a fosmid library. The string graph is a slight variation on the OLC 
assembly algorithm (Figure 20C).  Redundant information is removed by discarding 
reads that are entirely contained within another, which reduces the total number of 
vertices. Vertices are connected with bi-directional edges. An edge (v,u) leaving a vertex 
v and going into vertex u represents the sequence that precedes the start of the read 
sequence at vertex u. Similarly, the edge (u,v) represents the sequence of read u that 
comes after the end of read v. We chose the SGA assembler for the benefits of an overlap 
graph. This specific implementation uses compressed data structures (i.e. FM-index) so it 
can be run quickly and with minimal memory (Simpson and Durbin 2012). However, the 
computational time does not scale well as the number of reads increases which is why we 
only used it to pre-assemble subsets of reads and not for the entire assembly.  
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Figure 20. Graphical representations used in sequence assembly. The example reads 
that align as shown (A) could be represented by an overlap graph (B), string graph (C), or 
de Bruijn graph (D). The weights on the edges of the overlap graph correspond to the 
length of overlap (B). The edges leaving each node with red sequence above indicate the 
sequence from that read that comes before the node it is entering (C). The nodes pointing 
into a node with black sequence below represent the sequence that comes after the read at 
that node (C).  The de Bruijn graph is an example where k=4 (D). 
 
  
 
ASSEMBLY STRATEGY 
All sequencing of the humpback whale was done at the Genome Technology Center at 
the University of California Santa Cruz under the direction of Nader Pourmand. We 
prepared an 180bp paired end library and two mate-paired libraries with target insert 
sizes of 2Kb and 5Kb and sequenced each as 2x100bp reads (Table 7).  Our initial 
assembly (MegNov.v01) was done with ALLPATHS-LG, but only used the 180bp 
fragment library and the 2kb mate-pair library as input. This was done primarily as a test, 
and our first real attempt (MegNov.v02) was also done with ALLPATHS-LG but made 
R1:$CTCACTGAGGA$
R2:$$$$$$$$ACTGAGGAGAT$
R3:$$$$$$$$$$$CTGAGGAGATG$
R1$ R2$
R3$
8$
7$ 9$
R1$ R2$
R3$
CTC$
GAT$
CTCA$!$TCAC$!$CACT$!$ACTG$!CTGA$!$TGAG$!$GAGG$!$AGGA$
B.$Overlap$Graph$
D.$de$Bruijn$Graph$
C.$String$Graph$
A.$
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use of the 5kb mate-pair library in addition to the other two libraries.  The algorithm 
predicted that the genome size would be between 2.7 and 2.8 billion bases; however the 
resulting assembly was approximately 2.1Gb, suggesting we are missing a substantial 
portion of the genome. This result was partly due to the repetitive nature of the genome, 
which can collapse repeats, resulting in a smaller assembly. Another issue is that 
ALLAPTHS-LG highly recommends higher coverage for the paired end and mate-pair 
libraries in addition to at least one long insert library with an insert of greater than 10Kb. 
We had attempted to sequence a 10Kb mate-pair library and fosmid ends with a ~40Kb 
insert, but neither of these libraries were successful. However, we fragmented the fosmid 
library into ~425bp fragments and created a paired end library to add as input for the next 
assembly.  
 
Library Type Fragment/Insert Length # total reads Coverage 
Paired-end  180bp 1.27 billion 45X 
Paired-end  425bp (sheared fosmid clones) 500 million 100-200X*  
Mate-pair  2Kb 326 million 10X 
Mate-pair  5kb 269 million 9X 
 
Table 7. Sequencing libraries used for the humpback whale genome. All libraries 
were used for the assembly of MegNov.v03 using SGA and MaSuRCA. The MegNov.v02 
assembly did not include the paired-end 425bp fragment library that was created by 
sonicating fosmid clones. The MegNov.v01 assembly only used the 180bp fragment 
library and the 2Kb mate-pair library. * The fosmid library coverage represents the 
estimated coverage for the fraction of the genome represented by the fosmids, not full 
genome coverage. 
 
 
Our approach for improving the humpback whale assembly was three fold: (1) 
only use the highest quality input, (2) simplify the problem by pre-assembling smaller 
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pieces of the genome that we know belong together, (3) reduce the data to make our 
methods less computationally intensive. For the ALLPATHS-LG assembly, we had only 
removed the adapter sequences and poor quality reads were filtered by ALLPATHS. For 
this next assembly we invested a significant amount of time into pre-filtering our reads. 
This pre-filtering helps to eliminate errors in the assembly as well as decrease the number 
of input sequences to the assembler, which can speed up computational time. We 
removed all reads that did not pass the Illumina filter (indicated in the fastq header) and 
clipped poor quality bases from the ends of reads in addition to removing all adapter 
sequences and Illumina artifacts.  
After all reads were filtered, the 2x100bp reads from the 180bp fragment library 
were joined where their ends overlap. Typically the quality of the sequence decreases 
toward the end of the read, so by joining reads, we are able to eliminate low quality 
regions (Figure 21).  We were able to reduce the number of reads from 632,873,374 
paired reads (i.e. over 1.2 billion individual reads) to 509,915,678 single end reads, with 
an average length of 157bp. Only reads that were successfully joined were used in the 
assembly.    
To simplify the assembly problem, we pre-assembled contigs from fosmid 
sequence libraries. When the libraries were created, pools of approximately 50-100 
fosmids were given a unique barcode so we were able to assemble each pool individually, 
knowing that the each pool assembly should be roughly 2-4Mb (i.e. the number of clones 
x 40Kb). We sequenced a total of 120 pools of fosmids and assembled each individually 
using the String Graph Assembler (Simpson and Durbin 2012) and kept all contigs that 
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were at least 200bp long which resulted in approximately 570Mb of assembled clones.  
Out of 1.06 million contigs, the average size was 535bp, with a maximum of 35,612bp. 
10% of the contigs were at least 1Kb long and over 1,500 contigs were greater than 
10Kb. The maximum read length that MaSuRCA can take as input is 2,047bp so all pre-
assembled contigs were sheared to 2,047bp with an overlap of 1,500bp. This resulted in 
approximately 1.2 million long reads that now contain the information from over 500 
million sequence reads from the fosmid library.  
 
 
Figure 21. Base quality scores across reads. Before filtering and clipping of poor 
quality bases, the distribution of quality scores across the 100bp reads (from the 180bp 
fragment library) is highly variable and the quality drastically decreases toward the 3’ 
end of the reads (A). After filtering poor quality reads, clipping adapters and low quality 
bases and joining the forward and reverse sequences where they overlap we see the base 
quality across the long reads increase and maintain consistency for the full length (B). 
The green indicates good quality base scores, red is poor quality scores and orange 
defines the intermediate qualities. These graphs were are produced by FastQC  (Simon 
2012). 
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MaSuRCA further reduces the data by assembling the paired end reads into super-
reads before passing them to the adapted Celera Assembler based on OLC. We already 
reduced the number of paired end reads by joining the mates from the 180bp fragment 
library which condensed over 1.2 billion individual reads into 509 million reads. These 
reads, in addition to the unassembled fosmid reads, were assembled into 66.4 million 
super-reads. The super-reads have an average length of 305bp, a maximum of 29,585 and 
~6% are over 1Kb. Super-reads greater than 2,047bp are sheared into 2,047bp fragments 
with an overlap of 1,500bp, as we also had done with the fomid contigs. The full 
assembly using MaSuRCA with the pre-assembled SGA fosmid clones was run on the 
Genepool cluster run by the National Energy Research Scientific Computing Cluster. 
 
ASSEMBLY STATISTICS AND QUALITY ANALYSIS 
After completing this new assembly, we sought to assess the contiguity, completeness 
and accuracy of our humpback whale draft genome. Most notably, we have improved the 
overall assembly size from the MegNov.v02 assembly, which was approximately 2.1Gb 
to approximately 2.4Gb with MegNov.v03 (Table 8). Both ALLPATHS-LG and 
MaSuRCA estimate the genome size based on k-mer frequencies; however, the 
algorithms are slightly different so the ALLPATHS assembler estimates the genome to 
between 2.7Gb and 2.8Gb and MaSuRCA estimates the genome to be between 2.2Gb and 
2.3Gb. The exact reason for the discrepancy is unknown, but based on flow cytometry, 
the estimated genome size for some toothed whales (e.g. beluga whale, bottlenose 
dolphin and the Chinese River dolphin) suggest cetacean genomes are around 3 billion 
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base pairs (Gregory 2013). Therefore, when assessing the completeness using NG 
statistics we used an estimated genome size of 2.8Gb. We have summarized some of the 
assembly statistics in Table 8.   
Some of the most frequently reported genome assembly statistics are the N50 and 
the NG50. The Nx value is defined as the length at which x% of the assembled genome is 
contained in contigs (or scaffolds) greater than or equal to Nx. NG statistics are very 
similar; however they are normalized to the estimated full genome size as opposed to the 
length of the assembly. Larger N-statistic (e.g. N50 and NG50) values reflect a higher 
degree of contiguity in the assembly.  Our ALLPATHS assembly (MegNov02) has a 
scaffold N50 of 95.7Kb and a contig N50 of approximately 9.4Kb. If we use the genome 
estimate of 2.8Gb, the contig and scaffold NG50 values are 63Kb and 4.7Kb, 
respectively. It is obvious that the addition of the 5kb mate-pair library resulted in a large 
improvement in the scaffold length and overall contiguity compared to the MegNov.v01 
assembly (Table 8). The most recent version of the humpback whale genome 
(MegNov03) has not only improved on the total assembly length, but also shows 
significant improvements in contiguity which is reflected in the N50 and NG50 statistics 
(scaffold N50=144.2Kb; contig N50=11.2Kb; scaffold NG50=116Kb; contig 
NG50=8.8Kb) (Figure 22).  
Though the MegNov.v03 assembly contains many more scaffolds than the 
MegNov02, this is due to the fact that ALLPATHS-LG only outputs scaffolds (and 
contigs) that are at least 1Kb. The better comparison between the two is to only consider 
scaffolds that are at least this size for the MaSuRCA assembly. In doing this, we find that 
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98% of the assembly is contained in scaffolds greater than or equal to 1Kb, and therefore 
remains a significant improvement over the previous MegNov02.v02 assembly.  
	  	   MegNov.v01	   MegNov.v02	   MegNov.v03	  
Software	   ALLPATHS-­‐LG	   ALLPATHS-­‐LG	   MaSuRCA	  +	  SGA	  	  
Scaffold	  Length	  	  (bp)	   1,829,725,285	   2,093,296,260	   2,388,269,474	  
Len.	  of	  Scaff.	  	  ≥	 1Kb	  	  (bp)	   1,829,725,285	   2,093,296,260	   2,336,274,083	  
#	  Scaffolds	  	  ≥	 1kb	   166,643	   48,456	   64,606	  
#	  total	  Scaffolds	   166,643	   48,456	   182,196	  
Scaffold	  N50	  	  (bp)	   19,125	   95,714	   144,235	  
Scaffold	  NG50	  	  (bp)	   9,454	   63,182	   116,053	  
Scaffold	  L50	  count	   27,326	   6,176	   4,823	  
Scaffold	  LG50	  count	   63,225	   10,731	   6,413	  
Longest	  Scaffold	  	  (bp)	   285,317	   979,715	   1,243,294	  
#	  Scaffolds	  >	  1Kb	   165,796	   	  48,212	   64,561	  
#	  Scaffolds	  >	  10Kb	   60,091	   31,805	   26,468	  
#	  Scaffolds	  >	  100Kb	   217	   5,787	   7,528	  
#	  Scaffolds	  >	  1Mb	   0	   0	   2	  
%Gaps	   6.89%	   11.56%	   3.38%	  
Contig	  Length	  	  (bp)	   1,703,724,128	   1,851,304,040	   2,307,471,974	  
Contig	  N50	  	  (bp)	   6,350	   9,437	   11,273	  
Contig	  NG50	  	  (bp)	   2,922	   4,784	   8,828	  
Contig	  L50	  count	   80,066	   57,156	   60,573	  
Contig	  LG50	  count	   206,067	   127,279	   85,239	  
Longest	  Contig	  (bp)	   380,664	   128,011	   103,933	  
#	  total	  Contigs	   380,664	   320,806	   529,825	  
#	  Contigs	  >	  1Kb	   375,824	   317,618	   301,933	  
#	  Contigs	  >	  10Kb	   32,705	   52,238	   72,505	  
#	  Contigs	  >	  100Kb	   0	   3	   2	  
%GC	   40.81%	   40.81%	   40.74%	  
%AT	   59.19%	   59.19%	   59.26	  
Ambiguities/10Kb	   7.36	   7.9	   7.2	  
 
Table 8. Summary statistics for the humpback whale genome assemblies. NG50 and 
LG50 values are based on a genome size of 2.8Gb.  
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Additionally, the L statistics (L50 and LG50) are defined to be the number of 
contigs/scaffolds (greater than or equal to the N50) that contain 50% of the assembly 
(L50) or the estimated genome size (LG50). These values are lower in the MegNov.v03 
assembly, which means a larger portion of the genome is contained in a smaller number 
of scaffolds/contigs and therefore the assembly is on average more contiguous since this 
can only be explained by having some larger contigs and scaffolds than the previous 
assembly.    
 
Figure 22. NG statistics of three humpback whale genome assemblies. The length of 
the genome is assumed to be 2.8Gbases. The x-axis values (X) are the % of the genome 
length and the y-axis represent the NG(X) statistics for the scaffolds and contigs of the 
three humpback whale assemblies. The NG50 (i.e. X=50) values are indicated on the 
right side of the graph and correspond to where the plotted data line intersects with the 
gray, hashed line. The numbers of scaffolds/contigs that account for 50% of the genome 
(i.e. the LG50) are shown in parentheses. The y-axis is plotted on a log scale.  
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Another major improvement in the most recent assembly is the drastic decrease in 
the percentage of the scaffolds that are gaps (i.e. N’s). Almost 12% of the MegNov.v02 
humpback whale assembly is comprised of gaps and with the new MegNov03 assembly, 
we have reduced the number of gaps to just over 3%. The majority of length that was 
gained in the MegNov.v02 assembly relative to MegNov.v01 was due to scaffolding with 
the additional 5kb mate-pair reads, so there are substantially more gaps. Gaps can inflate 
the scaffold N50 values, so it is important to also look at the total number of bases 
(A,C,G,T) to assess a genome. MegNov.v03 is therefore a significant improvement over 
MegNov.v02 because not only is it more contiguous as shown by the NG50, but it also 
contains nearly 500 million additional informative bases.  
The three assemblies give similar values for the number of ambiguous bases as 
well as the GC content (Table 8). The number of ambiguous bases includes both 
sequencing errors as well as heterozygous single nucleotide polymorphisms (SNPs), 
which are inevitable in a diploid mammalian genome. Similar values are obtained from 
all three assemblies and are consistent with reported statistics from an individual human 
genome (6.15 heterozygous positions per 10Kb) (Levy et al. 2007). The average genome 
GC content, which is almost identical across all assemblies, is also consistent with other 
mammalian genomes (e.g. human ~41%) (Lander et al. 2001).  
 We assessed the overall repeat composition of the MegNov.v03 assembly using 
the annotated mammalian repeats in RepBase with the software Censor (Kohany, Gentles 
et al. 2006). We find that 34.9% of the assembly is annotated as repetitive. This is less 
than we would expect and is likely due to collapsed repeat regions. There are only 6,695 
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instances of the 1.7Kb common cetacean element, which only makes up 0.06% of the 
assembly. Based on previous estimates that this one repeat accounts for 15% of the 
genome, there should be approximately 250,000 copies the full genome totaling ~420Mb. 
This could explain the missing ~400Gb of our assembly compared to the estimated size 
of 2.8Gb. 8,118 instances of the heavy satellite are annotated by Censor in MegNov.v03, 
which also accounts for less than 1% of the genome (0.07%). We observe that these 
annotations are frequently found on short scaffolds (~500bp), which demonstrates the 
fragmentation that occurs with tandem repeats. L1 repeats make up 44.6% of all 
annotated repeats in the humpback whale genome and account for 18.75% of the total 
assembly (Figure 23). The second most common class of repeats are the SINEs which 
total approximately 9% of the genome if we combine those annotated as ‘SINE” and 
“SINE2/tRNA” and ~20% of the total repeats. 
The MegNov03 assembly is comparable to the published bottlenose dolphin 
(Tursiops truncatus) genome (Ttru14), which was done with low-coverage (2.6X) Sanger 
sequencing at Baylor College of Medicine and assembled by the Broad Institute. The 
dolphin in 240,900 scaffolds span 2.5Gb with a scaffold and contig N50 of 109Kb and 
11.8Kb, respectively (as reported by Ensembl, release 73). As additional cetacean 
genomes are published we will be able to do more robust comparative genomic studies in 
addition to working to improve our assembly to achieve higher contiguity and find ways 
to handle repeat regions more effectively. 
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Figure 23. Distribution of Repeat Elements in the Humpback Whale Genome. 
Repeats were annotated with Censor in the humpback whale assembly MegNov.v03 based 
on the mammalian library provided by RepBase (Kohany, Gentles et al. 2006). The 
majority of the repeats are L1 LINEs (large blue wedge) accounting for 44.6% of all the 
repeats. The most abundant repeats are listed in the legend and go clockwise starting 
from the large L1 wedge.  
 
 
Obviously improving the length and contiguity of a genome assembly is not 
enough; it is also imperative that the assembly is accurate. To get a general idea of they 
accuracy, we directly compared our assemblies (MegNov.v02 and MegNov.v03) to 
regions of the humpback whale genome that have been independently sequenced by 
Sanger sequencing and deposited in GenBank. There are currently 2,351 nucleotide 
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sequences in GenBank that exists for this species. We ran BLAST to query them against 
the MegNov.v02 and MegNov.v03 assemblies to get a measure of accuracy. We find that 
97.7% of the sequences are found in the MegNov.v02 assembly and 96.6% (only 27 fewer 
genes) produce a hit in MegNov.v03.  Though there are slightly fewer hits in the 
MegNov.v03 genome, the hits have higher percent identities on average (98.43% vs. 
95.44%). The distribution of all top hit percent identity scores for the two assemblies are 
shown in Figure 24, in which we clearly see hundreds of sequences that are aligning at a 
much lower identity in the MegNov.v02 assembly.  
 
Figure 24. Distribution of sequence identities from BLAST alignments. BLAST was 
used to align the humpback whale draft assemblies to previously (Sanger) sequenced 
humpback whale sequences in GenBank. The sequences from GenBank generally align 
better with the MegNov.v03 assembly compared to the MegNov.v02. The blend of the two 
colors defined in the legend represents the overlapping regions of the histograms. 
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As an additional test for assembly accuracy, we used gene transcripts that were 
independently assembled to determine their agreement with the genomic sequence, 
though in the case of disagreement it is not clear which sequence is likely to be correct. 
We sequenced the RNA that was isolated from the same skin biopsy of the whale and de 
novo assembled the transcripts with the Trinity pipeline offered by the Broad Institute 
(Grabherr et al. 2011). GenBlastG (She et al. 2011) was used to annotate the top 500 
longest predicted open reading frames (ORFs) in the MegNov.v03 assembly. We are able 
to successfully annotate at least part of all 500 genes; however short annotations may be a 
result of conserved protein domains. A more accurate representation is the number of 
genes that are annotated with good coverage (≥ 70% of the query ORF). We find that 
86.8% have at least 70% coverage on one scaffold and over half of these genes and have 
an average percent identity greater than 91%. Over half of the genes with quality 
coverage align with the predicted ORFs with greater than 98% identity. These results 
provide confidence in our assembly in addition to validating the predicted ORFs from the 
assembled transcript data.   
Though our overall goal was the assembly a complete humpback whale genome, 
many downstream analyses will focus heavily on the gene sequences. We used the 
software CEGMA (Parra et al. 2009) to estimate the completeness of our assembled genic 
regions.  CEGMA uses a set of 248 genes that are conserved across eukaryotes, but with 
varying degrees of sequence identity. The core eukaryotic genes (CEGs) are divided into 
four categories based on their sequence conservation across eukaryotes: low, medium-
low, medium-high and high. A well-assembled genome would contain a high fraction of 
genes in each category, whereas an incomplete genome would contain a low percentage 
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of genes in the four groups (Figure 25). In a well-assembled divergent genome (e.g. 
protozoans T. gondii and P. falciparum), genes that are most highly conserved would still 
be found while those that are less conserved would be harder to identify.  
We find that our humpback whale genome assemblies (MegNov.v02 and 
MevNov.v03) both cluster with the complete genomes such as chimp (Figure 25); 
however, the MegNo.v03 assembly does slightly better overall (Table 9). The total 
number of CEGs found in the two assemblies is almost identical, but 12 additional 
complete CEGs are found in the MegNov.v03 assembly, which is a 5% increase in 
complete genes. The number of CEGs that can be annotated is highly correlated with the 
total number of genes in the genome (Parra, Bradnam et al. 2009) so we estimate that our 
MegNov.v03 assembly should contain approximately 87% of the full set of humpback 
whale genes. 
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Figure 25. Evaluation of genome completeness with conserved core eukaryotic 
genes. The MegNov.v03 assembly is slightly more complete than the previous whale 
assembly based on the annotation of CEGs across variable levels of conservation. This 
figure was adapted from (Parra, Bradnam et al. 2009) to include our humpback whale 
data.  
 
 Assembly # Complete % Complete Total CEGs % Total CEGs  
MegNov.v02 205 82.66% 241 97.18% 
MegNov.v03 217 87.50% 242 97.58% 
 
Table 9. Core eukaryotic genes found in the humpback whale genome assemblies. 
CEGMA defines a gene to be complete within a genome if it is at least 70% of the query 
gene length. All other found core eukaryotic genes (CEGs) annotated in a genome are 
defined to be partial hits and the total number of CEGs (out of 248) that are found in a 
genome include the complete and partial annotations.   
 
MATERIALS AND METHODS 
Tissue Collection  
The tissue used for genomic sequencing was collected from a female humpback whale 
(Salt) off the coast of Cape Cod using biopsy techniques (Lambertsen 1987, Palsboll et 
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al. 1991) and immediately frozen in liquid nitrogen. The collection was organized by Dr. 
Per Palsboll, at the University of Groningen, and Dr. Jooke Robbins, at the Provincetown 
Center for Costal Studies.  
 
DNA Extraction 
Female humpback whale skin tissue was used for high molecular weight genomic DNA 
isolation following the standard protocol for the DNeasy Blood & Tissue purification kit 
(Qiagen).  
 
DNA Library Construction and Sequencing 
All sequencing libraries were prepared at the Genome Technology Center at the 
University of California Santa Cruz under the direction of Nader Pourmand. The paired-
end library was prepared with ~1µg of genomic DNA that had been sheared using the 
Covaris S2 sonicator. Quality and quantity of fragmented genomic DNA was confirmed 
using an Agilent Bioanalyzer 2100 DNA High Sensitivity chip. A standard ~180bp insert 
size paired-end library was constructed using TruSeq DNA sample preparation kit 
(Illumina). Final size selection between 290-310bp was done using Caliper LabChip XT 
DNA 750 chip following manufacturer’s recommendation. The quality and functionality 
of the library was confirmed by sequencing in a single HiSeq 2000 lane. After confirming 
the quality, library was subjected to 2X100bp paired-end sequencing in three lanes of 
HiSeq 2000. 
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 Two mate pair libraries (2.0Kb and 5.0kb) were prepared using the SOLiD Mate 
Pair Library Preparation Kit with modifications. Approximately, 10µg genomic DNA 
was fragmented using the S2 Adaptive Acoustic Device (Covaris). For the 2Kb mate-
paired library, size selection of DNA fragments (1.8-2.5Kb) was carried out through 
LabChip XT, developed by Caliper Life Sciences. For the 5Kb size selections, sheared 
DNA was electrophoresed in a 0.7% agarose gel for ~16 hours. A band corresponding to 
~4.5-5.5kb was excised from the gel and purified by ethanol precipitation. The size 
selected fragmented DNA was subjected to end repair followed by ligation of 5’ 
dephoshorylated biotinylated MP adaptor on both sides of the DNA fragments. The MP 
adaptor ligated DNA was circularized through intra-molecular hybridization at very low 
concentration, which results in a nick at the 3’ ends of the internal adaptors. In order to 
generate ~100bp paired tags, nicks in the circularized DNA were bidirectionally extended 
into the insert DNA using timed nick translation reaction by DNA polymerase I. The nick 
translated DNA was digested with T7 Exonuclease and S1 Nuclease to release the tags. 
These tags were subjected to end repaired, adenylation and then ligated with Illumina 
non-multiplexed adaptors. The final DNA molecules were bound to streptavidin beads. 
The library DNA molecules bound with beads were enriched by standard Illumina non-
multiplexed paired-end primers. Final amplified libraries were analyzed using an Agilent 
Bioanalyzer 2100 DNA High Sensitivity chip and size selection was done using a Caliper 
LabChip XT DNA 750 chip following manufacturer’s recommendation. Both mate-
paired libraries were subjected to paired-end sequencing in two lanes of HiSeq 2000 
sequencer generating 2×100bp reads.  
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The whale fosmid library was constructed by using the pCC2FOS Fosmid vector 
(CopyControl™ Fosmid Production Kit; Epicentre Technologies). Approximately, 20µg 
high molecular weight genomic DNA was end-repaired and purified by ethanol 
precipitation. The end repaired DNA was ligated to ready to clone pre-linear pCC2FOS 
fosmid vector according to manufactur’s specifications (10:1 molar ratio of vector and 
insert DNA). Fosmid clones were packaged using MaxPlax Lambda Packaging Extract 
and stored at 4°C in 1 ml of Phage Dilution Buffer according to manufacturer’s 
instructions. Primary packaged Fosmid libraries were transfected into EPI300-T1R Phage 
T1-resistant E. coli Plating strain and incubated for 1 hour at 37°C. The infected bacteria 
were spread at high density on LB plates containing 12.5µg/mL chloramphenicol and 
incubated at 37°C for 18 h. Random bacterial colonies were selected for bulk infection in 
10ml LB with 10mM MgSO4 and 0.2% maltose in a shaking incubator for 14 hours at 
37°C. Fosmid DNA was extracted using the Qiagen MiniPrep Kit following the 
manufacturer’s protocol and individually sheared using Covaris S2. Size selection of 
DNA fragments (400-450bp) was carried out through an automated electrophoretic DNA 
fractionation system, LabChip XT, developed by Caliper Life Sciences. Multiplexed 
paired-end sequencing libraries were prepared using TruSeq DNA Sample Preparation 
Kit. 120 fosmid pools (with roughly 50-100 fosmid clones per pool) were subjected to 
paired-end sequencing in HiSeq 2000 one lane generating 2×100bp reads.  
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RNA isolation and purification 
Total RNA was extracted with QIAzol Lysis Reagent, purified on RNeasy spin columns 
(Qiagen), and the RNA integrity and quantity was determined on the Agilent 2100 
Bioanalyzer (Agilent) with the manufacture’s protocol. The total RNA was treated with 
DNase using DNase mix from RecoverAllTM Total Nucleic Acid Isolation kit (Applied 
Biosystems/Ambion) and subjected to cDNA synthesis.  
 
RNA-seq Library 
The RNA library was prepared and sequenced by the Genome Technology Center at the 
University of California Santa Cruz under the direction of Nader Pourmand. The Ovation 
RNA-Seq system V2 (Nugen) was used for cDNA synthesis and RNA amplification was 
performed as described in detail in published literature (Tariq, Kim et al. 2011). Briefly, 
the total RNA was reverse transcribed to synthesize the first-strand cDNA by using a 
combination of random hexamers and poly-T chimeric primer. Double-stranded DNA 
was generated by fragmentation of the mRNA template strand using RNA-dependant 
DNA polymerase. The dsDNA was purified using Agencourt RNAClean XP beads. The 
DNA was amplified linearly using a SPIA process in which RNase H degrades RNA in 
DNA/ RNA heteroduplex at the 5’-end of the double-stranded cDNA, after which the 
SPIA primer binds to the cDNA and the polymerase starts replication at the 3’-end of the 
primer by displacement of the existing forward strand. Finally, random hexamers were 
used to amplify the second-strand cDNA linearly, as described previously (Tariq, Kim et 
al. 2011). 
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The double-stranded cDNA obtained after the Ovation V2 RNA-Seq system, 0.5–
1 µg of double-stranded DNA was used for library. The cDNAs were sheared down to 
350-450bp using the Covaris S2. A target insert size of 350-450bp was then size-selected 
using an automated electrophoretic DNA fractionation system, LabChip XT (Caliper Life 
Sciences) and paired-end sequencing libraries were prepared using Illumina’s TruSeq 
DNA Sample Preparation Kit. Following library construction, samples were quantified 
using the Agilent Bioanalyzer per manufacturer’s protocol. Libraries were sequenced 
using the Illumina HiSeq 2000 with sequencing paired-end read length at 2 x 100bp. 
Reads were de-multiplexed using CASAVA (version 1.8.2). 
 
Read Filtering 
For the ALLPATHS-LG assembly, Illumina and Solid adapter sequences were clipped 
from the ends of reads using fastq-clipper from the ea-utils package (Aronesty 2011). For 
the MaSuRCA and SGA assembly, all reads were filtered using fastq-mcf in the ea-utils 
1.1.2-484 package (Aronesty 2011). The adapter sequences were clipped from the ends 
and known Illumina artifacts were removed (a FASTA file of artifacts was provided by 
the Department of Energy Joint Genome Institute). The cloning vector sequence and E. 
coli contamination was also removed from the fosmid library reads.  Poor quality bases 
were clipped from the ends of reads (score cutoff=10) and reads less than 30 bases were 
discarded after these filtering steps. Reads were maintained as mates, so both were 
discarded if one did not pass the filters. Filtered reads from the 180bp fragment library 
were joined using fastq-join in the ea-utils package (Aronesty 2011).  Only pairs that 
were successfully joined were used as input into the MaSuRCA assembly.   
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Assembly of MegNov.v01 
The very first assembly (MegNov.v01) was run with ALLPATHS-LG provided by the 
Broad Institute (Gnerre, Maccallum et al. 2011). We used the default settings and set the 
ploidy equal to 2, the expected genome size to be 3Gb and the minimum contig size for 
reporting to be 1,000bp. The 2x100bp reads from the 180bp fragment library and the 2kb 
mate-pair library were used as input after clipping Illumina and Solid adapter sequences. 
The assembly was initialized by John St. John at the University of California Santa Cruz 
on a server with 1TB of RAM and 64 cores. It required over 524GB of RAM and took 
approximately one month to finish. 
 
Assembly of MegNov.v02 
The MegNov.v02 assembly was run using ALLPATHS-LG assembler provided by Broad 
Institute (Gnerre, Maccallum et al. 2011). We used the default settings and set the ploidy 
equal to 2, the expected genome size to be 3Gb and the minimum contig size for 
reporting to be 1,000bp. The 2x100bp reads from the 180bp fragment library and the 2kb 
and 5kb mate-pair libraries were used as input after removing any remaining adapter 
sequences. John St. John, at the University of California Santa Cruz, ran this assembly on 
a server with 1TB of RAM and 64 cores.  It required 630GB of RAM and took 
approximately one month to complete.  
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Assembly of MegNov.v03 
The most recent draft of the humpback whale genome (MegNov.v03) used both the SGA 
and MaSuRCA assemblers (Simpson and Durbin 2012, Zimin, Marcais et al. 2013).  
Fosmid contigs were pre-assembled with SGA with the parameters specified in the 
example bash script in the Appendix. Contigs that were greater than 2047bp long were 
sheared into 2,047bp long fragments with an overlap of 1,500bp using the program 
splitter, written by Gary Williams as part of EMBOSS (Rice et al. 2000). These were 
assigned quality values using the script provided by PBJelly (English et al. 2012) and 
converted into frg files for input into MaSuRCA. The 180bp fragment library joined 
reads along with the filtered 2kb and 5kb mate-pair libraries were also used for this 
assembly.  MaSuRCA was run on the Genepool cluster at the Department of Energy. Its 
peak memory usage was less than 300GB, and though the contigs were assembled in ten 
days, the scaffolding took approximately 40 additional days. 
 
De Novo Transcript Assembly from RNA-seq Reads 
The Trinity pipeline provided by the Broad Institute (Grabherr, Haas et al. 2011) was 
used to assemble the raw RNA-seq reads into putative transcripts. From approximately 
142 million paired reads (i.e. ~284 million individual reads), we assembled 156,162 
transcripts. We then used a Perl script that is part of Trinity 
(transcripts_to_best_scoring_ORFs.pl) to predict open reading frames (ORFs) in the 
transcripts. The longest ORF from each transcript was saved and translated into the 
corresponding amino acid sequence. This gave approximately 10,000 high-confidence 
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protein predictions. We used BLAST to align these protein sequences to the non-
redundant Swissprot database. Requiring an E-value of less than or equal to 0.001, 1,824 
transcripts remained. Predicted whale amino acid sequences were required to be +/- 15% 
of the length of the subject protein in the database. This eliminates significant hits due to 
highly conserved domains occurring in genes that are not true orthologs. 1,233 transcripts 
passed this final filter and were used for downstream analyses.  
 
Genome Statistics and Analysis 
Statistics found in Table 8 were generated with the script provided by Assemblathon2, 
which we adapted to properly split scaffolds into contigs (Bradnam et al. 2013). We ran 
the script on the scaffold files of each assembly and split on gaps (i.e. N’s). The values 
we obtained were in agreement with those that overlap the statistics provided in the 
output by the assembler software. Repeats were annotated with Censor using the 
mammalian repeat library provided by RepBase (Kohany, Gentles et al. 2006).  
 The assemblies were compared to the humpback whale nucleotide sequences 
available in GenBank, which were all done with Sanger sequencing. We ran blastn using 
the 2,351 GenBank sequences to query the MegNov.v02 and MegNov.v03 assemblies. 
The top hit of each query was used to compare the average percent identities and the 
distributions were plotted in R.  
 We also compared the assembly to the RNAseq transcripts that we assembled 
with Tritinty (Grabherr, Haas et al. 2011).  The top 500 longest open reading frame 
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predictions were translated to amino acid sequences. These were used as the query inputs 
to genBlastG to annotate these genes (based on homology) in the MegNov.v03 assembly 
(She, Chu et al. 2011).  We analyzed the number of genes with a hit, as well as the 
coverage and percent identity. 
The open source software CEGMA (Parra, Bradnam et al. 2009) was used in 
order to access the completeness of the genome. We executed this using mam parameter 
was used which is optimized to work on mammalian genomes.  
 
DISCUSSION 
We have successfully assembled the genome of the female humpback whale known as 
Salt.  After three assembly attempts we have continued to improve the assembly length, 
contiguity, completeness and accuracy. Data quality and data reduction were the key to 
the success of the MegNov.v03 assembly.  Without data reduction we would not have 
been able to take advantage of long pre-assembled reads to help overcome the highly 
repetitive nature of the genome.  Unfortunately we were not able to successfully perform 
end sequencing, which would provide mated reads 30-40Kb apart and span many repeat 
regions. If we had been able to do this and also provide more coverage of the other 
libraries, ALLPATHS-LG would likely have had improved results compared to the 
MegNov.v02 assembly. However, given our data, the flexibility of MaSuRCA allowed us 
to use long joined reads as well as pre-assembled fosmid contigs with an overlap-
consensus-layout assembler.  
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 Though there tends to be a lot of emphasis on statistics including N50, and total 
scaffold length, there are many other features of an assembly that determine its quality. 
The number of informative bases (i.e. the scaffold length minus gap length) is crucial, 
and it is also necessary that there is confidence in the order in which these bases are 
assembled. We have found that our MegNov.v03 genome assembly contains nearly 97% 
of the humpback whale Sanger sequences deposited in GenBank and the sequences agree 
with high percent identity. This is extremely promising because many of these sequences 
in the database are targeting variable regions of the genome in order to distinguish 
individual whales. Our CEGMA analysis is consistent with these results and also predicts 
that the genome contains 97% of the genic regions (both partially and completely 
assembled) and is estimated to have 87.5% of the genes assembled in a complete form. 
This in in close agreement with what we find by annotating the predicted ORFs from the 
de novo assembled RNAseq transcripts so we are confident that this is a good estimate of 
the fraction of well-assembled genic regions.  
 Our analysis demonstrates with a high level of confidence that the humpback 
whale genome has high enough quality to use in down stream analyses. We are now able 
to use this genome to address questions surrounding Peto’s paradox, which will be 
discussed in detail in Chapter 7. Multiple research groups have been pursuing genome-
sequencing projects of other cetaceans. Our humpback whale genome is one of the first; 
however, the minke whale genome publication was just released and the bowhead whale 
should follow shortly. Additionally, there are groups focusing on toothed whales 
including the harbor porpoise, killer whale, narwhal and the sperm whale. The release of 
this genome enables comparative genomic studies to be conducted and allows our group 
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to focus on determining how evolution has shaped cancer suppression in humpback 
whales with comparison to the African elephant genome, in order to inform future cancer 
prevention strategies.  
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CHAPTER 7: GENOMIC ANALYSIS OF CANCER SUPPRESSION  
 
 
INTRODUCTION 
The genomic sequence of a species is the result of millions of years of evolution acting 
through both drift and natural selection. By analyzing the genome of an organism, and 
comparing it to others, we can gain insight into the process of evolution that gave rise to 
the current state of that organism. Given the theory that cancer risk should increase with 
body size and lifespan, natural selection has played a critical role in shaping the 
mechanisms of cancer suppression in large, long-lived animals to allow them to 
overcome this burden. The signature of this selection should be evident within their 
genomes.  As we have shown with the African elephant, one possible way to combat an 
increased cancer risk is by duplicating tumor suppressor genes (e.g. TP53). In this study 
we investigate our genome assembly of the humpback whale (MegNov.v03) in search of 
duplicated tumor suppressor genes in addition to evidence of convergent and accelerated 
evolution of known tumor suppressors.  
 Convergent evolution describes the observation that similar features can arise 
independently in distant clades. On a molecular level, convergent proteins evolve from 
divergent amino acid sequences into more similar sequences along independent branches 
of life (Zhang and Kumar 1997). If tumor suppressor genes were evolving to have an 
enhanced or specialized function in large, long-lived organisms, we would expect the 
amino acid sequences of distantly related animals with similar body size and longevity to 
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look more similar to each other than we would expect based on our knowledge of species 
evolution (Figure 26). An analysis of the Prestin gene, which is thought to increase 
sensitivity and selectivity to high frequency sounds, reveals that dolphins cluster closely 
with echolocating bats in a phylogeny based on this amino acid sequence (Liu et al. 
2010). This is an example of convergent evolution at the molecular level. The results 
suggest that the evolution of this gene in dolphins and echolocating bats resulted in 
similar protein sequences, and therefore possibly more similar functions, despite having 
different initial sequences in their more recent ancestors. We have surveyed tumor 
suppressor genes across three mammalian clades (show in Figure 26) in search of gene 
trees that show the elephant and whale clustering together instead of with the species they 
are more closely related to evolutionarily (Figure 26).  
 
Figure 26. Illustration of convergent evolution.  The species phylogeny of the two 
large, long-lived species under investigation (elephant and whale) along with their closest 
relatives that have been sequenced (hyrax and dolphin) and human and chimp is depicted 
on the left (A). Time since divergence is marked on the internal nodes. If there has been 
convergent evolution for large, long-lived bodies, then the amino acid sequences of the 
genes might produce a gene tree where elephant and whale cluster together (B). 
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Additionally, accelerated evolution of specific genes or gene sets associated with 
a single lineage is often a sign of a lineage-specific adaptation. The rate of protein 
evolution is conventionally measured using the ratio dN/dS (referred to as ω), where dN 
is the number of non-synonymous changes per non-synonymous site and dS is the 
number of synonymous changes per synonymous site (Miyata and Yasunaga 1980). If 
non-synonymous and synonymous substitutions evolved at a similar rate, ω would be 
equal to 1, and this is considered neutral evolution. If this ratio (ω) is significantly greater 
than one it implies that the protein is under positive selection whereas a ratio (ω) 
significantly less than one is considered purifying selection (Miyata and Yasunaga 1980). 
The majority of protein coding genes are under strong selective pressures, where 
synonymous substitutions occur at a higher frequency per site than non-synonymous, 
consequently, most protein coding genes in mammalian genomes are under purifying 
selection (Ohta 1973). 
 To test for accelerated evolution, we are interested in comparing the estimated 
ω’s along different lineages to determine if a specific branch, or set of branches, have a 
higher ω value than the rest of the tree and therefore may be evolving at an increased rate. 
Thus, for accelerated evolution, ratio ω in a specific lineage does not have to be greater 
than one, just greater than the other branches. Previous work has shown that conserved 
non-coding elements near neuronal genes (Prabhakar et al. 2006) as well as genes 
involved in nervous system development have evolved at accelerated rates in the human 
genome (Dorus et al. 2004), which suggests these genes are in part responsible for the 
large, complex brain which has evolved in Homo sapiens. In this study we investigate 
three possible evolutionary scenarios (redundant genes, convergent evolution and 
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accelerated evolution) to elucidate the tumor suppressive mechanism(s) that have evolved 
in the humpback whale resulting in a decreased cancer risk relative to what we would 
predict based on their size and lifespan. 
 
COPY NUMBER OF TUMOR SUPPRESSOR GENES 
We previously analyzed the copy number of tumor suppressor genes in publically 
available mammalian genomes (discussed in Chapter 4), so we applied the same 
techniques to the humpback whale genome in search of redundant TSGs that may add 
robustness to their tumor suppressive pathways. We did not find any genes with extreme 
amplification in the humpback whale genome; however there are four tumor suppressor 
genes that appear to have one extra copy (i.e. two copies total) (Table 10). 
 
Gene Total Copy # Description 
TUSC2 2 1 retrogene, 1 full gene copy 
CDK2AP2 2 1 expressed retrogene, 1 full gene copy 
BECN1 2 2 full gene copies 
TCEAL7 2 2 full gene copies 
 
Table 10. Copy number of tumor suppressor genes in the humpback whale genome. 
TUSC2 and CDK2AP2 have retrotransposed genes as their additional copy and these are 
conserved in human. BECN1 and TCEAL7 have additional full copies of the genes, 
including introns and exons.  
 
Two of the gene duplications that we find have annotations consisting of a single 
exon, unlike the top ranked gene model, and are therefore likely a result of 
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retrotransposition. TUSC2 (tumor suppressor candidate 2), also known as FUS1, if often 
mutated or deleted in human cancers (Ji and Roth 2008) and normally functions to 
promote p53-dependent apoptosis (Deng et al. 2007). The human genome has a known 
processed pseudogene of TUSC2 on the Y-chromosome; however the expression and 
function are unknown.  
We also believe that the single exon additional gene copy we annotated for 
CDK2AP2 is a known retrogene. CDK2AP2 (cyclin-dependent kinase 2 associated 
protein 2) has three processed pseudogenes in the human genome (CDK2AP2P1, 
CDK2AP2P2 and CDK2AP2P3), which are all expressed in multiple tissues including 
brain, heart, liver, breast and colon, with the highest expression in testes, but has no 
reported function (Bu et al. 2012). We do not predict that the processed copies of TUSC2 
and CDK2AP2 are likely involved in solutions to Peto’s paradox because we also observe 
processed copies in smaller mammals, such as humans.  
BECN1 also has two retrotransposed gene copies in the human genome. 
Interestingly, our annotation of the humpback whale finds two intron-containing copies 
of BECN1, and no processed copies that pass our filters.  These genes are located on two 
different scaffolds; however one of the scaffolds is 7,519bp and just coding sequence of 
BECN1 spans 7,062bp so we cannot place the gene into context because it consumes the 
entire scaffold. The other scaffold containing a full gene model of BECN1 is 58,376bp 
long and BECN1 is at the very 5’ end. The two sequences are conserved between copies 
and because the assembler did not collapse these into one sequence, it is likely that the 
coverage depth was informative of a duplicated region, though we cannot rule out the 
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possibility of an assembly error. The protein product of this gene promotes autophagy 
(i.e. the degradation of cellular components) and is associated with inhibition of cellular 
proliferation (Liang et al. 1999). This gene is mutated in multiple cancer types (most 
commonly in breast and ovarian cancer) and is haploinsufficient (Qu et al. 2003), so a 
redundant copy would protect the gene’s function and require that more than one 
deleterious mutation occur to result in a phenotypic change.  
Additionally we found a duplicate copy of TCEAL7, which only has one coding 
exon, but both copies include non-coding exons as well as introns. Like the BECN1 gene, 
one copy of TCEAL7 is found on a short scaffold that contains only the gene and is 
highly conserved with the top ranking gene model that is found on a larger scaffold. The 
genic region contains repetitive LINE elements, which may have contributed to the 
fragmentation of the assembly and placement of the duplicate copy on a short (1,257bp) 
unplaced scaffold. Nonetheless, TCEAL7 is a negative regulator of the NF-kappa-B 
signaling pathway, which is often overexpressed in malignant cells (Arlt and Schafer 
2002, Karin 2006, Rattan et al. 2010), so an additional copy may help to regulate this 
more consistently. NF-kappa-B is a transcription factor involved in a wide variety of 
functions including inflammation, cell growth, differentiation and apoptosis (Gilmore 
2006, Karin 2006). 
Due to the fact that the humpback whale genome assembly is comprised of 
unplaced scaffolds, we cannot put the suspected duplicate copies in genomic context 
because each copy is found on a different scaffold. Additionally, we queried the predicted 
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ORFs of our de novo assembled RNA transcripts from the humpback whale biopsy, but 
did not find evidence for expression of any of these four genes in the skin.  
 
CONVERGENT EVOLUTION OF TUMOR SUPPRESSOR GENES 
Next we sought to determine if any tumor suppressor genes show signs of convergent 
evolution along the elephant and whale lineages. We used amino acid sequence 
alignments to construct gene trees for 501 tumor suppressor genes using six species: 
human, chimp, dolphin, humpback whale, African elephant and hyrax. The elephant and 
whale were chosen as our species of interest with regard to Peto’s paradox and we 
wanted to compare these to the known human tumor suppressor genes. The other three 
species were chosen as the most closely related sequenced species to the elephant, human 
and whale so we could determine changes that were specific to the large, long-lived 
animals (i.e. African elephant and humpback whale). Gene trees that appeared to be a 
result of a bad alignment after manual inspection were discarded.  
After filtering, one gene that gave the desired phylogeny (Figure 26) remained, 
UBE2D1, which codes for a ubiquitin-conjugating enzyme. The maximum likelihood 
phylogeny shows elephant and whale clustering closely together and the other four 
species as a separate clade (Figure 27A). We find that the amino acid sequence of 
UBE2D1 is perfectly conserved across 30 other mammals with sequences annotated in 
GenBank; however the first eight amino acids in the predicted elephant and whale 
sequences differ from all of the other mammals, yet are similar to each other (Figure 
27B). These amino acid changes lie within the N-terminal alpha-helix 1, which is part of 
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the catalytic core domain (along with the L1 and L2 loops) and is responsible for E3 
recognition and binding (Figure 28A) (Ye and Rape 2009, Kar et al. 2012). Due to the 
extreme conservation observed across other mammals, this finding is arguably an 
example of parallel evolution because both elephant and whale likely evolved from the 
same, or similar, ancestral amino acid sequences into their current sequences. When the 
starting points are the same, this is often referred to as parallel evolution as opposed to 
convergent evolution (Zhang and Kumar 1997).  
 
 
Figure 27. Evidence of convergent evolution of the UBE2D1 protein. The maximum 
likelihood gene of the UBE2D1 amino acid sequences shows the African elephant 
clustering with the humpback whale, though likely derived from the same starting 
sequence seen in other clades, which suggests parallel evolution (A). The first 8 residues 
in the elephant and whale sequences of UBE2D1 (outlined by a red rectangle) are more 
similar to each other than the other species, as shown in the multiple alignment (B). The 
position of alpha-helix 1 is indicated above the alignment and contains most of the altered 
amino acids.  
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Figure 28. 3D structures of UBE2D1 protein. The crystallized structure of human 
UBE2D1 (PDB code: 2C4P.A) (Dodd and Read 2009) is shown with the catalytically 
active core (alpha-helix 1, L1 and L2 loops) highlighted in red (A).  An overlay of the 
protein model prediction for elephant (yellow) and whale (blue) UBE2D1 onto the human 
crystallized structure (green) shows that the models match closely, but there are 
differences in the exact placement of loops and helices (B). 
 
Because the amino acid changes occur in a functional domain of UBE2D1, we 
used protein structure prediction models to assess if the altered N-terminal amino acids in 
elephant and whale would be expected to alter the three-dimensional structure of the 
protein. We used a de novo secondary structure prediction model PredictProtein (Rost 
A. 
B. 
alpha-helix 1 
L1 L2 
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and Liu 2003, Rost et al. 2004) to determine if the alpha-helix 1 would still fold given the 
different amino acid sequences of the elephant and whale relative to other mammals. This 
model predicted the same alpha-helix residues for the human, elephant and whale amino 
acid sequences. However, some amino acid changes were predicted to have a strong 
effect on the protein (Table 11) so we used ModWeb (Eswar et al. 2003) to model full 
tertiary structures of the protein sequences.  
 
Amino Acid 
Change 
Change in amino acid properties Lineage(s) with change 
M1L NP; HPhb ! NP; HPhb whale & elephant 
A2N NP; HPhb ! P; HPhl elephant 
A2S NP; HPhb ! P; HPhl whale 
L3I NP; HPhb ! NP; HPhb whale & elephant 
K4F P(+); HPhl ! NP; HPhb whale & elephant 
R5A P(+); HPhl ! NP; HPhb whale & elephant 
I6I NP; HPhb ! NP; HPhb whale & elephant 
Q7L P; HPhl ! NP; HPhb whale & elephant 
K8Q P(+); HPhl ! P; HPhl whale & elephant 
 
Table 11. N-terminal amino acid changes in UBE2D1 in elephant and whale. The 
first 8 residues of UBE2D1 and their changes seen in elephant and whale are shown. 
Residue changes that are predicted to have a strong (yellow) or weak effect (blue) are 
highlighted and those that are predicted to be neutral are white. Amino acid properties are 
abbreviated as NP: non-polar; P: polar; (+) positive charge; HPhb: hydrophobic; HPhl: 
hydrophilic. 
 
 
 
ModWeb is a homology-based prediction tool that uses the available entries from 
the Protein Data Bank (PDB). The template chosen by the program to use for the whale 
model was a zebra fish UBE2D1 structure (PDB: 2OXQ) (Xu et al. 2008), and the 
template used for the elephant model was the human UBE2D2 (PDB: 4DDG.A) (Juang et 
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al. 2012). Unfortunately the user cannot control the model choice, and because the amino 
acid changes differ by one residue between elephant and whale, and neither matches the 
sequence of other mammalian UBE2D1, the chosen template models differ. The overall 
structure of the protein models predicted for the elephant and whale amino acid 
sequences closely match that of the human model; however there are slight changes in the 
exact positioning of loops and helices (Figure 28B). The elephant sequence resulted in a 
slightly truncated model, where the N-terminus does not include the full alpha-helix 1 
because the first few amino acids are left out of the final model, which may be due to the 
PDB template choice made by ModWeb, or the A2N amino acid change may not result in 
a high confidence model of the full length alpha-helix.   
 
ACCELERATED EVOLUTION IN TUMOR SUPPRESSOR GENES 
Next we looked for evidence of accelerated evolution, which could suggest adaptation, or 
a change in selective pressure along a given lineage. We used codeML, which is part of 
the PAML software (Yang 2007) to search for tumor suppressor genes that may be 
evolving at a faster rate in elephants and/or whales. The same 501 filtered tumor 
suppressor genes that were used for the convergent evolution analysis were searched with 
PAML. We tested if the rates in the experimental model significantly differed from rates 
estimated by the null model in three different experiments: (1) the whale lineage 
independently, (2) the elephant lineage independently, and (3) both whale and elephant 
lineages at the same time to find any tumor suppressor genes that are undergoing 
accelerated evolution in both species.    
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In the first test, we found 16 proteins evolving at an accelerated rate specifically 
in the humpback whale (p-value < 0.05 after multiple testing correction by false 
discovery rate of q=0.05) (Table 12). Half of these genes (HDAC2, YEATS4, DKK3, 
PLA2G16, DNAJA3, PERP, EIF2AK2, and CCNG1) have dN/dS values greater than one, 
suggesting that they may be under positive selection. We used STRING (Franceschini et 
al. 2013) to look for how these genes may be related and we did not find any direct 
interactions or shared specific pathways. In the elephant genome we uncovered one 
protein sequence (CDC73) that is estimated to be evolving at an increased rate along the 
elephant branch and is statistically significant. Three genes are predicted to be evolving at 
an increased rate along both lineages, including UBE2D1, which we also found in our 
convergent evolution analysis (Table 12). All three shared genes showed evidence of 
relaxed purifying selection in elephant and whale (ω (other lineages) < ω (elephant and 
whale) < 1).  
Because our results show many more genes for the whale compared to the 
elephant, we performed an additional test to make sure this was not an artifact of our de 
novo assembly. We used the same methods to test for accelerated evolution in the whale 
within a set of housekeeping genes, which had previously been used in a comparison of 
dN/dS to neuronal genes (Dorus, Vallender et al. 2004). No housekeeping genes were 
found to be evolving at a faster rate in the whale. This gives us confidence that the longer 
list of significant TSGs in whale compared to elephant is not likely caused by frequent 
sequencing errors.  
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Gene 
Accelerated 
lineage 
Accelerated 
ω 
Non-
accelerated ω 
corrected 
P-value 
HDAC2* whale 1.685 0.018 2.7x10-10 
YEATS4* whale 8.1/0 0.011 1.9x10-7 
PBRM1* whale 0.235 0.026 0.001 
PHF17* whale 0.283 0.073 0.001 
UCHL1 whale 0.683 0.047 0.002 
YWHAQ whale 0.734 0.021 0.002 
SET* whale 0.570 0.070 0.004 
DKK3 whale 1.452 0.175 0.005 
WDR11 whale 0.574 0.059 0.005 
PLA2G16 whale 7.7/0 0.144 0.006 
DNAJA3 whale 5.1/0 0.057 0.006 
PCBP4 whale 0.368 0.018 0.009 
PERP whale 3.649 0.182 0.013 
DAPK1 whale 0.501 0.036 0.024 
EIF2AK2 whale 10.341 0.518 0.025 
CCNG1 whale 2.623 0.145 0.034 
       
CDC73* elephant 0.308 0.005 0.021 
       
UBE2D1 whale & elephant 0.598 & 0.309 0.000 0.000 
CYLD whale & elephant 0.151 & 0.159 0.036 0.014 
PRDM2 whale & elephant 0.273 & 0.226 0.119 0.033 
  
Table 12. Genes evolving at an accelerated rate. These genes were found to have 
higher dN/dS along the lineage(s) of interest (column 1). The p-value shown has been 
corrected for multiple testing by false discovery rate (q=0.05) and reflects that the model 
in which the specified lineage(s) had a different dN/dS fit the data better than the null 
model where each lineage has the same value. Those genes with a ratio greater than one 
are highlighted in bold. In cases where dS was estimated to be zero ω is shown as dN/0. 
An * next to the gene name indicates genes involved in chromatin organization and 
modification.  
 
 
Though these accelerated genes have some commonalties because they are all 
involved in tumor suppression, we wanted to determine if there were any specific 
pathways or functions that stood out among this set of genes that we infer to be 
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undergoing accelerated evolution. We used DAVID (Huang da et al. 2009, Huang da et 
al. 2009) to investigate whether this accelerated gene set was enriched for any functions 
or pathways compared to the full list of tumor suppressor genes that we used in this 
study. Interestingly, we find that the genes evolving at an increased rate in the humpback 
whale and African elephant genomes are enriched for genes involved in chromatin 
organization and modification. Six genes (indicated in Table 12) are annotated with the 
terms “chromatin organization” and “chromosome organization” and the uncorrected p-
values for the enrichment of these terms in the accelerated gene list over the background 
TSG list are 0.007 and 0.017, respectively. Other classifications that are significant 
include “histone modification”, “covalent chromatin modification” and “chromatin 
modification” (Table 13).  This suggests that regulation at the chromatin level may be 
important in the evolution of large, long-lived organisms, though the p-values are not 
significant (p > 0.05) after multiple testing correction.  
Gene Ontology Term # of genes uncorrected p-value 
Chromatin organization 6 0.007 
Chromosome organization 6 0.017 
Histone modification 4 0.019 
Covalent chromatin modification 4 0.022 
Chromatin modification 5 0.028 
 
Table 13. Gene Ontology Terms Enriched in Accelerated Gene Set. This analysis was 
done with DAVID. The p-values shown are not corrected for multiple testing. After 
correction for multiple testing they are no longer less than 0.05. 
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METHODS 
Gene Annotation for the Humpback Whale 
Tumor suppresser genes from the Memorial Sloan Kettering CancerGenes database 
(Higgins, Claremont et al. 2007) were annotated with genBlastG (She et al. 2009, She, 
Chu et al. 2011) based on homology to the known human gene. The human amino acid 
sequences were chosen for gene prediction because it is a highly curated genome whereas 
the dolphin genome, which is currently the most closely related public genome to the 
humpback whale, is based solely on computational predictions and frequently has gaps in 
genes that are fully sequenced in the human.  
 We applied a number of filters to obtain a set of gene models for the whale 
orthologs of the human tumor suppressor genes. The top predicted gene sequence in the 
humpback whale genome had to cover at least 70% of the human query gene and be the 
reciprocal best BLAST hit. This is done to remove hits to closely related paralogous 
genes in cases where the true ortholog may not be assembled as well so it would not be 
the top hit. For example, if a gene is split between scaffolds, genBlastG will not use it to 
make a gene model unless one scaffold contains enough sequence to cover 70% of the 
human gene. This cutoff of 70% is a parameter set by the user and we chose 70% to 
match the requirements of CEGMA (Parra, Bradnam et al. 2009). From the original set of 
830 tumor suppressor genes, we find that 724 are at least 70% coverage, but of these we 
only use 646, which are each the reciprocal best BLAST hit to the intended human 
protein. Additional filters were applied to this set for specific analyses as described 
below.   
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Copy Number of Tumor Suppressor Genes  
We used the annotations from genBlastG to look for duplication events of tumor 
suppressor genes in the humpback whale genome. The program provides additional gene 
annotations for a given query gene if multiple locations are found within the target 
genome. For an alternative gene model to be considered an additional gene copy we 
required that the amino acid sequence from the gene model was also a reciprocal best 
BLAST hit to the human ortholog and that it could not overlap with the top gene model 
annotation. We only considered genes that had similar scoring gene models to the top 
ranked version (+/- 10 points) and shared similar sequence identity to the human ortholog 
as the top hit. The alternate gene model could have a better percent identity than the top 
rank hit; however if it was below the sequence identity of the best gene model for that 
protein, it had to be within 10%. These filters were used to make conservative calls for 
increased copy number of tumor suppressor genes in the whale genome. We further 
curated the resulting set of genes to determine if they were found to have a one-to-many 
relationship with the human gene in other mammals.  
 
Obtaining Orthologous Gene Sequences 
The gene list of 830 human tumor suppressor genes was downloaded from the 
CancerGenes database maintained by Memorial Sloan Kettering Cancer Center (Higgins, 
Claremont et al. 2007). A list of housekeeping genes used as a control were obtained 
from a study that had used this list as background to analyze accelerated evolution in 
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nervous system genes (Dorus, Vallender et al. 2004). Ortholog information for chimp 
(Pan troglodytes), dolphin (Tursiops truncatus), African elephant (Loxodonta africana), 
and hyrax (Procavia capensis) were downloaded from Ensembl BioMart (release 72). For 
the whale, we used the top prediction of orthologous coding sequence for each gene, 
which we annotated with genBlastG as described above. Only genes with a single gene 
copy in each organism were used for downstream analyses and the longest open reading 
frame was used in cases of alternative splicing. This restriction resulted in 501 tumor 
suppressor genes and 45 housekeeping genes.  
 
Testing for Convergent Evolution  
Each set of homologous gene coding sequences were translated to amino acids and 
aligned using Prank+F (Loytynoja and Goldman 2008). These alignments were used as 
input into PhyML (Guindon et al. 2010), optimizing for tree topology and branch length 
(parameters: -o tl –s SPR –d aa).  The resulting tree topology was compared to a tree 
where elephant and whale were more closely related to each other than to any other 
species using the BioPerl module Bio::Tree::Compatible (Stajich et al. 2002). We 
manually inspected the resulting gene trees and alignments to remove those that were 
poor quality. To compare UBE2D1 sequences from other mammals, all mammalian 
sequences of UBE2D1 of length 147 (to avoid isoforms) were downloaded from Genbank 
and viewed in SeaView (Gouy et al. 2010). The protein models of UBE2D1 were viewed 
and overlaid using PyMol (Schrodinger 2013).  
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Testing for Accelerated Evolution  
Each set of homologous gene sequences were aligned by codons using Prank+F 
(Loytynoja and Goldman 2008). The alignments were output in PHYLIP format and used 
as input into codeML, which is part of the PAML software package (Yang 2007). We ran 
codeML with the parameters specified in the control file, which can be found in the 
Appendix.  
 For each gene, codeML was run to test both the null model as well as the 
alternative hypothesis. The null model assumes that all branches have the same dN/dS 
(the ratio of non-synonymous substitutions per non-synonymous site to the number of 
synonymous substitutions per synonymous site).  The alternative model tests whether a 
particular lineage has a different dN/dS value, indicating that is evolving at a different 
rate than the other lineages. We tested three alternative hypotheses for each gene: 
1.) The African elephant lineage is evolving at a different rate than the others. 
2.) The humpback whale lineage is evolving at a different rate than the others.  
3.) The elephant and whale lineages are evolving at different rates than the others, 
but they are not necessarily evolving at the same rate as each other.  
 
As suggested in the manual, codeML was run three times for each hypothesis 
tested for each gene (Yang 2007). This was done to check for reproducibility of the 
results since each instance begins with a random seed so the exact results are non-
deterministic.  
 All dN and dS values were plotted in a histogram to detect extreme outliers, as 
poor quality alignments result in abnormally high values. Based on manual inspection of 
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the histogram, a cutoff of 0.048 for dN values and 0.31 for dS values was implemented 
for all downstream analyses. 95% of all estimated dN and dS values using codeML were 
less than or equal to these cutoffs. Values that were higher were often associated with 
poor alignments; therefore by implementing these cutoffs we helped to minimize the 
number of false positives caused by alignments.  
The log-likelihood of the null and alternative models were output by codeML and 
used to compare the two hypotheses. We computed the log likelihood ratio test statistic 
D: 
𝐷 = 2× 𝐻!   − 𝐻! , 
where H1 and H0 are the log-likelihood values from the alternative and null models, 
respectively. The probability distribution of D is a chi-squared with degrees of freedom 
equal to : 
𝑑𝑓! = 𝑑𝑓! − 𝑑𝑓!, 
where df1  and df0 are the degrees of freedom in the alternative and null models. To test 
for accelerated evolution along one lineage (elephant or whale), 𝑑𝑓!  is equal to 1. 
Additionally, to test both lineages at once, while allowing for different ω values along 
each, 𝑑𝑓! equals 2. The values of D for the three repeated runs of codeML were averaged 
together. P-values were calculated based on the Chi-squared distribution with 𝑑𝑓! 
degrees of freedom. The p-values were then corrected for multiple testing by false 
discovery rate (FDR) correction with a significance of 0.05 (i.e. q=0.05) (Benjamini and 
Hochberg 1995).  We filtered for genes where ω along the lineage(s) of interest was 
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greater than estimated for the other branches. Alignments of genes with significant p-
values after FDR correction were manually inspected and those with poor alignments 
were removed from the list.  
 
DISCUSSION 
We have used the humpback whale genome, which we de novo assembled, to reveal signs 
of selective pressures acting on tumor suppressor genes during the evolution of this large, 
long-lived mammal. We do not find any outliers in gene copy number of TSGs; however 
we do find two genes (BECN1 and TCEAL7), which appear to have full gene duplications 
that include both the exons and introns. However, because this is a draft assembly, we 
cannot be sure that these copies are present in the full genome so future work would need 
to be done to address this uncertainty. We found that the second gene annotation for both 
BECN1 and TCELA7 genes on scaffolds that contain just that gene, which matches 
almost identically with the parent gene copy. Therefore, we cannot currently make 
primers to tease these apart, unless we can extend the sequence into unique regions for 
the shorter scaffold.  
Our most surprising finding from the whale genome is the apparent convergent 
evolution of the amino acid sequence for the ubiquitin-conjugating enzyme (E2), 
UBE2D1 (also known as UbcH5a). The process of adding ubiquitin onto a substrate 
typically requires the E1, E2 and E3 enzymes. The ubiquitin molecule is activated by the 
E1, transferred to the E2 and then the E3 transfers the ubiquitin to the substrate (Hershko 
et al. 1983).  Depending on the position and the number of ubiquitin molecules on a 
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substrate, this process can mark a protein for degradation, change a protein’s cellular 
location, or alter its activity (Welchman et al. 2005).   
The predicted protein sequence of the humpback whale UBE2D1 was annotated 
based on homology to the human sequence, not the elephant sequence, which should 
avoid bias in this result. We see perfect amino acid sequence conservation across other 
mammals, and because these changes are found within a catalytically active core domain 
which specifies the binding partners of the protein, we suspect that these differences in 
the elephant and whale would have an impact on the function of UBE2D1. Mutations to 
residues 5 and 9 in the N-terminal alpha-helix of UBE2D2 (an E2 in the same family as 
UBE2D1) expands its number of interacting E3 enzymes (van Wijk et al. 2009). We 
predict that the amino acid changes in the African elephant and humpback whale would 
also affect the number of interacting E3 ligases of UBE2D1, though we do not know if it 
would broaden the range of partners or create a specialist protein that has fewer binding 
partners, but perhaps with increased affinity for one another.  
To reliably predict the binding partners of an E2 ubiquitin-conjugating enzyme 
with computational methods remains a challenge. Though there are still many unknowns 
surrounding these molecules and their interactions, a global yeast-two hybrid study 
revealed that there are at least 28 E3 binding partners of UBE2D1 (van Wijk, de Vries et 
al. 2009).  UBE2D1, along with related E2s UBE2D2-4, act as hub proteins, so changing 
one would likely have a widespread impact on cellular functions (van Wijk, de Vries et 
al. 2009). One of the known binding partners of UBE2D1 is BRCA1, which functions as 
an E3 ligase when bound with BARD1 and UBE2D1 (Mallery et al. 2002). Disruption of 
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the interaction between BRCA1 and UBE2D1 has been associated with an increased risk 
of breast cancer (Morris et al. 2006) The E3 ubiquitin ligase activity of BRCA1 has been 
shown to ubiquitinate the sites of DNA double stranded breaks to signal for repair 
(Morris and Solomon 2004), which creates a logical connection to cancer incidence and 
ubiquitination. Additionally, polyubiquitination signals for protein degradation and can 
not only regulate processes like the cell cycle through this mechanism, but also functions 
to degrade abnormal proteins, which protects the cell from certain mutant phenotypes 
(Fredrickson and Gardner 2012).   
Our analysis of accelerated evolution along the elephant and whale lineages 
suggests that regulation of cellular processes through chromatin remodeling is important 
in the evolution of large, long-lived organisms. We found genes involved in chromatin 
modification and organization are over-represented in the set of genes that we predicted 
to be evolving more rapidly in the humpback whale and African elephant genomes. 
Though most of these genes in the list are accelerated only in the whale genome, the one 
gene we find to be specific to the elephant is CDC73, which is involved in the 
methylation and mono-ubiquitination of histones (Hahn et al. 2012). Chromatin 
modifications can have a wide range of influences on a cell. For example, HDAC2 is 
thought to contribute to the deregulation of gene expression by aberrantly removing 
acetyl groups from histones and silencing tumor suppressor genes in malignant cells 
(Jung et al. 2012); however in normal cells it represses the transcription of many proto-
oncogenes to regulate cell cycle progression (Ropero et al. 2008). 
 153 
As in any genomic analysis, one caveat that we cannot avoid is that results are 
dependent on the quality of the genome assemblies and annotations. Looking for 
signatures of selective pressures depends highly on the multiple alignments of the genes 
being investigated. The quality of the alignments is largely influenced by the quality of 
the genome assembly and the annotations of the gene sequences. We enforced various 
filters to minimize the number of false positives due to poor alignments and then 
manually went through each gene that gave a significant result and discarded those that 
we felt were due to poor coding sequence annotation and/or alignment. This is an 
unfortunate bottleneck, but because we often rely on computational gene predictions for 
genome assemblies of unknown correctness, manually curating the results of 
evolutionary analyses remains necessary.  
After carefully filtering all of our data, our results suggest that the evolution of 
cancer suppression in large, long-lived mammals is highly dependent on the precise 
regulation of gene and protein expression through chromatin remodeling and protein 
modifications, such as ubiquitination. We predict that this evolution is accomplished 
through the optimization of protein functions involved in these modifications, some of 
which we have revealed in this study. If the cellular levels of cancer-associated genes (i.e. 
proto-oncogenes and tumor suppressor genes) are not tightly regulated, cells can undergo 
transformation (Kitagawa et al. 2009). Previous work has also found that genes involved 
in the proteasome-ubiquitin pathway evolve faster along lineages that have increased 
longevity (Li and de Magalhaes 2013). Longevity is highly correlated with body size and 
in order to be large and live for many years, it is required that one can effectively 
suppress cancer.  
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CHAPTER 8: CONCLUSIONS AND FUTURE SUGGESTIONS 
 
 
 
SCIENTIFIC CONTRIBUTIONS 
Peto’s paradox has remained an unsolved mystery for more than 30 years (Peto 1977). In 
this thesis, I present the first large-scale analysis of why cancer risk does not increase 
with body size and lifespan across species. I used hundreds of necropsy and death reports 
of captive mammals to provide empirical evidence that cancer incidence does not 
increase with body size and lifespan. I explored multiple computational models of cancer 
incidence in humans to quickly determine biologically feasible solutions to Peto’s 
paradox which can serve as a focus of future experimental studies. I surveyed the copy 
number of cancer-associated genes in mammalian genomes and found that the African 
elephant genome contains 19 copies of the tumor suppressor gene TP53. Additionally, I 
analyzed the data collected by our collaborators at the University of Utah to demonstrate 
the novel result that African and Asian elephant cells undergo apoptosis at a much higher 
rate than human cells in response to γ-irradiation. The African elephant was previously 
the largest animal with an available genome assembly, so I undertook a de novo assembly 
of the humpback whale genome in order to expand our comparative genomic analyses. 
My analysis of the humpback whale genome revealed a set of tumor suppressor genes 
that are evolving at an accelerated rate and may play a role in increased cancer 
suppression.  
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One important impact of my work is to encourage more creative and innovative 
approaches to cancer research. Current therapies have harsh side effects and often do not 
cure the patient of the disease. It is important to focus more research efforts on improved 
prevention so we can decrease our lifetime risk of cancer and avoid these scenarios 
altogether (Etzioni, Urban et al. 2003). I believe that we can learn from the tumor 
suppression mechanisms that have evolved in large, long-lived animals to advance the 
field of cancer prevention. That said, the immediate translation of the results presented in 
this thesis to a clinical setting is not realistic. Further investigation of our comparative 
genomic findings in the African elephant and humpback whale is needed. Additionally, 
the field of comparative oncology and genomics should initiate new analyses and 
experiments to discover novel mechanisms of cancer suppression, which we may be able 
to mimic in humans as a new form of prevention.  
 
SUGGESTIONS FOR THE FUTURE 
If our current understanding of cancer is reasonable, there must be something 
fundamentally different in large, long-lived organisms to enhance their suppression of 
carcinogenesis. These mechanisms have allowed for the evolution of large bodies and 
extended lifespans without increasing the burden of cancer. In order to pursue this 
research and better out understanding of cancer suppression, we have had to make a 
number of assumptions and interpretations, which I will outline so that future work in this 
field can reassess these and determine the best course of action to move forward.  
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We have used mass as a proxy for cell number across species; however the 
composition of each animal is not identical. For example, whales have thick layers of 
blubber composed of adipose tissue and transformation of this tissue into malignant 
disease (e.g. liposarcoma) is rare (ACS 2013). Future work should consider whether it 
makes sense to compare cancer rates of individual tissue types instead of considering all 
cancers together. This would require accurate measurements of different organs across 
many species as well as the cancer incidence of the different tissues. We did not take this 
approach because cancer incidence in non-human animals is often not documented in a 
detailed manner so trying to make comparisons at this fine grain level would be 
challenging until this data improves.  
 Additionally there is the question of whether we should consider the lifetime risk 
of cancer or if it may make more sense to focus on pre-reproductive cancers when 
comparing rates across species. Selection acts to minimize pre-reproductive cancers 
(Graham 1992). Once an organism reaches an age at which are no longer able to 
reproduce, whether this is due to biological changes like menopause or sexual selection 
within the species, the need to suppress cancer decreases. The amount of time that an 
animal is able to reproduce and the time it takes to reach sexual maturity can vary not 
only between species but also between males and females of the same species. For 
example, female African elephant reach sexual maturity between 10-12 years of age and 
typically breed with a male shortly after. Though males also reach sexual maturity around 
the same time, the competition between males to mate with females strongly favors the 
largest males so most do not reproduce until 35 years old, with peak reproductive years 
from 45-53 (Holliseter-Smith et al. 2007). This suggests cancer suppression during this 
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time is still selected for in males. On the other hand, female African elephants begin to 
show a decrease in fertility around 35 years of age (Ward et al. 2009), so it would be 
interesting to see if there is a difference in the cancer rates of males and females. 
Cetaceans have a wide range of ages of sexual maturity and lifespans. Although most 
whales show no signs of reproductive senescence, the killer whale and the short-finned 
pilot whale go through changes similar to menopause in humans (Marsh 1986, Ward, 
Parsons et al. 2009). Because these species are unable to reproduce throughout their 
entire lives we would hypothesize that the selective pressure to suppress cancer would 
decrease with age in these animals relative to those that breed until old age. To account 
for these differences when comparing cancer incidence across species, future work 
should consider limiting the cancer rates to cases that occur only in early life and during 
reproductive years since selection may be acting differently in animals that have decline 
in fertility with age. Projects that expand on the work that I have outlined in the previous 
chapters should re-evaluate these assumptions about mass as a proxy for cell number and 
the proper comparisons for cancer rates in order to determine the best way to proceed 
with analyses.  
 Our analysis of computational models of cancer incidence provided us with the 
surprising result that a mere ~3-fold decrease in mutation rate can account for a one 
thousand-fold increase in body size (i.e. number of cells). Most researchers we have 
discussed with would have predicted that this value be significantly larger. The somatic 
mutation rate has not been measured for many species, especially non-model organisms 
like elephants and whales, so it would be interesting to get an estimate of these rates 
across animals spanning orders of magnitude in size and also ranging in lifespan. This 
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could be done in vitro using previously published techniques (Kondrashov 2003, Lynch 
2010). Alternatively, we could make use methods that can estimate mutation rate from 
temporally spaced sequenced samples (Drummond et al. 2002). Longitudinal samples 
from the same individuals could be obtained from zoos to capture a wide range of 
species. It is not easy to get skin biopsies from zoo animals for research, and it would be 
challenging to sample the same location over time, which would confound the mutation 
rate estimates. However, blood draws are routinely done so I would suggest deep 
sequencing on DNA from blood in longitudinal samples to monitor mutations. 
Additionally, as the technology for genome sequencing from single cells improves, 
comparing the genomes of hundreds of single cells at each time point to the normal 
reference genome of that individual would provide more precise measures of the somatic 
mutation rate.  
 We have found 19 copies of the tumor suppressor gene TP53 in the African 
elephant genome. Though 18 of these copies lack introns, we find evidence that they are 
actively transcribed. One caveat of this work is that we find additional copies of TP53 
that are expressed and we observe an increased apoptotic response to gamma-irradiation; 
however we have not been able to show a causal link between these two observations. 
There are many experiments that should be done to functionally characterize these genes 
and determine if they are responsible for the increased rate of apoptosis in response to 
gamma-irradiation. Two of the most interesting experiments, in my opinion, would be to 
knockdown the expression of the retrogenes in elephant cells with siRNA and to perform 
a knock-in of these genes in human cells. Both cell types would be subjected to the same 
irradiation experiment we discussed in Chapter 5, which would allow us to address 
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whether the expression of the TP53 retrogenes is required for the high apoptotic response 
in elephant cells and if expressing these genes in human cells confers this hypersensitive 
phenotype. Additionally, we could test if the severity of the apoptotic response is dose 
dependent by doing partial knockdowns and also overexpressing the retrogenes. This 
could be coupled with genome-wide expression analyses to determine downstream 
targets or effectors of these genes. I would also recommend deep sequencing of the total 
RNA (with the exception of the ribosomal RNA), with technical and biological replicates, 
to find evidence of which specific retrogene loci are being expressed because currently 
we are unsure whether it is just a subset of them or all of them.  
We were unable to produce protein from the retrogene clones using an in vitro 
coupled transcription/translation protocol, so it would be interesting to use mass 
spectrometry to determine if the retrogenes are producing protein. Additionally, the 
genomic location of these TP53 copies is unknown, but is crucial information to have in 
order to understand how this gene was propagated within the genome and in what context 
each copy exists. We have obtained chromosome spreads for the African elephant with 
which we had hoped to do FISH; however we were stalled by finding the proper probe 
design. Because we only know approximately 2Kb of sequence for these retrogenes, and 
FISH targets are typically one to two orders of magnitude larger, it has been a challenge 
to find a way to create a probe that will produce enough fluorescence when it binds with 
this short of a sequence. However, the cycling-primed in situ labeling technique can use a 
short probe and amplifies the target sequence so that many copies then exist on the newly 
synthesized strand, which can then be detected by FISH (Talia et al. 2011). We can 
experiment with this technique in the future in addition to performing the experiments 
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proposed above to address the remaining questions surrounding the additional TP53 
copies in the African elephant. These experiments should be done for both the African 
and Asian elephants since we have preliminary work indicating that TP53 retrogenes are 
also present in the Asian elephant and are currently cloning and sequencing them to 
determine their copy number and relationship to the copies found in the African elephant.  
Our copy number analysis of tumor suppressor genes also revealed 8 annotated 
copies of MAL in the horse genome, and additionally two in the microbat genome. Unlike 
the retrogenes in the African elephant, these genes contain introns and appear as a tandem 
array on scaffold 15. It would be interesting to investigate these copies further to 
determine if they are in the genome and are not due to assembly error and if they are 
functional. Depending on the genomic validation, these genes could be expressed in 
human and mouse cells to deduce any enhanced mechanisms of cancer suppression that 
redundant MAL may confer.  
 The genomic analysis of the humpback whale provided many leads on interesting 
genes and pathways, which are promising directions for future investigation. Genes that 
appear duplicated should be verified; however because of the problems posed by the 
short scaffolds that the duplicates are on, which was discussed in Chapter 7, it will be 
important to further improve the genome assembly. The genome assembly is something 
that can always be updated and we should always strive for a complete genome. Long 
insert read libraries have proven to be very successful in other genomes (Li et al. 2010, 
Dong et al. 2013). Another avenue to pursue is optical mapping to create a more 
contiguous assembly. This technique was used for the domestic goat (Capra hircus) 
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genome and reduced the number of scaffolds to 315 from over 200,000 which increased 
the N50 from 3Mb to just over 16Mb (Dong, Xie et al. 2013). The minke whale genome 
was just released and though the assembly size (2.44Gb) is comparable to our 
MegNov.v03 humpback whale assembly, they were able to obtain a significantly better 
scaffold N50 of 12.8Mb because they had four mate-pair libraries (2kb, 5kb, 10kb and 
20kb) (Yim et al. 2013). The 10Kb and 20Kb libraries allow the reads to span large 
regions of tandem repeats and link contigs in non-repetitive regions. Interestingly, our 
MegNov.v03 assembly has more nucleotide positions (A,C,G,T) even though they 
achieve a slightly longer assembly which means they have introduced more gaps, but 
have provided genomic context for the contigs. I believe if we could successfully prepare 
long insert mate-pair libraries, we too could get this contiguity with our genome 
assembly.  
 Further investigation of the UBE2D1 gene and other genes we found to be 
undergoing accelerated evolution in the whale and elephant lineages could be undertaken 
even before an update of the genome assembly. The functional consequence of the 
predicted amino-acid changes in the alpha helix 1 of the elephant and whale UBE2D1 
protein should be determined. This could be done with a yeast-two hybrid experiment to 
find if the E3 binding partners are affected by these changes (van Wijk, de Vries et al. 
2009). It would also be interesting to introduce these amino acid changes in human cells 
and see if there is any phenotypic change in response to stresses, such as DNA damage. 
We also have collaborators who will collect fresh humpback whale blood when there is a 
live stranding, so we could use this in the same irradiation experiment that we did on the 
elephants to characterize the response to DNA damage caused by IR in whale PBMCs. If 
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these experiments yield interesting results that are suggestive of the increased tumor 
suppression of the UBE2D1 protein in elephant and whale, it would be interesting to 
pursue a mouse model in which the whale or elephant protein, containing the altered 
alpha helix 1 residues, is expressed instead of the endogenous copy in order to study 
possible changes in cancer susceptibility.  
Due to computational constraints, we chose to run our analysis on a set of tumor 
suppressor genes that we annotated instead of doing a full genome annotation. In the 
future, when a full gene annotation is performed on the humpback whale genome, the 
accelerated evolution analysis can be repeated and one could look for enrichment of gene 
functions or pathway involvement in the accelerated gene set. This would be an unbiased 
approach and could result in not only genes that have been involved in the evolution of 
large bodies and long lifespans, but also in the transition from terrestrial life back to the 
marine environment and any other form of adaptation that a whale has undergone 
throughout its evolutionary history.  
Though I have proposed multiple experiments to continue the research I have 
done in elephants and humpback whales, Peto’s paradox transcends these two specific 
animals.  Large bodies have evolved multiple times in the history of life, so each clade 
could have evolved different mechanism(s) to boost their tumor suppression abilities. 
Most of the hypotheses that have been proposed to explain Peto’s paradox, as discussed 
in Chapter 1, have not been directly tested, and many related questions remain open.  
As more genomes are sequenced, the power of comparative genomics will 
increase. An approach based on independent contrasts (Garland et al. 2005) of small and 
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large species within each clade could prove fruitful for identifying cancer suppression 
mechanisms. Large, long-lived organisms might have evolved to suppress cancer better 
than small animals by duplicating tumor suppressor genes (Nunney 1999, Leroi, 
Koufopanou et al. 2003) or eliminating some proto-oncogenes from the genome. A 
simple linear regression cannot be used to study whether a correlation exists between 
body size and the copy number of cancer related genes because this assumes 
independence of each genome. In reality, the genomes share many traits in common due 
to evolutionary descent from a common ancestor. An independent contrast model 
(Felsenstein 2003) should be used to partition the variance among species into 
comparisons that are independent of their evolutionary relationships. This analysis could 
be done by studying multiple clades, each composed of closely related species which 
have large variance in body size.  
Marine mammals belonging to the order Cetacea are an ideal clade for this study 
since they range in size from small toothed whales like the harbor porpoise (~52.5Kg) (de 
Magalhães and Costa 2009) to the largest mammal on Earth, the blue whale (over 
100,000 kg) (de Magalhães and Costa 2009). Though there is an extreme range in size, 
these species only diverged approximately 20-34 million years ago (Murphy, Pringle et 
al. 2007, Jackson, Baker et al. 2009). We have contributed to an effort to expand the 
number of sequenced cetacean genomes and there are groups around the world that are 
working on the bowhead whale, minke whale, blue whale, harbor porpoise and many 
others. Studies should focus on clades that include animals larger than humans, as 
opposed to looking at differences among various sized rodents or between mouse and 
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human, because the goal is to find a way of preventing cancer that is superior to 
endogenous tumor suppression mechanisms in humans.  
Additionally, there are standard assays that could be used in comparative analyses 
to test many of the hypotheses for resolving Peto’s paradox, including measurements of 
DNA damage repair (Olive and Banath 2006), somatic mutation rate (Drummond, 
Nicholls et al. 2002), telomere lengths (Canela et al. 2007), differentiation (Li et al. 2010) 
and proliferation (Woosley 1991, Minor 2008), apoptosis (Ribble et al. 2005), and 
reactive oxygen species (Afanasev 2009, Kundu et al. 2009).  
Though this dissertation focused on cancer gene copy numbers and DNA-damage 
response, I also believe that basal metabolic rate plays a large role in the explanation of 
reduced cancer incidence in large animals. The metabolic rate impacts nearly all aspects 
of the cell and the byproducts, such as reactive oxygen species, are suspected to play a 
role in aging phenotypes and disease, including cancer (Ames 1989, Ku, Brunk et al. 
1993, Stadtman 2004, Ivanova and Yankova 2013).  Though our results suggest there are 
other mechanisms of cancer suppression in large, long-lived animals, they may merely 
supplement the cancer protection provided by a lower per cell metabolic rate. 
We are among the first empirical endeavors into Peto’s paradox and we hope to 
encourage other groups to pursue some of the research avenues I have suggested so that 
we may make advancements more rapidly. In order to truly change and innovate in 
cancer research we will need to address some shortcomings of the current state of the 
field. The majority of cancer research is done on a very small subset of organisms, which 
restricts our understanding of cancer to what we learn from those particular model 
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systems. Furthermore, the qualities of model organisms that make them ideal to work 
with in laboratory conditions (short lifespan and small body) are the very things that 
make them poor models for cancer suppression (Leroi, Koufopanou et al. 2003).  
The lack of functional data for non-model organisms is also a major gap in the 
field. Function is often assumed from homology, which is not necessarily correct. For 
example, TSGs in Drosophila are largely non-overlapping with human tumor suppressors 
(Pearson and Sánchez Alvarado 2008). We make these assumptions in our own work 
because we currently only have computational gene predictions for many species, which 
is why follow-up studies should focus on the functional annotations of our genes of 
interest. We are also lacking robust epidemiological studies of cancer incidence in 
wildlife and captive populations. Captive populations will be useful for longitudinal 
studies and the predation-free environment will allow for better estimates of cancer rates. 
Studies that aim at a better understanding of the evolution of cancer suppression 
mechanisms will have to expand the variety of organisms that are studied in the 
laboratory setting and pursue both genomic and functional studies.  
 
CONCLUSION 
There has been no observed correlation between body size, longevity and lifetime cancer 
risk. Every additional cell and extra year of life should increase the probability of 
carcinogenesis. The fact that large, long-lived organisms are not over burdened by cancer 
suggests that they are more resistant to malignant transformation than smaller, more 
short-lived animals. Since large, long-lived organisms have achieved cancer suppression 
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with minimal toxicity, this may be a fruitful avenue for cancer prevention research. 
People have only been invested in cancer research for decades while evolution has been 
tuning cancer suppression mechanisms for over a billion years. If we can harness the 
cancer suppression mechanisms of large, long-lived organisms, then we could potentially 
eradicate cancer as a public health threat in humans.   
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APPENDIX 
MULTIPLE ALIGNMENT OF TP53 RETROGENES 
The below alignment was generated with MUSCLE using CLC Main Workbench 7 and 
shows the TP53 retrogenes aligned to the coding sequence of the ancestral copy. 
 
1
ATGGAGGAGCCCCAGT CAGAT CT CAGCACCGAGCT CCCT CTGAGT CAAGAGACGT T
ATGGAGGAGCCCGAGT CAGAT CT CAGT ACTGAGCT CCCT CTGAGT CAAGAGACT T T
ATGGAGGAGCCCGAGT CAGAT CT CAGT ACTGAGCT CCT T CTGAGT CAAGAGACT T T
ATGGAGGAGCCT CAGT CAGAT CT CAGT ACTGAGCT CCCT CTGAGT CAAGAGACT T T
ATGGAGGAGGCT CAGT CAGAT CT CAGT ACTGAGCT CCCT CTGAGT CAAGAGACT T T
ATGGAGGAGCCCAAGT CAGAT CT CAGT ACTGAGCT CCCT CTGAGT CAAGAGACT T T
ATGGAGGAGCCCAAGT CAGAT CT CAGT ACTGAGCT CCCT CTGAGT CAAGAGACT T T
GTGGAGGAGCCT CAGT CAGAT CTGAGCAT TGAGCT CCCT CTGAGT CAAGAGACAT T
ATGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGAGACGT T
ATGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGAGACGT T
ATGGAGGAGCCT CTGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGAGACGT T
ATGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGAGACAT T
ATGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGGGACGT T
GTGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGGGACGT T
ATGGAGGAGGCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGAGACGT T
AAGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGGGACGT T
ATGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGGGACGT T
ATGGAGGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGAGACGT T
ATGGAAGAGCCT CAGT CAGAT CT CAGCACTGAGCT CCCT CTGAGT CAAGGGACGT T
T T CAT ACT T ATGGGAACT CCT T CCTGAGAAT CCGGT T CTGT CCCCCACACT ACCCC
T T TGT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CGT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CATGCT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CATGCT TGGGGAAACT CCT T CCTGAGAAGGTGGT T CTGT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T T CTGAGAAGCTGGT T CT AT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CT AT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT T CCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT CCCT CT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT T CCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT T CCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT T CCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT T CCCCT CACTGT CCC
T T CAT ACT TGGGGAAACT CCT T CCTGAGAAGCTGGT T CTGT T CCCCT CACTGT CCC
CGGCAGTGGAGGT CATGGACGAT CTGCT ACT CT CAGAAGACACTGCAAACTGGCT A
CAGCAGCGGAGGCAGGAGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCGGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCGGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGCCT A
CAGCAGCGGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGCCT A
CAGCAGCGGAGGCAGT AGACGAT CTGCTGCT CCCAGAAGATGCTGCAGACTGCCT A
CAGCAGCGGAGGCAGT AGACGAT CTGCTGCT CCCAGGAGATGCTGCAGACTGCCT A
CAGCAGCGGAGGCAGT AGT CAAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCGGAGGCAGT AGT CAAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGAAGCGGAGGCAGT AGACAAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCGGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCGGAGGCAGT AGATGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAAT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAGT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAAT AGACGAT CTGCT ACT CCCAGAAGATGCTGCAGACTGGCT A
CAGCAGCAGAGGCAAT AGACGAT CT ACT ACT CCCAGAAGATGCTGCAGACTGGCT A
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2
GAAAGCCAAGTGGAGGCT CAGGGAATGT CCACAACCCCTGCACCAGCCACCCCT AC
GAAAGCCAAGCTGGGGCT CAAGAAACAT CAGCAGCCCCTGCACCAGCCACCCT T A -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGCAGCCCCTGCACCAGCCACCCT T A -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGCAGCCCCTGCACCAGCCACCCT T A -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGCAGCCCCTGCACCAGCCACCCT T A -
GAAAGCCAAGCTGGGGCT CAAGAAAT AT CAGCAGCCCCTGCACCAGCCACACT T A -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGCAGCCCCTGCACCAGCCACCCT T A -
GAAAGCCAAGGTGGGGCT CAAGGAAT AT CAGAAGCACCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCGCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAGT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAGT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCCCT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCT CT A - - - - - - - - - - - - - - - -
GAAAGCCAAGCTGGGGCT CAAGGAAT AT CAGAAGCCT CT A - - - - - - - - - - - - - - - -
ACCGGTGGCCCCCGCACCAGCCACCT CCTGGACCCTGT CAT CT T CCGT CCCT T CCC
- - - - - - - - - - - - - - T ACCAGCCT CCT CCTGGACACT CT CGT CCT CTGT CCCT T CCC
- - - - - - - - - - - - - - CACCAGCCACCT CCT AGACACT T T CAT CCT CTGT CCCT T CCC
- - - - - - - - - - - - - - CACCAGCCACCGCCTGGACACT CT CAT CCT CTGT CCCT T CCC
- - - - - - - - - - - - - - CACCAGCCACCT CCTGGACACT CT CAT CCT CTGT CCCT T CCC
- - - - - - - - - - - - - - CACCAGCCACCT CCTGGACACT CT CAT CCT CTGT CCCT T CCC
- - - - - - - - - - - - - - CACCAGCCACCT CCTGGACACT CT CAT CCT CTGT CCCT T CCC
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT T CCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT T CCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGATGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CGCT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
- - - - - - - - - - - - - - CACT AGCCACCT CCTGGACGCTGT CAT CCT CTGT CCCT T CT C
AAAAGACCT ACCCTGGCACCT ATGGT T T CCGT CTGGGCT T CCT ACAT T CTGGGACA
AGAAGACCT ACTGCAGCAACTGTGGT T T CCGT CT TGGCT T CCTGCAT T CTGGGACA
AGAAGACCT ACTGCAGCAACTGTGGT T T CCAT CT TGGCT T CCTGCAT T CTGGGACA
AGAAGACCT ACTGCAGCAACTGTGGT T T CCGT CT TGGCT T CCTGCAT T CTGGGACA
AGAAGACCT ACTGCAGCAACTGTGGT T T CCGT CT TGGCT T CCTGCAT T CTGGGACA
AGAAGACCT ACTGCAGCAACTGTGGT T T CCGT CT TGGCT T CCTGCAT T CTGGGACA
AGAAGACCT ACTGCAGCAACTGTGGT T T CCGT CT TGGCT T CCTGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CAT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CAT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCTGCC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AAAAGACCT ACC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT AGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CACT T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CAT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CAT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
AGAAGACCT ACC- CAGCACCT AT CGT T T CTGT CTGGGCT T CT TGCAT T CTGGGACA
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3
GCCAAGT CCGT CACCTGCACGT ACT CCCCTGACCT T AACAAGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCTGCATGT ACT CCCCTGACCT T AACAAGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCTGCACGT ACT CCCCTGACCT T AACAAGCTGT T CTGCCAGCT
GCCAAGT CTGT CACCTGCATGT ACT CCCCTGGCCT T AACAAGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCTGCATGT ACT CCCCTGGCCT T AACAAGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCTGCATGT ACT CCCCTGGCCT T AACAAGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCTGCATGT ACT CCCCTGGCCT T AACAAGCTGT T T TGCCAGCT
GCCAAGT CCGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT CCGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT CCGT CACCT ACACAT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCGGCT
GCCAAGT CCGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCCAGT T CGT CACT T ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCT ACACGT ACT CCCCTGAACT T AACGTGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT CTGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT T CGT CACCT ACACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GCCAAGT T CGT CACCT AGACGT ACT CCCCTGAACT T AACATGCTGT T T TGCCAGCT
GGCAAAAACCTGCCCAGTGCAGCTGTGGGT CG- CCT CACCACC- - - - - CCCGCCCG
GGCAAAGACCTGT CCAGTGCAGCCGT AGCT CA - GCT CACCACC- - - - - CCACCCCA
GGCAAAGACCTGT CCAGTGCAGCCGT AGCT CA - GCT CACCACCCCACT CCACCCCA
GGCAAAGACCTGT CCAGTGCAACCGT AGCT CA - GCT CACCACC- - - - - CCACCCCA
GGCAAAGACCTGT CCAGTGCAGCCGT AGCT CA - CCT CACCAGC- - - - - CCACCCCA
GGCAAAGACCTGT CCAGTGCAGCCGT AGCT CA - GCT CACCACC- - - - - CCACCCCA
GGCAAAGACCTGT CCAGTGCAGCCGT AGCT CA - GCT CACCACC- - - - - CCACCCCA
GGCAAAGGCCTGT CCAGTGCAGCCGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCCATGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGCCCAGTGCAGCTGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCCGTGGGT CA - CCT CAACAAC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCTGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCCGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGCGCAGCTGTGGGT CACCCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCTGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCTGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCTGTGGGT CA - CCT CAACAT C - - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCTGTGGGT CA - CCT CAACACC- - - - - CCCGCCCA
GGCAAAGGCCTGT CCAGTGCAGCTGTGGGT CA - CCT CAACACC- - - - - CCCGCCAA
GCACCCGTGT T CGCACCATGGCCAT CT ACAAGAAGT CAGAGCAT ATGACGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGACAGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGATGT C- - AGCACATGACAGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGATGT C- - AGCAT ATGACAGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGATGT C- - AGCAT ATGACAGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGATGT C- - AGCAT ATGACAGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGACAGAGGTG
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACAT C - - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACAT C - - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGATGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
GCACCTGTGT T CACACCATGGCCAT CT ACCAGACGT C- - AGCAT ATGATGGAGGT C
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GTCAAGCGCTG- CCCCCACCATGAGCGCTGCT CTG- ACT CT AGCGATGGCCTGGCC
ATGCAGCACTG- CCCCCACCT TGAGTGCTGCT CTG- ACT AT AGCGACGGCCTGGCC
GTGCAGCACTG- CCCCCAT CT TGAGTGCT ACT CCG- ACT AT AGCGATGGCCTGGCC
GTGCAGCACTG- CCCCCACCT TGAGTGCTGCT CCG- ACT AT AGCGATGGCCTGGCC
GTGCAGCACTG- CCCCCACCT TGAGTGCTGCT CCG- ACT AT AGCGATGGCCTGGCC
GTGCAGCACTG- CCCCCACCT TGAGTGCTGCT CTG- ACT AT ACCGATGGCCTGGCC
GTGCAGCACTG- CCCCCACCT TGAGTGCTGCT CCG- ACT AT AGCGATGGCCTGGCC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CTG- ACT AT AGCGAT TGCT TGGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CT A - ACT AT AGCGAT TGCT TGGAC
ATGAAGCACTG- CCGCCACCT TGAGTGCCGCT CTG- ACT AT AGCAAT TGCT TGGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCTGTG- ACT AT AGCGAT TGCT TGGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCTGTG- ACT AT AGCGAT TGCT TGGAC
ACGAAGCACTG- CCGCCACCT TGAGTGCCGCT CTGT ACT AT AGCGAT TGCT TGGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CT A - ACT AT AGCGAT TGCT TGGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CTG- ACT AT AGCGAT TGCT T AGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CTG- ACT AT AGCGAT TGCT T AGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CTG- ACT AT AGTGAT TGCT T AGAC
GTGAAGCAT TGCCCCCCACCT TGAGTGCCGCT CTG- ACT AT AGCGAT TGCT TGGAC
GTGAAGCACTG- CCCCCACCT TGAGTGCCGCT CTG- ACT AT AGCGAT TGCT TGGAC
CCT CCT CAGCACCT CAT CCGGGTGGAAGGAAACCTGCGTGCTGAGT AT CTGGAGGA
GCT CCT CAGCAT CT T AT CCAGGTGGGAGAAAT CCTGTGTGCTGA - T AT T TGT AGGA
GCT CCT CAGCAT CT T AT CCAGGTGGGAGGAAT CCTGCGTGCTGA - T AT T TGT AGGA
GCT CCT CAGCAT CT T AT CCAGGTGGGAGGAAT CCTGCGTGCTGA - T AT T TGT AGGA
GCT CCT CAGCAT CT T AT CCAGGTGGGAGGAAT CCTGCGTGCTGA - T AT T TGT AGGA
GCT CCT CAGCAT CT T AT CCAGGTGGGAGGAAT CCTGCGTGCTGA - T AT T TGT AGGA
GCT CCT CAGCAT CT T AT CCAGGTGGGAGGAAT CCTGCGTGCTGA - T AT T TGT AGGA
CCT CCT CAGCACCT CATGCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT ACT CAGCACCT CATGCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT CAT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT CAT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT CAT CCA - GT AGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT CATGCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT CAT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT T AT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT T AT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT T AT CCA - GTGGGAGGAAACCTGCATGCTGAGCAT T TGGAGGA
CCT CCT CAGCACCT CAT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CCT CCT CAGCACCT CAT CCA - GTGGGAGGAAACCTGCATGCTGAGT AT T TGGAGGA
CAGCAT CACT CT CCGACACAGTGTGGTGGTGCCCT ACGAGCCGCCCGAGGT CGGGT
CACCAT CACT CT T TGACAT AGTGTGG- GGT ACCCT ATGAGCT ACCT CAGGT CGGCT
CACCAT T ACT CT T CGACAT AGTGTGG- GGT ACCCT ATGAGCT ACCT CAGGT CGGT T
CACCAT CACT CT T CGACAT AGTGTGG- GGT AT CCT ATGAGCT ACCT CAGGT CGGT T
CACCAT CACT CT T CGACAT AGTGTGG- GGT AT CCT ATGAGCT ACCT CAGGT CGGT T
CACCAT CACT CT T CAACAT AGTGTGG- GGT ACCCT ATGAGCT ACCT CAGGT CGGT T
CACCAT CACT CT T CGACAT AGTGTGG- GGT ACCCT ATGAGCT ACCT CAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGT AGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT ATGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CAGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT AGGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGTGTGG- GGTGCCCT ATGAGCCACCAGAGGT CGGT T
CACCAT CACT CT ATGACAT AGCGTGG- GGTGCCCT ATGAGCCACCAGAGGT CGGT T
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CTGACTGT ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AGCA - GCT CCTGCAAGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AGCA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AGCA - GCT CCTGCATGGGGCG
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AGCA - GCT CCTGCATGGGGCG
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AGCAGGCT CCTGCATGGGG- -
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AGCA - GCT CCTGCGTGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- C
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- C
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT - - - - - - T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACT T CATGTGT AACA - GCT CCTGCATGGGG- G
CTGAC- - T ACCACCAT CCACT T CAACCT CATGTGT AACA - GCT CCTGCATGGGG- G
GCATGAACCGGCGGCCCAT CCT CACCAT CAT CACACTGGAAGACT CCAGTGGT AAT
GGAGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCAGTGGT AAT
GGGGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCGATGGT AAT
GGGCGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCGATGGT AAT
GGGGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCGATGGT AAT
GGGGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCGATGGT AAT
CGGGAAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCGATGGT AAT
GCATGAA - - - - - - - CCCAT T CT CACCAT T ATGACAATGGAAGACT CCAATGGT AAT
GCATGAA - - - - - - - CCCAT T CT CACCAT T ATGACAATGGAAGACT CCAATGGT AAT
GCAGGAA - - - - - - - CCT AT CCT CACCAT CAT CACACTGGAAGACT CCAACGGT AAT
GCAGGAA - - - - - - - CCCAT CCT CACCAT CAT CACT CTGGAAT ACT CCAATGGT AAT
GCATGAA - - - - - - - CCCAT CCT CACCAT CAT CACT CTGGAAT ACT CCAATGGT AAT
GCAGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCAATGGT AAT
GCAGGAA - - - - - - - GCCAT CCT CACCAT CAT CACACTGGAAGACT CCAAAGGT AAT
GCAGGAA - - - - - - - CT CAT CCT CACCAT CAT CACACTGGAAGACT CCAATGGT AAT
GCAGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCAATGGT AAT
GCAGGAA - - - - - - - CCCAT CCT CACCAT CAT CACACTGGAAGACT CCAATGGT AAT
GCAGGAA - - - - - - - GCCAT CCT CACCAT CAT CACACTGGAAGACT CCAATGGT AAT
GCAGGAA - - - - - - - GCCAT CCT CACCAT CAT CACACTGGAAGACT CCAATGGT AAT
CTGCTGGGACGT AACAGCT T TGAGGTGCGCAT T TGTGCCTGT CCTGGAAGAGACAG
CTGCT AGGACACAACAGT T T CGAAGTGCAT AT T TGT ACCTGT T CTGGGAGAGACAG
CTGCT AGGACACAACAGT T T CGAGGTGCAT AT T TGT A - CTGT T CTGGGAGAGACAG
CTGCT AGGACACAACAGT T T CGAGGTGCAT AT T TGT A - CTGT T CTGGGAGAGACAG
CTGCT AGGACACAACAGT T T CGAGGTGCAT AT T TGT A - CTGT T CTGGGAGAGACAG
CTGCT AGGACACAACAGT T T CGAGGTGCAT AT T TGT A - CTGT T CTGGGAGAGACAG
CTGCT AGGACACAACAGT T T CGAGGTGCAT AT T TGT A - CTGT T CTGGGAGAGACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACCTGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACCTGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACCTGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACCTGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACCTGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
CCGCTGAGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
CCGCTGGGACACAACAGT T T CGAGGTGCAT AT T TGT ACT TGT CCTGGGAGACACAG
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ACGT ACAGAAGAAGAAAA - T T T CCACAAGAAGGGAGAGCCT TGCCCAGAGCCGCCA
ACGT ACAGAGGAAGAAAA - T T T CCACAACAAGTGGGA - - - - - - - - - - - - - - - GCCA
ACGT ACAGAGGAAGAAAAT T T T CCACAACAAGTGGGGA - - - - - - - - - - - - - - GCCA
ACGT ACAGAGGAAGAAAA - T T T CCACAACAAGTGGGA - - - - - - - - - - - - - - - GCCA
ACGT ACAGAGGAAGAAAA - T T T CCACAACAAGTGGGA - - - - - - - - - - - - - - - GCCA
ATGT ACAGAGGAAGAAAA - T T T CCACAACAAGTGGGA - - - - - - - - - - - - - - - GCCA
ACGT ACAGAGGAAGAAAA - T T T CCACAACAAGTGGGA - - - - - - - - - - - - - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCACAACAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCACAACAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAG- T T T CCACAAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAGAAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAGAAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAGAAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
AT AT ACAGAGGAAGACAA - T T T CCAT AAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAT AAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAT AAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
AT AT ACAGAGGAAGACAA - T T T CCAT AAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAGAAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
ATGT ACAGAGGAAGACAA - T T T CCAT AAGAAGTGGGAGCCT TGCCCTGA - - - GCCA
CCCCCTGGG- AGGAGCACT AAGCGAGCACTGCCCACCAACACCAGCT CCT CT ACCC
CCCT CTGAG- AGGAT CACT AAGT AAGCACTGC- CACCAGCACT AGCT CCCCT ACCG
GCCT CTGAG- AGGAT CACTGAGT AAGCACTGCCCACCAGCACCAGCT CCT CT ACCG
CCCT CTGAG- AGGAT CACT AAGT AAGCACTGCGCACCAGCACCAGCT CCT CT ACCG
CCCT CTGAG- AGGAT CACT AAGT AAGCACTGCCCACCAGCACCAGCT CCT CT ACCG
CCCT CTGAG- AGGAT CACT AAGT AAGCACTGCACACCAGCACCAGCT CCT CT ACTG
CCCT CTGAG- AGGAT CACT AAGT AAGCACTGCACACCAGCACCAGCT CCT CT ACCG
CCCT CTGGG- AGGAT CACT ACGCAAACACTGCCCACCAGCACCAGCT CCT CT ACGA
CCCT CTGGG- AGGAT CACT ACGCAAACACTGCCCACCAGCACCAGCT CCT CT ACGA
GCCT CTGGGAAGGAT CACT AAGCGAACACTGCCCACCAGCACCAGCT CCT CT ACCA
CCCT CTGGG- AGGAT CACT AAGCAAACACTGCCCACCAGCACCAGCT CCT CT AT CA
CCCT CTGGG- AGGAT CACT AAGCAAACACTGCCCACCAGCACCAGCT CCT CT AT CA
GGCT CGGGG- AGGAT CACT AAGCAAACACTGCCCACCAGCACCAGCT CCT CT ACCA
GGCT CGGGG- AGGAT CACT AAGCGAACACTGCCCACCAGCACCAGCT CCT CT ACCA
GGCT CGGGA - AGGAT CACT AAGCGAACACTGCCCACCAGCACCAGCT CCT CT ACCA
GGCT CGGGG- AGGAT CACT AAGCGAACACTGCCCACCAGCACCAGCT CCT CT ACCA
GGCT CGGGG- AGGAT CACT AAGTGAACACTGCCCACCAGCACCAGCT CCT CT ACCA
GGCT CGGGG- AGGAT CACT AAGCGAACACTGCCCACCAGCACCAGCT CCT CT ACCA
GGCT CGGGG- AGGAT CACT AAGCGAACACTGCCCACCAGCACCAGCT CCT CT AT CA
AGCCAAAGAAGAAGCCACTGGATGAAGAAT AT T T CACCCT T CAGAT CCGTGGGCGT
AGCCAAAGAAGAAGCCAGTGGATGAAAAAT AT T T CACCCT T CAGAT CCATGGGCAT
AGCCAAAGAAGAAGCCAGTGGACGAAAAAT AT T T CACCCT T AAGAT CCATGGGCAT
AGCCAAAGAAGAAGCCAGTGGATGAAAAAT AT T T CACCCT T AAGAT CCGTGGGCAT
AGCCAAAGAAGAAGCCAGCGGATGAAAAAT AT T T CACCCT T AAGAT CCGTGGGCAT
AGCCAAAGAAGAAGCCAGTGGATGAAAAAT AT T T CACCCT T AAGAT CCGTGGGCAT
AGCCAAAGAAGAAGCCAGTGGATGAAAAAT AT T T CACCCT T AAGAT CCGTGGGCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACCCT T CAGAT CCATGGGCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACCCT T CAGAT CCATGGGCAT
AGCCAAAGAAGAAGCCACTGGAT AAAAAAT ACT T CACCCT T CAGAT CCATGGGCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACCCT T CAGAT CCATGGGCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACCCT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
AGCCAAAGAAGAAGCCACTGGATGAAAAAT ACT T CACT CT T CAGAT CCATGGCCAT
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GAACGCT T CAAGATGT T CCT AGAGCT AAATGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGAT T CAAGAT AT T CCT AGAGT TGAATGAGGCACTGGAGCTGAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AGAGT TGAACGAGGCAT TGGAGCTGAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AGAGT TGAATGAGGCAT TGGAGCTGAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AGAGT TGAATGAGGCAT TGGAGCTGAAGGATGCCCA
GAATGT T T CAAGATGT T CCT AGAGT TGAATGAGGCAT TGGAGCTGAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AGAGT TGAATGAGGCAT TGGAGCTGAAGGATGCCCA
GAATGT T T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGT T T CAAGATGT T CCT AAAGCT CAATGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGAT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGT T T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGT T T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGT T T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCTGAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCT CAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCT CAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCT CAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCT CAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGT TGAAGGATGCCCA
GAATGCT T CAAGATGT T CCT AAAGCT CAACGAGGCCT TGGAGCTGAAGGATGCCCA
GGCTGGGAAGGAGCCAGAGGGGAGCCGGGCT CACT CCAGCCCT T CGAAGT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAATGCAGCCT T CCAAACT CT AAGA
GGCTGGGAAGCAGT CAGAGGGGAGCAGGGAT CAATGCAGCCT T CCAAACT CT AGGA
GGCTGGGAAGCAGCCAGAAGGGAGCAGGGCT CAATGCAGCCT T CCAAACT CT AAGA
GGCTGGGAAGCAGCCAGAAGGGAGCAGGGCT CGATGCAGCCT T CCAAACT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAATGCAGCCT T CCAAACT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAATGCAGCCT T CCAAACT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAAT CT AGCCT T CCCAAGT CT AAGA
GGCCGGGAAACAGCCAGAGGGGAGCAGGGCT CAAT CT AGCCT T CCCAAGT CT AAGA
GGCTGGGAGGCAGCCAGAGGGGAGCAGGGCT CAACCCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAACCAGGGGGGAGCAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAACCAGGGGGAAGCAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAAT CCAGCCT T CCCAAGT CT AACA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAACAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAACAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GACTGGGAAGCAGCCAGAGGGGAACAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
GGCTGGGAAGCAGCCAGAGGGGAGCAGGGCT CAAT CCAGCCT T CCCAAGT CT AAGA
AGGGACAGT CT ACCT CCCGCCAT - - AAAAAACCAATGT T CAAGAGAGAGGGACCTG
AAGGGGAAT CT ACCACCCACTGT - - AAAAAACT AATGT T CAAGAGAGAGGGGCCTG
AAGGGGAAT CT ACCACCCACTGT - - AAAAAACT AATGT T CAAGAGAGAGGGGCCTG
AAGGGGAAT CT ACCACCCACTGT - - AAAAAACT AATGT T CAAGAGAGAGGGGCCTG
AAGGGGAAT CT ACCACCCACTGT - - AAAAAACT AATGT T CAAGAGAGAGGGGCCTG
AAGGGGAAT CT ACCACCCACTGT - - AAAAAACT AATGT T CAAGAGAGAGGGGCCTG
AAGGGGAAT CT ACCACCCACTGT - - AAAAAACT AATGT T CAAGAGAGAGGGGCCTG
AAAGGCAAT CT ACCT CCTGCCAT - - AAAAAACT AATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACT AATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCTGCCAT AAAAAAAACT AATGT T CT AGAGAGAGCAGCCTG
AAAGGCAAT CT AT CT CCCACCAT - - AAAAAAAT AATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT AT CT CCCACCAT - - AAAAAACT AATGT T CAAGAAAGAGCAGCCTG
AAAGGCAAT CT T CCT CCCGCCAT - - AAAAAACT AATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACT T ATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACT T ATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACT T ATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACT T ATGT T CAACAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACAT ATGT T CAAGAGAGAGCAGCCTG
AAAGGCAAT CT ACCT CCCGCCAT - - AAAAAACT T ATGT T CAAGAGAGAGCAGCCTG
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SGA PIPELINE FOR FOSMID ASSEMBLY 
CPU=8 
DISTANCE_EST=DistanceEst 
 
$SGA preprocess -p 1 -o SGA_pp_reads.fastq -v $1 $2 
$SGA index -t 8 --no-reverse SGA_pp_reads.fastq 
$SGA correct -v -k 31 --metrics=kmer_errors.log -o reads.ec.fastq --learn -t 8 
SGA_pp_reads.fastq 
 
MIN_OVERLAP=35 
ASSEMBLE_OVERLAP=40 
 
TRIM_LENGTH=200 
MIN_CONTIG_LENGTH=1000 
MIN_PAIRS=3 
D=2000000 
 
# 
# Primary (contig) assembly 
# 
# Index the corrected data. 
$SGA index -d $D -t $CD=2000000 -t $CPU reads.ec.fastq 
 
 
8
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
ACT CAGACTGA
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# Remove exact-match duplicates and reads with low-frequency k-mers 
$SGA filter -x 2 -t $CPU reads.ec.fastq 
 
# Compute the structure of the string graph 
$SGA overlap -m $MIN_OVERLAP -t $CPU reads.ec.filter.pass.fa 
 
# Perform the contig assembly 
$SGA assemble -m $ASSEMBLE_OVERLAP --min-branch-length $TRIM_LENGTH -
o primary reads.ec.filter.pass.asqg.gz 
 
# 
# Scaffolding 
# 
 
IN1=$1 
IN2=$2 
PRIMARY_CONTIGS=primary-contigs.fa 
PRIMARY_GRAPH=primary-graph.asqg.gz 
 
# Align the reads to the contigs 
$BWA_BIN index $PRIMARY_CONTIGS 
$BWA_BIN aln -t $CPU $PRIMARY_CONTIGS $IN1 > $IN1.sai 
$BWA_BIN aln -t $CPU $PRIMARY_CONTIGS $IN2 > $IN2.sai 
$BWA_BIN sampe $PRIMARY_CONTIGS $IN1.sai $IN2.sai $IN1 $IN2 | 
$SAMTOOLS_BIN view -Sb - > libPE.bam 
 
# Convert the BAM file into a set of contig-contig distance estimates 
$BAM2DE_BIN -n $MIN_PAIRS -m $MIN_CONTIG_LENGTH --prefix libPE 
libPE.bam 
 
# Compute copy number estimates of the contigs 
$ASTAT_BIN -m $MIN_CONTIG_LENGTH libPE.bam > libPE.astat 
 
 
# Build the scaffolds 
$SGA scaffold -m $MIN_CONTIG_LENGTH -a libPE.astat -o scaffolds.scaf --pe 
libPE.de $PRIMARY_CONTIGS 
 
# Convert the scaffolds to FASTA format 
$SGA scaffold2fasta --use-overlap --write-unplaced -m $MIN_CONTIG_LENGTH -a 
$PRIMARY_GRAPH -o sga-scaffolds.fa scaffolds.scaf 
 
 
 
 176 
MASURCA PARAMETERS 
GRAPH_KMER_SIZE=auto 
CA_PARAMETERS = ovlMerSize=30 cgwErrorRate=0.15 ovlMemory=4GB 
WINDOW=10 
MAX_ERR_PER_WINDOW=3 
TRIM_PARAM=2 
EXTEND_JUMP_READS=0 
NUM_THREADS= 32 
JF_SIZE=30000000000 
DO_HOMOPOLYMER_TRIM=0 
USE_LINKING_MATES=1 
 
PAML CONTROL FILES 
Null Model Ctl File: 
seqfile = <alignment.phy>  
treefile = <null.model.tree> 
outfile = <null.paml.out> 
model = 0 
noisy = 0   
verbose = 0   
runmode = 0  
seqtype = 1   
CodonFreq = 3   
aaDist = 0   
NSsites = 0  
icode = 0  
Mgene = 0  
fix_kappa = 0   
kappa = 2   
fix_omega = 0  
omega = .5   
fix_alpha = 1   
alpha = 0  
Malpha = 0   
ncatG = 1  
clock = 0    
getSE = 0   
RateAncestor = 0  
cleandata = 1   
Experimental Model Ctl File: 
 
seqfile = <alignment.phy>  
treefile = <exp.model.tree> 
outfile = <exp.paml.out> 
model = 2 
noisy = 0   
verbose = 0   
runmode = 0  
seqtype = 1   
CodonFreq = 3   
aaDist = 0   
NSsites = 0  
icode = 0  
Mgene = 0  
fix_kappa = 0   
kappa = 2   
fix_omega = 0  
omega = .5   
fix_alpha = 1   
alpha = 0 
Malpha = 0   
ncatG = 1  
clock = 0    
getSE = 0   
RateAncestor = 0 
cleandata = 1
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